Copiparvovirus genetic vector platform
The copiparvovirus-based gene-transfer platform addresses the limitations of AAV vectors by enhancing DNA capacity and immunogenicity while eliminating the need for helper viruses, offering a more efficient and safer gene transfer method.
Patent Information
- Application Number
- PCT/US2024/031301
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-05-28
- Publication Date
- 2024-12-05
AI Technical Summary
Current AAV gene transfer vectors face limitations such as low passenger DNA capacity, immunogenicity, and the requirement for helper viruses during production, which restrict their versatility and safety in gene therapy applications.
Development of a viral gene-transfer platform utilizing copiparvoviruses, which offers increased genetic material capacity, reduced immunogenicity, and the ability to package DNA without the need for helper viruses, using copiparvovirus-derived capsids and non-copiparvovirus promoters to enhance gene transfer efficiency.
The copiparvovirus-based platform significantly increases the capacity for genetic material transfer, reduces immunological challenges, and eliminates the need for helper viruses, providing a more versatile and safer gene transfer method compared to traditional AAV vectors.
Smart Images

Figure US2024031301_05122024_PF_FP_ABST
Abstract
Description
COPIPARVOVIRUS GENETIC VECTOR PLATFORM CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application claims the benefit of U.S. Provisional Patent Application No. 63 / 469,337, filed May 26, 2023, which is incorporated by reference. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with Government support under NIH Z01 Project No. Z0100695 awarded by the National Institute of Dental And Craniofacial Research, National Institute of Health. The Government has certain rights in this invention. INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY
[0003] Incorporated by reference in its entirety herein is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: One 134,818 Byte XML file named “770496.xml,” dated May 28, 2024. BACKGROUND OF THE INVENTION
[0004] For decades, various gene-transfer vectors have increasingly become available. These comprise a viral-based vector systems (e.g., adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), among others), which are engineered to carry desired “passenger” DNA or RNA into cells, whereupon the passenger genetic material is expressed within such cells. Using such vectors, researchers and clinicians have been able to engineer cells to express or repress, or otherwise modify the expression and production of, various proteins and RNAs in a wide variety of research and therapeutic contexts. The technology has revolutionized biological research and medicine.
[0005] A commonly-used vector system employs AAV vectors. There are more than a thousand AAV variants, generally falling within the five primate clades. Despite this incredible diversity, research into AAV’s infection pathway has been based on only a few serotypes. AAVs are dependoparvoviruses, which are members of a broad phylogenetic taxa, Parvovirinae,which includes several other taxa, including copiparvoviruses, tetraparvoviruses, bocaparvoviruses, erythroparvoviruses, protoparviviruses, amdoparvoviruses, as well as other parvovirus isolates.
[0006] As vectors, AAV has become one of the more standard platforms employed. However, despite widespread use, AAV vectors suffer from some well-recognized drawbacks, which have not been overcome despite extensive efforts on the part of many groups of virologists. One such drawback is that AAV’s capacity to carry “passenger” DNA is notoriously limited; AAV capsids are typically about 26 nm in diameter, and they typically cannot carry and efficiently transfect cells with DNA above about 5 kB, which severely limits them for use in transferring larger genes.
[0007] Another limitation is that AAV vectors are immunogenic, especially at high doses. Adaptive immunity to the AAV capsid represents a significant cause for decreased efficacies in the use of AAV. Although the single-administration dosing often possible with the use of AAV gene therapy may limit the need for sequential dosing, for many therapies, especially those involving cancers, this is not possible because AAV does not persist in dividing cells. Even where single-dose AAV-based therapies are achievable, patients exposed to AAV serotypes on which a gene therapy is based (of which serotypes, despite the wide diversity amongst AAV, there are relatively few), necessarily have a high probability of subsequently reacting against the vector capsid.
[0008] Another limitation is that AAV vectors require helper viruses, typically adenoviruses or HSV, during manufacture to permit packaging of DNA into AAV capsids. The requirement for such helper viruses necessarily raises concerns about the safety of vectors, due to potential contamination with helper virus, which presents challenges involved with purification of AAV following production. While attempts have been made to engineer helper-free systems, such as using three-plasmid “helper-free” transfection approach (Grieger et al., Mol. Ther.24, 287–297 (2016); Mietzsch et al., Hum. Gene Ther.25, 212–222 (2014)), these approaches are imperfect and costly and challenging to employ for larger-scale or commercial-scale production.
[0009] Accordingly, a need exists for a vector system that is of similar versatility to existing AAV systems but which is not plagued with its drawbacks, namely low passenger DNAcapacity, immunogenicity, and AAV’s requirement for helper virus (or virus functions) for production. The present invention addresses these concerns. BRIEF SUMMARY OF THE INVENTION
[0010] The invention provides a new viral gene-transfer platform. The inventive viral gene- transfer platform incorporates elements derived from a parvovirus taxon that is separate from dependoparvoviruses (which, as noted above, include AAV): namely that of copiparvoviruses.
[0011] In a first aspect, the invention provides a genetic vector, such as a non-encapsulated vector, comprising a first DNA sequence encoding a polypeptide able to form viral capsids with a CAP (capsid) protein of a copiparvovirus and a second DNA sequence comprising a non- copiparvovirus promoter operably linked to the first DNA sequence. In a second aspect, the invention provides an encapsulated genetic vector comprising a capsid comprising polypeptide able to form viral capsids with a CAP (capsid) protein of a copiparvovirus and a genome comprising non-copiparvovirus DNA.
[0012] Compositions comprising the inventive vectors, as well as methods of making such and using such, are provided as well.
[0013] Distinct advantages to the present inventive gene-transfer platform when compared to standard AAV vectors include (a) vastly increased capacity for carrying genetic material (up to at least about 8.0 kB as opposed to 5.2 kB for AAV), (b) the ability to be able to package desired trans-DNA (“passenger”) payloads into copiparvoviral-derived capsids without the requirement for helper (e.g., adenovirus or HSV) vectors, and (c) immunological advances. In particular, a copiparvovirus capsid protein is less than 24 % identical to that of AAV2, suggesting a unique immunological and tissue transduction mechanism. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)
[0014] Figure 1 graphically depicts the organization of the porcine copiparvovirus 6 (generally referred to herein as “Copi6” or sometimes as “Co6” or “PPV6”) genome (nucleotides 21-6178 (6007 bp).
[0015] Figure 2 schematically depicts the production of the inventive vectors, using Copi6 as an example (left two examples) in comparison with the commonly-employed AAV vectorplatform (rightmost example). While Copi6 is indicated in this figure, it is representative of other copiparvoviruses discussed herein.
[0016] Figure 3 is a plasmid map displaying features of CMVpo6 tj. In this construct, the CMV promoter is engineered to drive expression of the Copi6 NS (nonstructural) protein.
[0017] Figure 4 is a plasmid map displaying features of U3795HA140-3 MMTVpo6 tj. In this construct, the murine mammary tumor virus (MMTV) promoter is engineered to drive expression of NS1, and the CMV promoter is engineered to drive expression of VP1 and VP2.
[0018] Figure 5 is a plasmid map displaying features of mmtvNSCMVVP2po6 tj. In this construct, the MMTV is engineered to drive expression of NS and the CMV promoter is engineered to drive expression of VP2.
[0019] Figure 6 is a plasmid map displaying features of mmtvpo6. In which the Copi6 NS (nonstructural)- (SEQ ID NOs: 25 (DNA) and 12 (protein)), and CAP (capsid)- (SEQ ID NOs: 25 (DNA) and 13 (protein)) -encoding ORFs under the transcriptional control of an MMTV promoter MMTV promoter is engineered to drive expression of the Copi6 NS and CAP ORFs and VP2. The DNA sequence of mmtvpo6 is set forth as SEQ ID NO: 25.
[0020] Figure 7 is an illustration of a portion of the sequence of mmtvpo6 (SEQ ID NO:25), indicating the placement of the MMTV (driving the expression of NS) with an upstream ORF and AUG (ATG) to limit transcription, which is suitable for use in creating a vector according to the present invention.
[0021] Figure 8 is a plasmid map displaying features of VB220316-1106had, a cloning vector employed to introduce the nano luciferase (Nluc(ns)) and the human CF transmembrane conductance regulator (hCFTR) coding sequence into Copi4, Copi5, Copi6, Copi6-2, and other vectors and which is suitable for use in creating a vector according to the present invention. The DNA sequence of VB220316-1106had is set forth as SEQ ID NO:17.
[0022] Figure 9 is an electron photomicrograph of particles of Po66.8. The scale is as indicated with the bar representing 70 nm.
[0023] Figure 10 graphically presents data demonstrating that COS cells are permissive for the Po66.8 vector but not Pk15, also showing the background signal (control).
[0024] Figure 11 graphically presents data concerning the titer (solid line) and refractive index (RI, dashed line) of fractions of the Po6 AAV 7.3 vector comprising a genome (comprising exogenous genetic material) of 7.3 kb.
[0025] Figure 12 graphically depicts assembly of contigs to make a full-length map of the Copi6 genome.
[0026] Figure 13 graphically depicts the organization of the Roe deer copiparvovirus genome (nucleotides 21-6178 (6007 bp)).
[0027] Figure 14 depicts the predicted structures of the terminal elements of the Roe Deer copiparvovirus. The image at the top depicts the right-hand element (RHE), whereas the image at the bottom depicts the left-hand element (LHE).
[0028] Figure 15 depicts the predicted structures of the terminal elements of Copi6. The image at the top depicts the RHE (SEQ ID NO: 29), whereas the image at the bottom depicts the LHE (SEQ ID NO:28). Conserved within the two right terminal element is a 72 base direct repeat sequence.
[0029] Figure 16 is a plasmid map displaying features of mmtvpo62_qbq, a vector based on Copi6-2, which is a copiparvovirus variant of Copi6, and which is suitable for use in creating a vector according to the present invention. Depicted are the MMTV promoter, which drives the expression of the NS (nonstructural)- and CAP (capsid)-encoding ORFs from Copi6-2. The DNA sequence of mmtvpo62_qbq is set forth as SEQ ID NO:18, and the translated ORFs are set forth as SEQ ID NOs: 19 (Copi6-2 NS protein) and 20 (Copi6-2 CAP (capsid) protein).
[0030] Figure 17 graphically depicts the organization of a linearized genome (MMTVPo4) comprising the Copi4 NS1 (SEQ ID NOs: 7 and 21 (DNA) and 8 (protein)), NS2 (SEQ ID NOs: 7 and 21 (DNA) and 9 (protein)), and CAP (SEQ ID NOs: 7 and 21 (DNA) and 10 (protein)) ORFs under the transcriptional control of an MMTV promoter, which is suitable for use in creating a vector according to the present invention.
[0031] Figure 18 graphically depicts the organization of a linearized genome (MMTVPo5) comprising the Copi5 NS (nonstructural)- (SEQ ID NOs: 22 (DNA) and 23 (protein)), and CAP (capsid)- (SEQ ID NOs: 22 (DNA) and 24 (protein)) -encoding ORFs under the transcriptionalcontrol of an MMTV promoter, which is suitable for use in creating a vector according to the present invention.
[0032] Figure 19 is a plasmid map displaying features of an AAV ITR vector (paav4.6), an 8660-nucleotide vector comprising 5’ and 3’ AAV ITRs flanking a sequence that includes the GFP ORF.
[0033] Figure 20 is a plasmid map displaying features of an AAV ITR vector (paav7.3), an 10,573-nucleotide vector comprising 5’ and 3’ AAV ITRs flanking a sequence that includes ORFs encoding the nano luciferase (Nluc(ns)) and the human CF transmembrane conductance regulator (hCFTR) coding sequences, which can be employed to introduce such genes into Copi4, Copi5, Copi6, Copi6-2, and other vectors and which is suitable for use in creating a vector according to the present invention.
[0034] Figure 21 is a plasmid map displaying features of Po66.8 (see also Figure 8), a vector comprising a 6,070 nucleotide ORF encoding the nano luciferase protein and the human CF transmembrane conductance regulator (CFTR) protein with a Copi6 vector backbone.
[0035] Figure 22 presents a ribbon graphic depicting the predicted structure of the Copi6 capsid protein (CAP), indicating as well the site at residue 1034, which can be mutated (D1034R) to create an “RGD” domain for altered binding.
[0036] Figure 23 graphically presents data concerning the PLA2 activity of Copi6 CAP in comparison with AAV2 CAP.
[0037] Figure 24 presents plasma maps pertaining to Sika deer- and Roe deer-based vectors.
[0038] Figure 25 presents ribbon graphics depicting the predicted structures of Roe deer copiparvovirus (left panel) and Sika deer copiparvovirus (right panel) AF2 (capsid) monomers.
[0039] Figure 26 graphically presents data concerning the AAV ITR transducing units measured with respect to Roe deer copiparvovirus production (left panel) and Sika dear copiparvovirus production (right panel) in the presence and absence of adenovirus. Data are expressed as transducing units / 1010particles. DETAILED DESCRIPTION OF THE INVENTION
[0040] Certain copiparvovirus strains derived from pigs are referenced herein, i.e., porcine copiparvoviruses 4, 5, 6, and 6-2. In general, these generally are referred to herein as “Copi4,”“Copi5,” “Copi6,” and “Copi6-2” respectively, although occasionally they may be referred to as “Co4,” “Co5,” “Co6,” and “Co6-2,” respectively, as “Po4,” “Po5,” “Po6,” and “Po6-2,” respectively or as “PPV4,” “PPV5,” “PPV6,” and “PPV6-2,” respectively.
[0041] The genomic organization of copiparvoviruses, such as, for example, Copi6, is similar to that of other parvoviruses (see SEQ ID NOs: 1, 4, 7, 11, and 14). For example, in reference to Copi6, the nearly full length Copi6 genome (SEQ ID NO:11) consists of negative strand DNA of approximately 6100 nucleotides (nt). The Copi6 genome comprises two putative ORFs separated by eight nucleotides and flanked by 5′ and 3′ UTRs (333–364 nt and 219, respectively of SEQ ID NO:11). ORF1 encodes a putative non-structural protein (“NS” or “NS1”) of 662 amino acids (see SEQ ID NO:12) that functions as the viral replicase. ORF2 encodes the putative capsid protein (CAP) that is predicted to be 1189 amino acids in length (see SEQ ID NO:13). Comparison of the predicted lengths of the capsid proteins of various parvoviruses reveals that the capsid protein of Copi6 is predicted to be larger than the other parvoviruses. The capsid protein of Copi4, for example, is predicted to be 728 amino acids in length (SEQ ID NO:10), and the putative capsid proteins of other copiparvoviruses consist of 1035 amino acids (Bosavirus MS-2016a; SEQ ID NO:2), 1038 amino acids (Bovine parvovirus 2, SEQ ID NO:6), 1093 amino acids (Roe deer copiparvovirus, SEQ ID NO:16), and 1112 amino acids (Sika deer copiparvovirus, SEQ ID NO:32), respectively. Slight variations of these sequences are reported and can be found among various protein and nucleic acid databases, in part based on the characterization of different strains of each virus.
[0042] In a first aspect, the invention provides a genetic vector, which can be a non- encapsulated vector, comprising a first DNA sequence encoding a polypeptide able to form viral capsids with a CAP (capsid) protein of a copiparvovirus and a second DNA sequence comprising a non-copiparvovirus promoter operably linked to the first DNA sequence. In a second aspect, the invention provides an encapsulated genetic vector comprising a polypeptide able to form viral capsids with a CAP (capsid) protein of a copiparvovirus and a genome comprising non- copiparvovirus DNA. The vector according to the first aspect of the invention can be co- transfected into suitable packaging cells, together with a sequence to be packaged, to generatethe vector according to the second aspect of the invention (see Figure 2 for a schematic representation).
[0043] In either aspect, a genome of a genetic vector according to the present invention can comprise a variety of genetic elements, including cloning sites, linkers, etc., which are commonly employed in the art. Also, the genome of the inventive genetic vector of the first or the second aspect of the invention also can comprise other functional genomic elements, such as IRES sites, enhancers, upstream ORFs, cloning and restriction endonuclease consensus sites, etc. Additionally, the genome of the inventive genetic vector can additionally comprise one or more ORFs encoding one or more proteins / polypeptides other than copiparvovirus proteins.
[0044] Within the genome of the inventive genetic vector according to the first aspect of the invention, the first DNA comprises a sequence of nucleotides (open reading frame (ORF)), which encodes a protein able to form a viral capsid when in the presence of a copiparvoviral capsid protein. Often, such polypeptide encoded by the first DNA itself comprises a parvoviral structural protein (VP or SP), capsid (CAP) protein, or functional variant thereof. For example, the first DNA can encode a protein that is at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 97%, such as at least 99% identical, or 100% identical to the VP or SP, or CAP (capsid) protein of a copiparvovirus, such as (but not limited to) for example, as set forth in SEQ ID NOs:2, 6, 10, 13, 16, 20, 24, and 32. Examples of such parvoviral CAP proteins include, but are not limited to, those from Bosavirus MS-2016a, Bovine parvovirus 2, Porcine parvovirus 4 (Copi4), Porcine parvovirus 5 (Copi5), Porcine parvovirus 6 (Copi6), Porcine parvovirus 6-2 (Copi6-2), Roe deer copiparvovirus, Sika deer copiparvovirus, and others known in the art. Relevant genomic sequences of these copiparvovirus, and nucleic acids representing the relevant VP or SP, CAP, and other proteins thereof, are set forth generally in SEQ ID NOs:1-25 and 27-37 below, which also reference certain accession numbers. However, the VP or SP, or CAP protein encoded by the first DNA of the genome within the inventive genetic vector according to the first aspect of the invention can comprise any polypeptide able to form recognizable copiparvoviral capsids, preferably together with native copiparvovirus VP or SP, or CAP proteins.
[0045] Additionally, the parvoviral VP or SP, or CAP proteins for inclusion in the inventive vector, and encoded by, for example, the first DNA within the vector genome, can be modified, such as to alter ligand binding. For example, mutation of the native “D” residue at position 1034 of the native Copi6 CAP protein, e.g., to “R” (“D1034R” mutation creates an “RGD” domain, which can serve to alter binding of capsids comprising such version of the Copi6 CAP protein or the sight of attachment of a targeting ligand, for example. This mutation is reflected in SEQ ID NO:13 as “X” at residue 1034 (see also Figure 22).
[0046] The second DNA sequence within the genome of the inventive genetic vector comprises a promoter genetic element, which is preferably a non-copiparvoviral promoter. The promoter is placed in operable linkage to the first DNA such that the promoter is able to promote (or “drive”) the expression of the first DNA sequence. Thus, for example, the promoter can be placed upstream (5’ to) the start codon of the ORF encoding the capsid protein within the first DNA. The exact positioning of the promoter relative to the start codon will vary in accordance with the type of promoter chosen, and other elements associated with the regulation of the ORF, such as enhancer elements, upstream ORFs, etc.
[0047] In principle, any promoter able to drive or promote the expression of the first DNA (i.e., comprising the ORF encoding the VP or SP, or CAP protein) can be selected; however, a non-native (a non-copiparvovirus promoter sequence) may be preferred over a native copiparvoviral promoter genetic element. Indeed, as copiparvoviral proteins can be toxic to cells, it is useful to use a weaker promoter than a native copiparvoviral promoter in some embodiments to produce the structural and non-structural copiparvovirus proteins in packaging cells.
[0048] A preferred promoter for use in the present invention is derived from the murine mammary tumor virus promoter (MMTV), the sequence of which is set forth herein at SEQ ID NO:26. The sequence need not exactly match that of SEQ ID NO 26; rather, an MMTV promoter for use in the present invention can comprise, consist essentially of, or consist of all or an active portion of SEQ ID NO:26. Moreover, in certain embodiments, the MMTV promoter for use in the present invention can comprise a nucleic acid sequence at least 80%, such as atleast 85%, such as at least 90%, such as at leas 95%, such as at least 97%, such as at least 99% identical, or 100% identical to all or an active fragment of SEQ ID NO:26.
[0049] In certain embodiments in which an MMTV promoter (or other promoter) is used as the second DNA in operable linkage with the first (and desirably the third, see below) DNA within the inventive genetic vector according to the first aspect of the invention, it may be desirable to further regulate (e.g., limit) transcription to avoid potential toxicity associated with the expression of high levels of copiparvovirus genes. Such limitation of transcription may serve to optimize the production of viruses. For example, as depicted in Figure 7, in addition to the MMTV promoter (an example of a type of second DNA) in operable linkage with the ORF encoding the CAP protein (i.e., the first DNA), the genome of the inventive genetic vector also can include elements, such as an upstream ORF and stop codon (AUG or ATG), which can attenuate the activity of promoters and help limit transcription.
[0050] In certain embodiments according to the first aspect of the invention, based on results reported in the Examples below, the cytomegalovirus constitutive promoter (CMV promoter) is not preferred for use as the second DNA in operable linkage with the first DNA, as it has been shown to result in poor viral production for at least some vectors tested. However, it is possible the CMV promoter nonetheless may be used in certain constructs according to the present invention. Moreover, the CMV promoter certainly can be used as a promoter in connection with other genes (ORFs) that may be included in the inventive vectors (such as in accordance with the second aspect of the invention).
[0051] Typically, a vector according to the first aspect of the invention also includes a third DNA, which can be also in operable linkage with the second DNA, and which encodes a nonstructural (NS or NS1 or NS2) protein, which operates analogously to AAV REP to drive replication of the copiparvovirus within packaging cells. Often, such polypeptide encoded by the third DNA itself comprises a parvoviral nonstructural protein or functional variant thereof. For example, the first DNA can encode a protein that is at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 97%, such as at least 99% identical, or 100% identical to the nonstructural protein of a copiparvovirus, such as (but not limited to) for example, as set forth in SEQ ID NOs:3, 5, 8, 9, 12, 15, 19, 23, and 31. Examples of suchparvoviral nonstructural proteins include, but a e not limited to, those from Bosavirus MS-2016a, Bovine parvovirus 2, Porcine parvovirus 4 (Copi4), Porcine parvovirus 5 (Copi5), Porcine parvovirus 6 (Copi6), Porcine parvovirus 6-2 (Copi6-2), Roe deer copiparvovirus, Sika deer copiparvovirus, and others known in the art. Relevant genomic sequences of these copiparvovirus, and nucleic acids representing the relevant nonstructural (and other) proteins thereof, are set forth generally in SEQ ID NOs:1-25 and 27-37 below, which also reference certain accession numbers. However, the nonstructural protein encoded by the third DNA of the genome within the inventive genetic vector according to the first aspect of the invention can comprise any polypeptide able to function as a copiparvovirus nonstructural protein. Also, while it may be desirable, in some embodiments (see, e.g., Figures 6, 16, 17, and 18), for the CAP protein encoded by the first DNA to be selected from the same type of copiparvovirus as the third DNA (e.g., a Copi6 CAP encoded by the first DNA and a Copi6 NS protein encoded by the third DNA, etc.), this is not a strict requirement; chimeras are contemplated.
[0052] The genetic vector according to the second aspect of the invention comprises a capsid. The capsid comprises a protein able to form a viral capsid when in the presence of a copiparvoviral capsid protein. Often, such polypeptide itself comprises a parvoviral capsid (CAP), structural protein (SP), or VP protein or functional variant thereof. For example, the polypeptide comprise an amino acid sequence that is at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 97%, such as at least 99% identical, or 100% identical to the VP or SP, or CAP (capsid) protein of a copiparvovirus, such as (but not limited to) for example, as set forth in SEQ ID NOs:2, 6, 10, 13, 16, 20, 24, and 32. Examples of such parvoviral VP or SP, or CAP proteins include, but are not limited to, those from Bosavirus MS- 2016a, Bovine parvovirus 2, Porcine parvovirus 4 (Copi4), Porcine parvovirus 5 (Copi5), Porcine parvovirus 6 (Copi6), Porcine parvovirus 6-2 (Copi6-2), Roe deer copiparvovirus, Sika deer copiparvovirus, and others known in the art. Relevant genomic sequences of these copiparvoviruses, and nucleic acids representing the relevant VP or SP, CAP, and other proteins thereof, are set forth generally in SEQ ID NOs:1-25 and 27-37 below, which also reference certain accession numbers. However, the VP or SP, or CAP protein can comprise anypolypeptide able to form recognizable copiparvoviral capsids, preferably together with native copiparvovirus CAP proteins.
[0053] The capsid protein within the inventive vector can be modified to include targeting peptides or whole domains from other parvovirus or from other sources (e.g., antibodies or other binding moieties). For example, as noted above, the parvoviral VP or SP, or CAP proteins for inclusion in the inventive vector, and encoded by, for example, the first DNA within the vector genome, can be modified, such as to alter ligand binding. For example, mutation of the native “D” residue at position 1034 of the native Copi6 CAP protein, e.g., to “R” (“D1034R” mutation) creates an “RGD” domain, which can serve to alter binding of capsids comprising such version of the Copi6 CAP protein or the sight of attachment of a targeting ligand, for example. This mutation is reflected in SEQ ID NO:13 as “X” at residue 1034 (see also Figure 22).
[0054] Additionally, a comparison of sequences has revealed certain conserved motifs conserved among copiparvoviral VP or SP, or CAP (capsid) proteins but not shared with AAV. These are reflected in SEQ ID NOs: 35-37. Accordingly, the inventive genetic vector can comprise a structural capsid (VP or SP, or CAP) protein comprising one or more of SEQ ID NOs:34-36. Moreover, a sequence comparison reveals that the copiparvoviral VP or SP, or CAP (capsid) proteins share a consensus sequence (SEQ ID NO:33) among them and with AAV, which is attributable to PLA activity. Indeed, data presented herein (see Figure 23) reveal the Copi6 CAP protein, at least, to possess PLA activity. Accordingly, the inventive genetic vector can comprise a structural capsid (VP or SP, or CAP) protein comprising SEQ ID NO:33 and / or another shared sequence, SEQ ID NO:34.
[0055] In addition to the capsid, the genetic vector according to the second aspect of the invention comprises a genome, which preferably comprises non-copiparvovirus “passenger” DNA. For instance, in the examples below, various vectors include ORFs encoding nano luciferase, full-length human cystic fibrosis transmembrane conductance regulator (hCFTR), viral DNA, etc. Also, in preferred embodiments, the genetic vector can comprise AAV ITRs, such as that of an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9, AAV10, AAV11, AAV12, AAV44.9, AAAV, BAAV, ITR (or others known in the art), for example, which flank non-copiparvovirus DNA to be packaged. Typically an AAV type 2 repprotein, such as from AAV12 (repx26), is co-t ansfected with a vector according to the first aspect of the invention (See Figure 19) and the vector plasmid to rescue and replicate the AAV vector from the plasmid backbone. If AAV5, bovine, or avian ITRs are used then the appropriate rep with activity on their respective ITRs must be added. The AAV helper function can be chimeric as well, e.g., comprising portions from different serotypes of AAV. Such AAV helpers and chimeras additionally can include transgenes, such as non-AAV, non-copiparvovirus ORFs. In this manner, the inventive genetic vector can effectively deliver an entire AAV vector, with transgenes, to cells in vivo and in vitro.
[0056] It has been discovered that the inventive vector has a capacity for packaging a larger genome than possible with standard AAV vectors. In this respect, the size limit for AAV2 to efficiently package DNA is about 5.2 kb of DNA. However, the inventive genetic vectors can efficiently package DNA far exceeding that limitation. Thus, the genome of the inventive genetic vector can comprise greater than 5.2 kB of DNA, such as greater than 6.2 kB of DNA, such as greater than 7.2 kB of DNA, such as greater than 7.7 kB of DNA. In this respect, as depicted in Table 1 below, experimental evidence with mmtvpo6 demonstrates that a high titer of virus can be produced with a genome size of about 6.7 kB, but that the titer of vectors containing 8.7 kB was at background, irrespective of the presence of adenoviral helper vector. Based on these data, in certain embodiments, the genome of the inventive vector may comprise less than 8.7 kB, such as less that about 8 kB (e.g., equal to or less than 7.9 kB). This tremendous increase of the genomic capacity of the inventive copiparvovirus genetic vector relative to that of the commonly-employed AAV platform is one notable advantage achieved by the present invention.
[0057] The larger capacity of the inventive encapsulated copiparvovirus-based vectors can open new avenues to study genetic expression and therapeutic applications. For example, while the small capacity of AAV limits the platform to the transfer and expression of relatively small ORFs, the present invention provides parvoviral vectors that can package much larger ORFs. As non-limiting examples, the vectors of the present invention can package a full length CFTR gene (as demonstrated by the examples below) and other larger coding sequences, and / or multiple coding sequences, thus can likewise be delivered to cells using the inventive vector system.
[0058] To produce the inventive genetic vector comprising a capsid and a genome including one or more non-copiparvoviral ORFs (i.e., a vector according to the second aspect of the invention), cells (such as 293 T cells or others known in the art as suitable parvoviral packaging cells) can be co-transfected with a vector comprising the copiparvoviral elements, such as a vector according to the first aspect of the invention (e.g., mmtvpo4, mmtvpo5, mmtvpo6, mmtvpo6-2)) or other desired constructs (for example, containing variant copiparvovirus sequences and / or promoters other than MMTV) and a second vector containing a genome to be packaged (such as an AAV vector comprising ITRs flanking a desired transgene ORF, for example, as denoted as “AAV ITR vector” in Figure 2 or using asymmetrical copiparvovirus terminal elements (TEs)). A third vector or ORF encoding an appropriate AAV rep protein (as discussed above) may be employed as well to provide helper function specific to the terminal repeats used as origins of replication in the vector plasmid containing the trans-gene of interest. For instance, in Figure 2, the middle example notes that an “AAV Rep vector” is co-transfected along with an AAV ITR vector (which comprises AAV ITRs flanking a transgene of interest) and the Copi6 NS+CAP vector (such as mmtvpo6 described herein). After incubation, typically for about 48 hours, the resulting vectors according to the second aspect of the invention (genomes encapsulated in the capsid) can be harvested (for example, these are denoted in Figure 2 as “Copi6 / Copi6 vector” and “Copi6 / AAV vector”). Thereafter, these can be purified, if desired (e.g., using CsCl gradients or other suitable method), and then used to prepare preparations having desired titers of the virus.
[0059] It will be observed in accordance with this method, that no viral helper (e.g., adenoviral or HSV vector) is mentioned in connection with the production of the inventive vectors according to the second aspect of the invention. While a helper can be added as with standard AAV production, in many embodiments of the present invention, particularly the Copi6- and 6-2- and Copi4- and Roe deer copiparvovirus-derived vectors (see Tables 1 and 2 below) discussed in the Examples herein, such helper virus is not required to produce acceptable titers of viral particles. This property provides an advantage over the AAV vector platform, in which Ad or HSV helper functions are necessary (see Figure 2, example depicted on the right). While some embodiments thus far tested shows some level of influence by Ad helper virusfunction, none appears to be strictly reliant on d helper function for the production of encapsulated copiparvovirus vectors. This ability to produce the inventive vectors without requiring any Ad, HSV, or other helper virus in the process is another notable advantage achieved by the present invention over the commonly-employed AAV platform.
[0060] While the larger payload potential and the ability to manufacture vectors without requiring helper virus are advantageous distinctions between the present inventive genetic vector platform and the commonly-employed AAV platform, some additional distinctions may be noted as well. For example, through investigation of the copiparvoviral genomes in connection with the production of the inventive vectors, it was observed that, whereas in AAV the terminal repeat sequences of standard AAVs are symmetrical, those of at least Copi6 and the Roe deer copiparvovirus are not. As depicted in Figures 14 and 15, the terminal repeat elements of both Copi6 and the Roe deer copiparvovirus show marked asymmetry, with clearly distinct left and right elements. Thus, the genome of the inventive genetic vector also can comprise left and right terminal elements (TEs), which are asymmetrical.
[0061] Other data from experiments discussed in the Examples below reveal that the refractive index (RI) measured for an encapsulated Copi6-based vector according to the second aspect of the present invention comprising an AAV genome of 7.3 kB was 1.395 (see Example 3 and Figure 11). By contrast, the refractive index of standard AAVs typically is 1.372.
[0062] However, produced and purified, the inventive genetic vectors can be included in various desired compositions. Accordingly, the invention also provides a composition comprising the inventive genetic vector and a carrier (e.g., a pharmaceutically or physiologically acceptable carrier). For example, such compositions can include an aqueous solution, such as a physiologically compatible buffer. Examples of excipients to be included in the compositions include water, saline, Ringer's solution, and other aqueous physiologically balanced salt solutions. In some aspects, excipients are added to, for example, maintain particle stability or to prevent aggregation. Examples of such excipients include, but are not limited to, magnesium to maintain particle stability, pluronic acid to reduce sticking, mannitol to reduce aggregation, and the like, known to those skilled in the art.
[0063] Compositions are conveniently formulated in a form suitable for administration to a subject, if the inventive genetic vector is to be used in vivo. Techniques to formulate such compositions are known to those skilled in the art. For example, the inventive genetic vector can be combined with saline or other pharmaceutically acceptable solution. In some aspects, excipients are also added. In another aspect, a composition comprising inventive genetic vector is dried or lyophilized (and can contain a cytoprotectant, such as trehalose), and a saline solution or other pharmaceutically acceptable solution can be added to the composition prior to administration.
[0064] For administration to a subject (i.e., for in vivo use), the composition can, in addition to the inventive genetic vector (especially that according to the second aspect of the invention), comprise other agents as desired, such as adjuvants, preservatives, and pharmaceutically active agents (e.g., drug substances or therapeutic biological agents). In such applications, the formulation can be selected to be suitable for the desired use. For example, the inventive vector and other desired components within the carrier can be formulated for topical, transdermal administration, or administration by injection, inhalation, or other known technique. In this context, a “subject” can be a human subject (e.g., a patient undergoing therapy involving the inventive vector) or a non-human animal, such as a companion animal (cat, dog, horse), a laboratory animal (e.g., a rat, a mouse, a non-human primate), or other animal. For use in a human subject, the inventive genetic vector can serve as a therapeutic agent to deliver desired proteins via gene-transfer applications (“gene therapy”).
[0065] For in vivo use, especially for medical or veterinary use, the dose of the composition comprising the inventive genetic vector (such as according to the second aspect of the invention) to be administered to a subject to be effective will depend on the subject’s condition, manner of administration, genetic payload (e.g., transgene or ORF), and judgment of the prescribing physician or veterinarian. Often a single dose can be sufficient; however, the dose can be repeated if desirable. In general, the dose can range from about 104viral capsids per kilogram to about 1013viral capsids per kilogram. A preferred dose is in the range of from about 106viral capsids per kilogram to about 1012viral capsids per kilogram. A more preferred dose is in the range of from about 108viral capsids per kilogram to about 1012viral capsids per kilogram.
[0066] Lastly, it will be understood by persons of ordinary skill in this field that the inventive genetic vector is primarily used to introduce and express transgenes within cells, either in vivo as noted above (e.g., for medical or veterinary uses, or for laboratory studies in animals), as well as in vitro. For any such use, in general, the inventive vector is administered to a cell, or a population of cells in vivo or in vitro, under conditions for the inventive genetic vector to contact, and (when encapsulated, such as in accordance with the second aspect of the invention) infect, the cell or population of cells. Thereafter, the genetic vector delivers its payload of genetic material (such as including AAV genomes comprising desired transgenes, for example) within the infected cell(s). Once inside the cells, the transferred genome of the inventive genetic vector is able to be processed by the machinery of the infected cell(s). SEQUENCE LISTING
[0067] The following biological sequences are referred to in the present application. Reference may be made to accession numbers. Also, certain notes pertaining the features of various sequences are provided. SEQ ID NO:1: Bosavirus MS-2016a, complete genome; Accession NC_031959 1 gaacttccgg tgacgtgtaa gtcccgcctc cacagcaacc aataagagtt taggggttca 61 aacccggaag tgtggaagca taaatgtgca ggcaaaaagg ggaagttact gctgtcgcgg 121 agaactcgcc tctcggtaag caccatgctc tcttactact acggggtagc taatttattc 181 cctgatatgt ccattatacc aggggtagct aaaaagccat atgttactac ttctaaatta 241 ctaaaaggag tgaaccctga ttggccagaa ctaccagaaa aatatgtctt tgcggcacaa 301 acagctcaag gactatactt agagcttcta aaacaaatta gaattgaaat caaagatcct 361 tacggagtac ccattttctt ccaacttgaa gagggagaaa atggaaaact ccattttcac 421 tggatgatat ccacaatggt aggaacagca agagacctag gacaaataat taaaacagct 481 gaaacccaat ttaatcactt ttggttaggg actagaggaa tcacatactt taaacctaac 541 aaaaacagaa acggttcttg gagcactact aacagtacat ttctccaagt ttacctactg 601 cctaaactac cactcaaaga tgttttatgg gcatggagca acttagacgg aaaagaagga 661 gaagccactt taaaccagac acttagaaaa gaatttttag acatgaaaaa agggaaaaca 721 tacctcacta caaacacaac atcagatgat gaagatgatg aacaccaagc acccatatac 781 aaacaccaga gtggagtaca agtaaaaact ttgttaaatt ttatggtaga gaatgacatt 841 actactgaag agaaatacca aaatagattc atgacttcat actgctcata cattgcaacc 901 caaaacggaa cacacctact aaaacaaacc ctacagctag ctaaaacaga aattgctaga 961 aacaaaccat tagcattaac tttgtgtgga ttcaaatcca gaactgaact gctcacattt 1021 ttgaatgaat acacacctca atctatggag gaaagcaaaa tttggaaact atttttagaa 1081 aacgggtacg atccagatga agctgctgca gttttctttg catgggcgta cagactaact 1141 gggaaaagaa atgctatttg gataagcgga cctcctacca caggaaaatc taatttagcc 1201 caggcaatag ctagaacagc agcttcatat ggatgtgtaa actggaacaa ccctcatttt 1261 ccattccaag acattataaa cacccaacta gcattatggg acgaaggtag aatagacgaa 1321 gcaataattg agcaaacaaa aagcttatta tctgggatac aaacgagaat agatagaaaa1381 tgcaccacca gcaaagagac aactcacca ccatttctta tcactagtaa ctgtgatatc 1441 acacttgtat actcaggcaa catgacaact acattacaca ggcaagcttt agaagataga 1501 attcttcact ttacattttc aaccaaatgt aaacctgatt ttggcctttt aacaaccaat 1561 gatgttaaaa actttatgaa atggggagca tggtccttaa tgagagcgaa acacaaccgt 1621 tacagcctaa ttaggaaagg cccaacgact tggccttgcc acatccctca acaagccaca 1681 gaaactcagt taggatatgt cttacgtaaa aaaccactat ggcccacgac caatgaggaa 1741 gaagacatta tatatataga agacgatgaa attcttaaag cagctgaaac tgcagaagaa 1801 gctgaaactg aaaacataga ttccatacta gaagacccaa acacagacac aggaccaaaa 1861 aaggtaagag ttgggataat acctaacact acaatttttg ctgctcacta aataactgac 1921 aatgattaac tgacagctat tatcccttct cttacagaaa aaacaaaaaa ctcaccacgt 1981 ggaacctcct gacagcccac ctaaagaggt ggttgacgca gctgaagccc tgcttaccct 2041 ggctggcgtg gggactccgc caagtaatcc tgctaccccg gagaaccctg tgcaggaaga 2101 caatatacaa gaacagtaag tgtatttttc caacatgcaa ctcaaccaac aagactacca 2161 ggacagttta gctattttaa gacacagaac tcccggtgat ttaatacata ataatcaacc 2221 aattacaggc tcatactttg gccctaaaac atttctaaga gttaaactag accactgggc 2281 aggccaccac aactggtcaa tgacacagcc atgggaatac gaaagaagag catggatcta 2341 cagctacttg actgctcttc actttgtaaa catgaatgca gcagggctag actacaaata 2401 caatcttttc gatgaagtgc ttcagcactt aatgcaagaa tactttacag gagcaagaga 2461 ctccgctaac tttaacagac atttatacac actttataac agcgctctaa gatacaatgc 2521 accagacgaa gtactaaaac acattagaga tgtaatgagc atctccagcc cagtagacct 2581 atttgacgat aaagaaataa gattcctaca agacacagac atttcatggg acagatggag 2641 gctagcagct tccaacttca tagaagactc aattagagaa attgagataa tgatagatca 2701 caaagcaaaa gaaaaacaac accaggcaga acttgaagaa caaaacagac taaaacaagc 2761 atacgaagaa caaatgaaac gtagatatcc acacactaat caccaatatg acggaccaca 2821 tattgactgg gacattcttc aaaaagtact gcatgaacag cagtacagaa aacaatttga 2881 cagacaatac ccacacactg actacggacc atacggagga ccgaatattg attttgacag 2941 gctaactgaa cagctgcaaa aagagcatga tctccatggg aaggcgcatc aacagccacc 3001 agatacagat tccggaggag gtcttacata tccagggaca agatatgttg ggccgggaaa 3061 tgtggtaccg gctggccctc ctgttaatcc tattgatgac ttggctctac aacacgatct 3121 taggtatgca acagttatgg aacatgggga atggccatat atatatgatg agtctgatga 3181 tgtgttagcc gcagacattt cacattacgg gcaagataaa acttttttag ggaacttgat 3241 taaagcaata atgcggttaa aaaaaaactt gggtgaactg ccacgcaata tgctaagatc 3301 cgtgtggccg ttaaatccgt tagaccaccc acaaaaacag gaactagcgg gtaaacgact 3361 ttctcctcca cccccacaga taaaggagga accgatatca cctcagaagc cacccaccac 3421 tggagacgac tcaaaggcga aaagatttaa acaagatatg tctcatcaaa ctgcaccaga 3481 tcaacacatg ggccatgggg gaatggactc taacatggga tcagactctg taactattgg 3541 ggacgggggg ggaggagggt ctaaatctga atgtgaaaaa cattggtggg gaggaactag 3601 atgggaaggg aacactgtaa ctacttttgg aactagacgc tgcgtagtca aaccattccc 3661 agataattat tatgctgtaa aaagctggga taatatccca ggtatatgtg tagtcacccc 3721 ttggtattay ccagatctta acattatgag cgcacattgg agccccgcaa actggcaaac 3781 tctactagaa acagaagacc aaattcgacc taaatcttta acattaaaaa tacacacact 3841 aatctttaaa gatgtaacaa aaaactcaga aggtggctcc agtattcaag acattaactc 3901 aggtatcctt ctagtacata gagacaatga ctacacatac ccttacccta tgggaggagg 3961 acaactaaca gtaccaggat caatgccagg aagcttctac actttaccta gatacagcta 4021 cagaacctta ggcacaattg acactgataa aacacctact ggtatacatc acgcatctgc 4081 tgatgatttc cactacaaaa taacacaaaa cagtgaactt ttccttttag aagactcacc 4141 aagcagaatg ctcttttctg gggactgcta ctcttacagc tatgattttc cagctttgcc 4201 attcgctaac ttaacacagt acccatggaa cacaagaaga caagacaacc ctatgtcaca 4261 gcagaaatac cttgttatgg acaacattct atcatcagat atctttgcac ctcacggagg 4321 gagcaaactc acaccactac cattcaattc caaacttaga ccatctcaat ggttaccagc 4381 acctagattt aaacagggag aatacaatat aattcaaccc acagaagaca aaacacaaca 4441 ctggtacaaa aaaacagtca aggcaggaga aggagtagga gtcagactag tcagagaaac 4501 agacgcaaaa attataaaaa acacaaactg ggaaacacta cagccaggtc cagacacagt 4561 ttctaacatt gtgagaaaac cagacggagc aatagtagta accactaacg ctattgcagt4621 tcttcaacaa gacgaagtga accaaacca taaccaacaa aacacaacac aagcacaaaa 4681 atatgtcaaa ctaccaatcg aaaaccacaa aggttataac caaccatcag acccacagcc 4741 aattagacaa caaaacattc acgacagctc aacaactgaa attacttacg ggacattccc 4801 agggtcaaca tgggaaaagg catcgataca cttagaatcc caaatttgga cacgaatccc 4861 aaacgtcgaa ttcacacact tgccacaaca caacccacta gcagaatggg ctatgagaga 4921 cccaccacca acattattcc tgagaatgct tcaacaagct ggaccaccaa aagaagatca 4981 atacaatgga acaataccct cagatacagt ccttaaccag tacggacaat ttttcctttc 5041 ctactcaatg acatgggaaa caacacacag aaacagagga acaaaaagat ggaaccctat 5101 tgatccccca ggactaccac aaagaagtga caaaaaaccc atatttgtaa tgaatctaga 5161 tgatgggaaa catgaaggaa acttatacca caccccagat gaagtatgga cagcaaaaca 5221 gagattcaga gcaaagcgct aactttccta tgcttacctg ctttcaccca aaaaaatgaa 5281 taaaattttg aaaaagctaa aaagatgtac ttctttcgcg ggggagaatt gggagagaag 5341 gcggagtcaa aaagaggaag taaaaaaaat g SEQ ID NO:2: Bosavirus MS-2016a, structural protein; Accession NC_031959 and YP_009325418 1 mqlnqqdyqd slailrhrtp gdlihnnqpi tgsyfgpktf lrvkldhwag hhnwsmtqpw 61 eyerrawiys yltalhfvnm naagldykyn lfdevlqhlm qeyftgards anfnrhlytl 121 ynsalrynap devlkhirdv msisspvdlf ddkeirflqd tdiswdrwrl aasnfiedsi 181 reieimidhk akekqhqael eeqnrlkqay eeqmkrryph tnhqydgphi dwdilqkvlh 241 eqqyrkqfdr qyphtdygpy ggpnidfdrl teqlqkehdl hgkahqqppd tdsgggltyp 301 gtryvgpgnv vpagppvnpi ddlalqhdlr yatvmehgew pyiydesddv laadishygq 361 dktflgnlik aimrlkknlg elprnmlrsv wplnpldhpq kqelagkrls ppppqikeep 421 ispqkppttg ddskakrfkq dmshqtapdq hmghggmdsn mgsdsvtigd gggggsksec 481 ekhwwggtrw egntvttfgt rrcvvkpfpd nyyavkswdn ipgicvvtpw yypdlnimsa 541 hwspanwqtl letedqirpk sltlkihtli fkdvtknseg gssiqdinsg illvhrdndy 601 typypmgggq ltvpgsmpgs fytlprysyr tlgtidtdkt ptgihhasad dfhykitqns 661 elflledsps rmlfsgdcys ysydfpalpf anltqypwnt rrqdnpmsqq kylvmdnils 721 sdifaphggs kltplpfnsk lrpsqwlpap rfkqgeynii qptedktqhw ykktvkageg 781 vgvrlvretd akiikntnwe tlqpgpdtvs nivrkpdgai vvttnaiavl qqdevnqyhn 841 qqnttqaqky vklpienhkg ynqpsdpqpi rqqnihdsst teitygtfpg stwekasihl 901 esqiwtripn vefthlpqhn plaewamrdp pptlflrmlq qagppkedqy ngtipsdtvl 961 nqygqfflsy smtwetthrn rgtkrwnpid ppglpqrsdk kpifvmnldd gkhegnlyht 1021 pdevwtakqr frakr SEQ ID NO:3: Bosavirus MS-2016a, nonstructural protein; Accession NC_031959 and YP_ 009325417 1 mlsyyygvan lfpdmsiipg vakkpyvtts kllkgvnpdw pelpekyvfa aqtaqglyle 61 llkqirieik dpygvpiffq leegengklh fhwmistmvg tardlgqiik taetqfnhfw 121 lgtrgityfk pnknrngsws ttnstflqvy llpklplkdv lwawsnldgk egeatlnqtl 181 rkefldmkkg ktylttntts ddeddehqap iykhqsgvqv ktllnfmven ditteekyqn 241 rfmtsycsyi atqngthllk qtlqlaktei arnkplaltl cgfksrtell tflneytpqs 301 meeskiwklf lengydpdea aavffawayr ltgkrnaiwi sgppttgksn laqaiartaa 361 sygcvnwnnp hfpfqdiint qlalwdegri deaiieqtks llsgiqtrid rkcttskett 421 pppflitsnc ditlvysgnm tttlhrqale drilhftfst kckpdfgllt tndvknfmkw 481 gawslmrakh nryslirkgp ttwpchipqq atetqlgyvl rkkplwpttn eeediiyied 541 deilkaaeta eeaetenids iledpntdtg pkkvrvgiip nttifaahSEQ ID NO:4: Bovine parvovirus 2, comple e genome; Accession NC_006259 1 acttccgggt cacgcccggt agttccgggt caagtgacgt agttccggtg acgtgtcgct 61 cacggctagg gggttgggtt acgagtgtcg aaaaaattta cataagagga acgaatatta 121 atgaggtggc gaaacattgt cctaatatgg tgctgaacgc tgattggttg tctatataag 181 gtaacacaca acctgattgg ctagcgtcac atcctgatag gaggtatata aagcacaaca 241 cggaagtgac agctcattct tctctcagct gtcagagagg gaggacgtct cttggtgagt 301 acaaaatgag ctactacact tttgttgtaa ctatacctga taaaattgaa gactatggac 361 aagcttacta tgatgtagtt aacagagtaa ctttaactca tagagacaat gagaaatggg 421 tatatgaccc agaagacagg gaaattattt ttaaacaggc tcaggtatat gttgactgct 481 tagaaagaag gttaaaacag atgttagtgt ccggaagtat gtacaattac tttatacagc 541 tagagcaagg agaaaagcac aagaggtggc acatacacgt agtgttagac ataagcgtgg 601 gaaatccaag aaactgtaga gaagtgatag aaaaggtaga atatgaatac aacagcattt 661 gctacggtag accagtaaga cagactcaga ttaatagaac aagcaacggt agttggaaga 721 tagagactga agactttatt atcaactact tactatgcaa aataccacct aaagaagcta 781 agtatgcctg gactaacatt aaaaacaaga taggagacgc ttgtttaaac attgacttaa 841 gaaaagaaat ttcagttaga ccggacatag acgtaccgat gtggagacaa gctagcggag 901 acagaatgag agacttggta gaatggtgca taaaaaacca tgtatttaca gaagaccaat 961 acatggctaa atttgaagaa agctactaca gctttgcatg cactaatcaa ggcagacaca 1021 tgctacaaac aagcttagaa ttagcagcaa aaaggacgac tagcatgata ccgctcggcg 1081 tttacttagc aggattcagt aacattcaag aagcaattga agaggctaac aaaacagaat 1141 ttgcagacat atacaacaac aaagtgtttg acttgctaca gtttcaaggc tacgacccag 1201 tagtagcagg atacattata tacgcttgga gcatacgagc gacaggacgt agaggagcct 1261 tatggttcta cggaccagga caaacaggaa aaagtataat ggcaagggct atggctacat 1321 gcagcgtccg atacggctgc gtgaactgga caaactctaa ctttccattt caagacttag 1381 caacaaactg ccaaatagga tggtgggaag aaggggtaat cacagaagac attgtggaaa 1441 gtgctaaagc actactgagc gggggtaaaa taagagtaga cagaaaatgt agagacagcg 1501 tagaaattac accgccacca tttgtgatta ctagcaacaa cgacatgaca ttagtgcaag 1561 gaggaaatca agtaagcttt gtccacaaaa aaccgctaga agacaggatg attaaattta 1621 acttcaacaa gagacttcca cctaactttg gcatagtaga gagagaagac atgaaacaat 1681 tttttaaatg gagcagtttt atctactaca acaaactgct accaaaagaa caggcatact 1741 taagtgatcc taaactgata gggcacgtag tcccatacac aagcttttta agacagactg 1801 caaaagtaga gaaaattgta agaccattcg aggaacaaga acaagaagac ttggcagaac 1861 tagactcttg gtttgcggac cccccataca tggggaagcc cccaaaaaag agtgagtagc 1921 tacatatatt ttgtactcac tttgtgtgcg tgacacgtca ctgacacaca cgattttttg 1981 cagaagtacg ctttgaggac aaacagttac ttccgcaaga agaattagac cacatctgtc 2041 acaatcaaga gtgctgtcaa tacccatcgt gcgcaggatt tcaacagtaa gtgaaatctt 2101 gcattactta ttgcgtaact tgccaagggc aacgacttag caatgcatgg tttcccttgc 2161 aggccgccga ccacctcttc acacctacca gaactcacag acgaagaagt ctgtagcata 2221 ctagatagtg aagaaggctg ggacggggac aactttgcag aacagtaatg gccgctaaac 2281 tgggaggggg cttagtaggg gaagcagcta tacaccgcat agaaagctta tcaggcaaag 2341 tacactataa ggacaaatac tggtttccag acaactacgt atatacaaca ggaaaccaag 2401 aggaagaaga caaaatagta gcaaaacttt tactagatcc taatgcacca gttaaagaat 2461 ggggaaacgg caggtggtcc tttgaatacg gaccagaatg gcgtagactg ggctttatac 2521 cacacacaga tgacattaat taccgcggac tctcatacca caaagcacct gggacacagc 2581 tgctagaagg tatacacgag atacctccag aacagaaaca aggccctgaa agtataacac 2641 aaatagcacc acccacacaa gactctgtac tgttagagcc catgacaaat gacccacact 2701 ataaaaaacc aaaacctccg ggggacttag gagacattcc aaagccgctc acaccatggc 2761 aactggcaaa caaaataggg ccagactatg caaggcaatt attgacgatg tcgggacacg 2821 attttactgg acgtacaccc ccagtacaaa ttcctgaccc tggcatccga gaaggcctaa 2881 aagaattgga agaacaaagt aaactcatgg aaagagtaca agccggtgaa ggggacgaaa 2941 aacccagagg cggtcttact cttccaaaac acaggtatgt cggacccgga ggggacctcc 3001 cggcagggcg tccaatgtcc aaactggatg aaattgctgc tcgacatgat attgggtacc 3061 acactgaaat aaaacataaa cataaccctt attactggta taacttttac gatgagcaaa3121 tggttaaaga aataaatgaa aacatgacc aaatagcaga ggaaggggaa tcctggctag 3181 caaactttat acttgctaca tggaaagcca aagctagctt tactaaccct ttaggtatat 3241 tattagaaca cttacaacca gattgggcta catactatga cccagcaaac acacatcata 3301 aacaatggat tgcatttcag cgtgccttaa cacagcacgg gacagcgtcg acggagcgac 3361 cgaggacacc tccgaccccg gacaacgaga tgtttccaca cttggctaaa cgaccccgac 3421 tagatgaacc taataaatct gcttcttgct ctacagacat gtcgtcctgt gaaatttctt 3481 ccacacaatg cacaaacgac gaagacatgg agctcaacca gactacagtc atggggatgc 3541 caagttcaac tacagacagc acaatcggga acactgggat ccagggcaca ggtgactgtg 3601 cgggaggcgg ggggggagcg caacgatgta ccaacaaatg gttaggggga atatcatgga 3661 cgcataacac atttaccaca taccaaacac gacgatgcat actgcaaccg tttacaaaca 3721 aatacacatt tacaagcagt gtagatagca caccaggaat tacagtaacc acaccatggt 3781 actacataga cttaaactgc ttctacagcc acattcctcc atctacaatg caagaaataa 3841 ttgaaactac agacggcttt aagccgttaa cattaacagt aacaattaca gaaattgtgg 3901 gaaaagacgt aagctgcaca actacatcat ctggggtgcc aaacacagtt acagactcac 3961 aaacagcaac tttgctgcta cacagggacg atcactacga actgccatac gtgattggcg 4021 gtggacaaga aacagtgcct gagcacttac caggggactg gtacaagctg ccacaatact 4081 gctacacaac cgtaggcatg gaaagtccat ggggtaactg gtcacaagcg cgaccagatg 4141 actgcgcagg aaacacctgg tcggttaatt gcacaaacta ctacagtaca caagacagtg 4201 aactatttct actagaaaac ttagtgaaca cacaactgca tccagggtgc tcctggacgt 4261 cacaatacca ctttccacac ttacctatgg catacactac acaatacccg tggagcacaa 4321 gacggcaaga caacccatgt caaaaacaaa gaatagtggc tgtacgaaac tgttgctcca 4381 caacaaatac agacgccaac aaacgccagg ttatagaggt agaccaggac caagcagaca 4441 tgggtttttt cagaaagccg acaatgtggt tgccggctaa cagacacaga gacggcgact 4501 gccaaatcat ccctcccaaa ggcagagaat accacgtact accagttaga tcaggactcc 4561 caccagtcat agttgtacga cagggaattt ttaacccact cccagcaagt ggtgtttttg 4621 gcttaacctc gggaacagaa cagccagggc caccgacaga agacaaagca gtcattacgc 4681 caggaggcac cacggtgctt acatctaaca cactaacggt gaaacgcaaa cacaaataca 4741 aaaaccaaaa ccacgacgtg cacacagtat acgaaggcaa acaagaacaa aaacgcctgt 4801 accaactggt ggtgcagcga gaaaggggag ttggaggacc agcagagccc aaccacgtac 4861 aagagcgaat tataggtagc accggggaaa aacttccggg cagcagatac ccgctacaaa 4921 gcgaaattac atacgggcaa cacacagggg ctgtagaaga gagtgagtcc gggttctacg 4981 aatttcaaat ctgggagaga aatccaaaca cagacctagg gaaaggggga cacaaaccac 5041 ccttagctca gtgggctatg gaaaagccac cgcctacaat atacctccga atgcttccta 5101 tgccctgtgc gccttgcaaa aacaaataca caaaaagtcc aggaatgaaa ggagttataa 5161 acagctacat tacatttcag ctacagtact ctatcaaatg ggcttatact cctaggaccc 5221 acaccagaag gtggaaccct accagtccag cacttcttcc accaccactt cctggttcta 5281 ccgtcgtgta caaccttgac tcccagaagt tcaccaccga caatcaatac accatcgcag 5341 cagaatcctg gcaattcaaa aacagattga gacataacag atgattacgt agttgttgtc 5401 atagctttta tgtccatgta cttttatttg atcttgttgt gtattttaaa tcaaaatgat 5461 ttgatttgat tttaacttaa tttgatttga tttgatttga tttgattgta tcacaaatat 5521 tcttgtgaaa gaaataaaga aaaagaaaac ccaagacatc cgagtgagct accacgctgg 5581 tgtcccgcgc ctttggcgcg ggacacccag SEQ ID NO:5: Bovine parvovirus 2, putative non-structural protein; Accession NC_006259 and YP_077175 1 msyytfvvti pdkiedygqa yydvvnrvtl thrdnekwvy dpedreiifk qaqvyvdcle 61 rrlkqmlvsg smynyfiqle qgekhkrwhi hvvldisvgn prncreviek veyeynsicy 121 grpvrqtqin rtsngswkie tedfiinyll ckippkeaky awtniknkig daclnidlrk 181 eisvrpdidv pmwrqasgdr mrdlvewcik nhvftedqym akfeesyysf actnqgrhml 241 qtslelaakr ttsmiplgvy lagfsniqea ieeanktefa diynnkvfdl lqfqgydpvv 301 agyiiyawsi ratgrrgalw fygpgqtgks imaramatcs vrygcvnwtn snfpfqdlat 361 ncqigwweeg vitedivesa kallsggkir vdrkcrdsve itpppfvits nndmtlvqgg421 nqvsfvhkkp ledrmikfnf nkrlpnfgi veredmkqff kwssfiyynk llpkeqayls 481 dpklighvvp ytsflrqtak vekivrpfee qeqedlaeld swfadppymg kppkkse SEQ ID NO:6: Bovine parvovirus 2, putative capsid protein; Accession NC_006259 and YP_077176 1 maaklggglv geaaihries lsgkvhykdk ywfpdnyvyt tgnqeeedki vakllldpna 61 pvkewgngrw sfeygpewrr lgfiphtddi nyrglsyhka pgtqllegih eippeqkqgp 121 esitqiappt qdsvllepmt ndphykkpkp pgdlgdipkp ltpwqlanki gpdyarqllt 181 msghdftgrt ppvqipdpgi reglkeleeq sklmervqag egdekprggl tlpkhryvgp 241 ggdlpagrpm skldeiaarh digyhteikh khnpyywynf ydeqmvkein enmdqiaeeg 301 eswlanfila twkakasftn plgillehlq pdwatyydpa nthhkqwiaf qraltqhgta 361 sterprtppt pdnemfphla krprldepnk sascstdmss ceisstqctn dedmelnqtt 421 vmgmpssttd stigntgiqg tgdcaggggg aqrctnkwlg giswthntft tyqtrrcilq 481 pftnkytfts svdstpgitv ttpwyyidln cfyshippst mqeiiettdg fkpltltvti 541 teivgkdvsc tttssgvpnt vtdsqtatll lhrddhyelp yvigggqetv pehlpgdwyk 601 lpqycyttvg mespwgnwsq arpddcagnt wsvnctnyys tqdselflle nlvntqlhpg 661 cswtsqyhfp hlpmayttqy pwstrrqdnp cqkqrivavr nccsttntda nkrqvievdq 721 dqadmgffrk ptmwlpanrh rdgdcqiipp kgreyhvlpv rsglppvivv rqgifnplpa 781 sgvfgltsgt eqpgpptedk avitpggttv ltsntltvkr khkyknqnhd vhtvyegkqe 841 qkrlyqlvvq rergvggpae pnhvqeriig stgeklpgsr yplqseityg qhtgaveese 901 sgfyefqiwe rnpntdlgkg ghkpplaqwa mekppptiyl rmlpmpcapc knkytkspgm 961 kgvinsyitf qlqysikway tprthtrrwn ptspallppp lpgstvvynl dsqkfttdnq 1021 ytiaaeswqf knrlrhnr SEQ ID NO:7: Porcine parvovirus 4, complete genome; Accession NC_014665 1 tgtttttgaa aagcgccagg cctctcgccg gtcgcccctg acgtcacatc cgcttccggg 61 tcaaagggcg gggtcaaagg tcaaaggtct tcatacgtca tatccgcttc cgggtcatga 121 cctttgaacc ggaagtaccg gaagtgaccc ggaagtaccg gatgacctct tgcgcaatct 181 ctgagaaaga gagaatcttt ttcgagtgtt gggcgacgcc ggcctgctaa tcaatacact 241 agagggcttc gccatctttg acagatatgt tgcagtcaac ttccgggggt gggacttccg 301 gggtcaaagg tcacttccgg gtcaaaggtt gtttttccgg tgacgtcacg ggatgtgacg 361 cagtacagac cgacgagata tttggcgctt ttcatacgtc atttccggag gaggagttca 421 tttgcataat ttatgcaaag taggaggagc taattagctc ttcccacttt gcataaatta 481 tgttaatgag atgctaatta attaatgcaa agtaggagga gcttattgac ttctcctact 541 ttgcataatt tatgcaaatg agatgtaaat taatttatgc aaagtaggag gagccttttt 601 tgattggacg gggcttcaaa tccattaatt tgcataattt atgcaaagag gaagttaacc 661 tgattggtca gtttttttgg cgggaagcaa tttgattgga cgggaactta agtcctaatt 721 tgcattgacg tggaccaatc agaattgagt acatattata taaggagggc gaaaaagagg 781 aagtttgcca tttgcgtttt ggagaccgtc gcgagcagaa ctccgtcgtt ttcggcctgt 841 atttgaagat ggaaacctac tggacaggta tttgcagact ttttcctgat gttttaaaaa 901 tacctggtgt ttatgaagga cgctatattt ttgaagttcc tgtttctacg cgtgattgca 961 tgaaatggcc tgatatattt ggcaacgaga ataatagtga aaatcaacag tctggcgcgg 1021 cgcctccggc gccgcgcgaa aatcttagta gtaatctggt aatcgctgtt cggcaggcgg 1081 aggctttgtt tagagagctg cagaaagagc ttagaaaatc atgtcgttta ggggtagatc 1141 ctggcatttt tatgcagtta gaagaagtag actcaaaagg tggcttgcac ttgcattggt 1201 gtgtgtctgt gtccgctggt actccgcggg atgtgcttac aattttcaaa aatacagaga 1261 agaaggtctc tctgtactat tttggggtgg agggtctgag cttctttgtg ccccataaga 1321 ataaacacgg ggcctggaag agcacggacg agggctttat ctacaactat ctgcttaaaa 1381 aactgccgct gaaagagtgt ttatatgctt ggaccaccat cggtggagcc atcggtgatg 1441 cttgcctaaa tactgataag agaaaggagt tgctggataa tagacaggac ccagcggtga1501 tcgaagagct ctcagctccc atgtaaaat gtgccaccgg ggagaaaatg cttgatatcg 1561 tgcagtggct ggtggataac aacatctgct ctgagagcag atgggaaaat aagaatgctc 1621 taagtctata ctcgtttctg gccacccaag caggtggata catggctaaa cagtgtctga 1681 gaatcgctca gcaaaagtta ttaaaagaga aacccctggg gttgactctg atggatttca 1741 aggatatgaa tgctctgcgg cgctttcagc aggatgaggg ggaaatgact tttgacaata 1801 acagaatgca ttatatcttt gccattaaca actatgatcc taaaattgct tcggtgataa 1861 tgtacttttg gagcatgaaa caaacgggaa agaggaactg tgtgtggttt tacgggcctg 1921 ccacaacagg aaagactaac atggctcaag ccatctgcca cagttctgca aactatggca 1981 atgtgaactg gaataatgca aatttcccgt ttcaagatat cgcgggggct caggtagggt 2041 ggtgggaaga gggaaagatg actggtgata tggtcgaagc tgctaaagca ctactggggg 2101 gaactgcttt gcgaatcgac cgcaagtgca tgcaatctat tgaggttaac agtccacctt 2161 tcctcataac ctcaaatgtg gacatgacta ttgtacaaga gggaagtttt gtaagctttg 2221 aacatcagca accattagag gacaggatga taaagtttag ctttaatatg accctgccgg 2281 gcaattttgg tttgattacc agtgaggaag tgaaatcttt ttttcggatg ggagctaaac 2341 ttgctgcgca accggacatt atgaactgcc ctatatttaa aaaaggacct gccagtatta 2401 gacatttagt tcctgttgga gagatcccac ccccaaaaga aatgaagcat aaaaggcagc 2461 cactctacat gagagcggaa ccagatgaaa ttcaagacaa tccagaagaa ctggaccact 2521 ggttcgaaga agaagcaccg agaaagaaga aacagaaaac aaaaaatact gcaactaaga 2581 accctgctga gacggtggag attataactg agactgaatt catccctgca ccaggtaaga 2641 gatgagtact tatttactat cagaataaag gataaactgt acccagcagt agttgataag 2701 tgcccctctc ttacagatac acagccacaa ctggtgtttg acatccagtt agaagaggaa 2761 gcagaaattt cagatatcat cggagaacaa taaaatgttc ggcggacaag gtattatacc 2821 gatactaaca tgggagcaat tagaagcttt tatgtgggct gggcaaggaa tgtcaattga 2881 ctattacaga agctgtttaa gcgattgtat gctatttggg gaaaaattta acatccatat 2941 gccaaaaaca aaaaatttat tattagaagc tgaataccta tatagacttt ttcacagtgg 3001 ttttgccaat agtgcacaag gtttcagaga aagagtagaa agatggagaa cagaaagcaa 3061 actgagatgt ccccaatttg atagacccat ggatgcctca caaaggcatg catacttagg 3121 atttttctat caagccctca gtaaattgcc ggaaaatgcc tctgaggaag atattctgca 3181 gaccatacat gattctgatg acaccagtaa agaaaaattc tatgcattta tggaaaaaat 3241 tcagcaagaa ccagaatatg tgtttaaaga gcctgatagc attccgcaac cagaagctcc 3301 tgttacagca gttccggttg agacatcacc aactgaaaac aggtaccttc tcttacacat 3361 caagatacta agaaagacaa ggtggaggaa cgtttgcctt gtcccttaga tttttgtgat 3421 gaacattggc agggcagaca cccgctagga ttcaaggaag aagaagaaga aatacaaaaa 3481 gaaatagaag aagatagaag agaagaaaca gaaacaatcg aaaaagcgca acagggtgaa 3541 ggagaacatg aaaagggagg actcacctgg cccggtcatc gctacacagg tccattcaat 3601 cctctccctc atggaaaacc tgctgatcaa cttgacgaag cagctcttcg acatgataca 3661 aggtacaaaa caatgcagaa acacggtcac tggcctcatt tatgggcacc atttgttgac 3721 agacagatga gccaagaaat tcaacaggtt ttaaaaggtt ctacaaaact gagccaaaaa 3781 ctacttgcaa acttcatcat agcactatgg cgagcaaaag aaaaaatagg agctcctata 3841 tatgagattg taaaaggggt ttttccaagt gttgataaaa aaactgttga aagcctttta 3901 ccgcaccctg accctatacc tgctcctcca tcttctccac agcgaggatc caaacgtgca 3961 tctcctcctc agagtcctaa tgcacatgat gaagatacaa tgagcgggca caagcgtcag 4021 aaaactatgg aagtggaatc tgaatgtgat aagtctttgc tttgtccaac gcagaatgct 4081 ggagctgatt ttgagctttg cgggacggga gggggggcaa ctaatgagaa agggacatgg 4141 gtgggaggga cacaatttac cgatacatct attaggacat ttggtactag aagatgtgtt 4201 ctctcagcgt ttcctgacac ttactgttct atgatgtctg gagacgctat accttctatt 4261 atttttaata caccatggta ctattatgat ctaaacatta tgtcctgcca tttctctcca 4321 agtgcttttc aaactttaat tgaagattat gatgcattta gacctagatc gctaacagtt 4381 catttaaaag agcttgtaat aaaagatgta tgtcagcaac aaggtttaca agctgagcag 4441 gtatctgaca ataactctgc tacactgctt gctttcgaag atgttaatta tgaacttcca 4501 tatgttttag gtggtggtca agtatctgtg ccaggacatc taccgggaca accatatcaa 4561 ctgccaaaat actcatacag aactgttgga aaaccagacc caaacagcgg cttcgtgccg 4621 ggaaggaaca cacatccaga tcaaggacca ggacatccaa aagcaagtaa aacaatttgg 4681 tactcgcaat atttagaaac ccaagacacc gaattctata tattagaaaa ccacaaagca4741 acaattttac actctggaaa tacatttcc caaaattaca attttcctga tctgcctttt 4801 gagcagttga cacagtatat gtgggatgca cggaggcagg acaatccatt gatagatcag 4861 agaatacagg tgatgagcag aatgtatgat gacggcccac agaaaacatt tgctatcgaa 4921 gtgaacccat acattgtacc attcacagta aaaagcacca gcagaccagc tatgttctta 4981 gcgggaggaa gatttaaaga tggtgattat tcaataacag gtccaggaga tagagaaaaa 5041 acgagtttca gatattacaa tgatcctcca tggatcatca ccagagatac ctatctcttc 5101 tccagcgatt tagctaaaac tgaaagagaa cagccaggac ccagacaggg agacacagta 5161 gttaggaccc ctgatggaac actgatagtg actactaatg cattagctta tgggtacaca 5221 acagaatatc taaaaaacat tccgcttttg agttccaaat accatggggt tgaaaacttc 5281 agactagctg ttgaaaatga aagaggatat tcaatgccag gtcacccgtc acatatcaga 5341 gaaacattat tcagaggtaa actgccaagt gggataaggg aatcaactat taaatcagag 5401 gatcaaagaa aagaaataac atttccagat tacatgggtt ctgtaaatga aaaaacaaca 5461 gcaaatttag aatcgcagat atggtctcag ataccgaaca ctgatatcac tgaaaaatgt 5521 acaacaccac cactatccat ttggggtatg aaaaacccac caccgatggt tttcctgaga 5581 ctcctggcac agatgggacc accaagaaga agcgcctgca gcggatccat tccaagcaat 5641 acatatttga accaatattg ccaatttttg cttacatatg aaatggaatg ggatgttatt 5701 aaaagaacca ggaaaacggt gaggtggaat ccaattcctc ccccgcaaat tccgatggga 5761 cctaacaatc ttcctgttta tattttgaac aaagagggac aatacagaat gccgacggaa 5821 gtttggaccg caaaacagag acccagacac cgcagatgat atcaataaag tttttgaaat 5881 taaaaaaaag acttcctctt tattg SEQ ID NO:8: Porcine parvovirus 4, replicase (NS1, or nonstructural protein 1); Accession NC_014665 and YP_004013956 1 metywtgicr lfpdvlkipg vyegryifev pvstrdcmkw pdifgnenns enqqsgaapp 61 aprenlssnl viavrqaeal frelqkelrk scrlgvdpgi fmqleevdsk gglhlhwcvs 121 vsagtprdvl tifkntekkv slyyfgvegl sffvphknkh gawkstdegf iynyllkklp 181 lkeclyawtt iggaigdacl ntdkrkelld nrqdpaviee lsapmykcat gekmldivqw 241 lvdnnicses rwenknalsl ysflatqagg ymakqclria qqkllkekpl gltlmdfkdm 301 nalrrfqqde gemtfdnnrm hyifainnyd pkiasvimyf wsmkqtgkrn cvwfygpatt 361 gktnmaqaic hssanygnvn wnnanfpfqd iagaqvgwwe egkmtgdmve aakallggta 421 lridrkcmqs ievnsppfli tsnvdmtivq egsfvsfehq qpledrmikf sfnmtlpgnf 481 glitseevks ffrmgaklaa qpdimncpif kkgpasirhl vpvgeipppk emkhkrqply 541 mraepdeiqd npeeldhwfe eeaprkkkqk tkntatknpa etveiitete fipapgkr SEQ ID NO:9: Porcine parvovirus 4, ORF3 protein (NS2, or nonstructural protein 2); Accession NC_014665 and YP_004013957 1 mfggqgiipi ltweqleafm wagqgmsidy yrsclsdcml fgekfnihmp ktknllleae 61 ylyrlfhsgf ansaqgfrer verwrteskl rcpqfdrpmd asqrhaylgf fyqalsklpe 121 naseedilqt ihdsddtske kfyafmekiq qepeyvfkep dsipqpeapv tavpvetspt 181 enrylllhik ilrktrwrnv clvp SEQ ID NO:10: Porcine parvovirus 4, capsid (CAP) protein; Accession NC_014665 and YP_004013958 1 mqkhghwphl wapfvdrqms qeiqqvlkgs tklsqkllan fiialwrake kigapiyeiv 61 kgvfpsvdkk tvesllphpd pipappsspq rgskrasppq spnahdedtm sghkrqktme 121 vesecdksll cptqnagadf elcgtgggat nekgtwvggt qftdtsirtf gtrrcvlsaf 181 pdtycsmmsg daipsiifnt pwyyydlnim schfspsafq tliedydafr prsltvhlke 241 lvikdvcqqq glqaeqvsdn nsatllafed vnyelpyvlg ggqvsvpghl pgqpyqlpky 301 syrtvgkpdp nsgfvpgrnt hpdqgpghpk asktiwysqy letqdtefyi lenhkatilh361 sgntfsqnyn fpdlpfeqlt qymwdrrqd nplidqriqv msrmyddgpq ktfaievnpy 421 ivpftvksts rpamflaggr fkdgdysitg pgdrektsfr yyndppwiit rdtylfssdl 481 aktereqpgp rqgdtvvrtp dgtlivttna laygytteyl knipllssky hgvenfrlav 541 energysmpg hpshiretlf rgklpsgire stiksedqrk eitfpdymgs vnekttanle 601 sqiwsqipnt ditekcttpp lsiwgmknpp pmvflrllaq mgpprrsacs gsipsntyln 661 qycqflltye mewdvikrtr ktvrwnpipp pqipmgpnnl pvyilnkegq yrmptevwta 721 kqrprhrr SEQ ID NO:11: Porcine parvovirus 6, complete genome; Accession NC_023860 1 gcgtgagaga gggcgttttt catttacgtt ttgatgacgt tgctgttctc tgattggtta 61 gtttttcaag tcctcatttg catatttaat ggaccaatag gatttacttc tgctttttat 121 ggtataaaag ttcgtacttc tgctttttcc ctcattctgt gctttggagc tgatctgttt 181 agatcttttt gcttctctgc gccgaaagcc tctgtattat gtctcagacc ttctggacgg 241 gtatttgcag gcttttccct gatattggga agattcctgg ggtgactcct gagcggtata 301 tttatgctgt aaacgtgagt acccgtaatg ggcaaaagtg gccgaaagtt gggaccgagg 361 ggccattggc tgcaggtgtc ttacaggggg aggccctttt ccgtgagacc cttaaagagg 421 tccggaaggt gtgccggctg ccgcaagacc cccatctttt ctttcaattg gagaaagttg 481 attccaaagg gggtcttcac cttcattttt gtattagtgt tgctgctggc actcctagag 541 atgtgtcttc gatgtttaaa gccattgagc gtcgagtttc cttttactac tttggtgtag 601 agggcttgac tttttttact cctcataaaa ataagcatgg ggcttggaag agtaatgatg 661 aggggtttat tgtgaattat cttcttaaaa aattgccttt gtctgagtgt gtgtatgcgt 721 ggactaatat ggatggggtg attggcgatg cctgtctgaa tgaagataag cgcagggaat 781 tgttgtctga gcgtcaagat cagggagtca ttaaagagct cactgctcct acttttaaag 841 cggctacggg tgataaaatg ttgagtgtgg tggattggat gtgtgataat gatgtgacta 901 cggagcgccg atgggaggaa atatcggctg cgtccctgta ctctttcctt gctaccccag 961 ctggcactca tttggctaaa cagtgtctta gagctgcgaa tcagcgtatt gtgagcacta 1021 aacctcttgg tttgagtctc tgtaaatttg ccagtgaaaa ggagcttcgt gcttttcaaa 1081 atggggatcc tgagttgtct tcagacaaca ataggatcta ttacttattt gctatgaata 1141 attactgccc tgatatggcc agtatgattt tcttttggtg gtctatgcgc caaacgggta 1201 agagaaacag tatttggctg tttggacctg ctacaaccgg taaaaccaat ttagcaagtg 1261 ctattgcaca tactgctgcc agttatgggt gtgttaactg gaataacgca aatttcccgt 1321 ttcaagacat tgtgaatgtg caactgggtt ggtgggagga aggaaagatg acagaggatg 1381 tggttgaatg tgctaaggca ttgctagggg gaagtaatgt aagagttgac cgcaaatgta 1441 tgcaatctgc ggaagtgcaa tctcctcctt ttattatcac atccaatacg gatatgtgcc 1501 ttgtttctca aggcagttac atcagttttg agcaccagca gcctctccag gatagaatga 1561 ttaaatttga gtttaaccat gttcttcctg gcaatttcgg cctcatttct gaagatgaag 1621 tcgtggcctt cttcagaaat ggtgcttata atgtgttgaa gcatgcgtac atgagaaagg 1681 cccagctttt tgctctcggt ccagcttcct tgccatataa gccccctacg ggtgaattag 1741 tgtgtataga ccaagctaag tctccttctc cctctgcttc tcgccgcagt gtgagaaatt 1801 ggatgacgtg tccccctgat cctgtccagg acgatcccgc tgaactggac gagtattttc 1861 ctccagatac tcctccagag gattgtcctt gtcctatttc tcctgtgagg gagtcttgtc 1921 cctcgccagg gccttgccct acccctcctc gcaaaaaaca acggaagagc aagcattgct 1981 ccttgtctgt ctctgcgggt aaagttcctg tggtggttgt gggtgattct gactcagtcc 2041 cccccgaaga aaaagaaaaa gaggaagttt ccgtggggga ttcccaggat ccacaactgt 2101 actgggacct aactctcagt caatccgacg ttcctgtgcc tgaagacgag agtacccagt 2161 ttcctgacga cgctgtggac gcttctgatc tcattgctga acagtagtta aggtatgagc 2221 cgttctactc aaagagatct ttggtctttg ttaagggaga gacttgaaac gtataaggat 2281 cgagttaaat attatggtat tttggtgcca gaacgtcctt ctacctttgc atcttatttt 2341 agtaaagacc cacctccaga tcctccaact gttaaatttg ataaacccta tcaggatgta 2401 gatagattct ggtttccaac agacgactat actgactggt atgtctggca tggagaggac 2461 agacctccta gatttaccga gcattccggt gttcagggtt ttaaaactag gtgtgagggg 2521 gggcttcctt taatccccag tgatcccaaa ttttgcccca tacaaaattt ttgggatcag2581 ttcgctaatt ttaatgaggg gtctcgtcc ccccagatcg gtgagagtgt ttcatggagt 2641 gatcattttg gaagtcccga tccctctcat catcaggagg tgagggatgc tgatgaagta 2701 gtttcagagc gacagcaata taaaaatagg attgtcacct tattaagaaa agtttattgg 2761 gctaagcagt ggtctgggaa attacaaatt aatgttcctt ccctcgaaag cctttatgag 2821 cagatcccct atatgctagc ctatatggac gctgataatt ggcgtcagaa tttgttagct 2881 gctaaaactc tgcgaaccac tttggaagca ttttcctgtg ttccagatcc ttccacgtgc 2941 gatgtcacaa tctccacacc cctatctggt gaaacggatc ccgcctcttt tgcaaaatac 3001 ttatgttccc ttgtatgcaa caggtctcaa gaaaaagaac aggcgcagac gccttctttg 3061 tctccatcta aacaagaagg gcagatgtca agtcctgatt ctgcatcgat ctcccaacct 3121 ccccccgaaa gtcacaagga tagactgctt cctaaaactg atccccttca ggaagcaggg 3181 ccccttcccg ctccccccac agctcagaag cctattatct ctaagggtgc aggcggtgga 3241 gggtcgtctg gcttcataat ccctccaaaa cctcctagcc ccgatcatac taaagatccc 3301 ccccctcctc ctcctccctc tccaattcct cctcctacat ctgcgcctga cgcagaggag 3361 cacgagctag agcgtgctaa gcaggagaaa caagaggaag atgagctcat gcaaagaatc 3421 aaatcaggag aaggagaagg agaacgagga ggcttcgtct tgccttctca ccactacact 3481 ggtcctagaa atcctgtccc agctggcaag cctgctgacc ccgttgatga atcttctgcg 3541 agacatgaca tcaggtatgg gcaacgtctt aaacatggag actggccata cctgtggggg 3601 aaggacttgg ataatgctca gcgagatgag attatcaaag ctcttcatag tcatgtcaaa 3661 gtgggaaccc aattggcagg gaatatagtg aggagtatct ggaaggctaa ggagctctta 3721 acagaacctg tgtatgagct gttaaagtct attctccctc cttcagattt atctaaagtt 3781 cctcttcctc attcccaaca gacagacaga acagaagatc cagaaactcc aggggagact 3841 agaggaactg gatcagacag tcctcgatct cctcggcctt ctggatcaac tgaagacggg 3901 ggaggtcctt cttccgagtc cagattacct gggactaaag ttccagtaga cccatctgcc 3961 accacgtccg aagcaaagag gcagaggact gaggagggga tggacatatc ttcttgctgt 4021 ccagggggga tttctgcttc tggggctgct tcaaataact ctggtcttgc ttgtgggggt 4081 ggggggggta ctaatttagg gacagaatct cttgtatccg gctgtcagtt tggtaaaaac 4141 tctgtgatca cttcatcttt tagacgatgt cttatttcac cctggcctga taaatactgt 4201 tgctcttctg ctcatgatct tattcctgga gtggtctacg agaccccttg gtgctattat 4261 gatctgaacg tcatctcagc ccatttttct ccttctgctt ggcagaggct tctagaggat 4321 tatgatgcct ttcggcctaa atcccttaaa gtgaccatcc agtctctagt gtttaaagat 4381 gtttgtcaag gagcagaaaa acaaacgacc gttcaggatt cccagtcagc caccatcgct 4441 atctttgagg ataaagacta tgactacccc tatgtgatgg gagggggtca gaaaacagtt 4501 cccggtcact tgcccggtca gccttacaat cttcccaagt attcttacag aacccttggt 4561 tccgtcaaag aaagtaatag ggccagtatg ggcggttcag ggtacacttt caaatccaat 4621 caagacacgg aattgttcct gcttgaaaca catgatgcta ctcttattcg aggcgggggt 4681 acttttgaac agtactatga atttccaaac gatcttcctt tcgaaaattt gactcagtat 4741 ccttgggata tccgccgtca ggataacccc ctctatcagc agaggatcac tgtcatgtca 4801 ggttctgaca gagatcaggt aggcattcta gatggagatt tttactctcc ttttcggttc 4861 aaaggtcatg atagacccgc catgtggctg ccaggacaga ggttgattca gggcaaattc 4921 atagatacgc atccaatacc caatacaggg aggagtgggg ttcatcctaa tgattttcac 4981 acaaggggtg atggtcatgg ggatacccat agaacacatg aagagaggat ttacagtcta 5041 gatacaggtc ttgctgctat gccacgtgcc gctcatagac ccacccttca gcccggacct 5101 aggactctgt ctcatgccgt acgcagaccc gatggttcca ccgtggtcac ggctaatgcg 5161 tgtgcttacg cttacaccca ggagaatcct catcaggaac cctggagtga tctcaatgtc 5221 agacatacca tgtataggtt agcctatcaa cgtcaaaaag gttttcagca acccggggac 5281 cctcttcata ttcgaaccca tgcttgttat ggggacgggg atgttaccat tccaaaagaa 5341 gagtccttat ggcctactgt tctgggtagt tgcacagaaa agtcccctgc ctgtttagag 5401 tcccagattt ggtgtaaaac accaaatgtg gacatggtct atggagaaca cacaccccct 5461 cttgctttat ggggtatgca tgctccccca ccccatgtat ttctcaggat gcttgctcaa 5521 gagggtcctc ctaatgtcag tacttgcaga ccggctcaat ctggtcagac cttcatcaat 5581 caatatggtc agtttctcct ctgttttacc atggtatggg aagttaagcc tagacccaag 5641 tccatcaagc agtggaatcc acgtccgccc atcagcattc ctgttggtca gtctggtcct 5701 gctttcattc ttgatcaaga tggctactac cgtctcccag aacatgtctg gtctgccagg 5761 gaacgtatcc gcagcaaacg ctagtgcccc cagcaataca cttactacag tattgatgtg5821 tcaggcattc tggttgattg ttttatttg gctccgccta ctgtatggcc catgtaaacg 5881 catctattat gaaaataaaa tacgtcaatt tctgatgtaa ttcgtgttgt gattcttcct 5941 tgaaaagcgc atattttctt gccggtctga gtgacaccac ctatgacatc atataaattt 6001 gattacgtaa cttcctcttt ttacttcctc ttttttgatt acgcaatatc acaattctag 6061 cagtcgacta ttacacaata tcacactttg agaccctgac catcacactt ttattttgtg 6121 cgcgagatgc gagcatgggc cgcttcgc SEQ ID NO:12: Porcine parvovirus 6, nonstructural protein (NS1, replicase); Accession NC_023860 and YP_009021566 1 msqtfwtgic rlfpdigkip gvtperyiya vnvstrngqk wpkvgtegpl aagvlqgeal 61 fretlkevrk vcrlpqdphl ffqlekvdsk gglhlhfcis vaagtprdvs smfkaierrv 121 sfyyfgvegl tfftphknkh gawksndegf ivnyllkklp lsecvyawtn mdgvigdacl 181 nedkrrells erqdqgvike ltaptfkaat gdkmlsvvdw mcdndvtter rweeisaasl 241 ysflatpagt hlakqclraa nqrivstkpl glslckfase kelrafqngd pelssdnnri 301 yylfamnnyc pdmasmiffw wsmrqtgkrn siwlfgpatt gktnlasaia htaasygcvn 361 wnnanfpfqd ivnvqlgwwe egkmtedvve cakallggsn vrvdrkcmqs aevqsppfii 421 tsntdmclvs qgsyisfehq qplqdrmikf efnhvlpgnf glisedevva ffrngaynvl 481 khaymrkaql falgpaslpy kpptgelvci dqakspspsa srrsvrnwmt cppdpvqddp 541 aeldeyfppd tppedcpcpi spvrescpsp gpcptpprkk qrkskhcsls vsagkvpvvv 601 vgdsdsvppe ekekeevsvg dsqdpqlywd ltlsqsdvpv pedestqfpd davdasdlia 661 eq SEQ ID NO:13: Porcine parvovirus 6, capsid protein (CAP); Accession NC_023860 and YP_009021567 1 msrstqrdlw sllrerlety kdrvkyygil vperpstfas yfskdpppdp ptvkfdkpyq 61 dvdrfwfptd dytdwyvwhg edrpprfteh sgvqgfktrc egglplipsd pkfcpiqnfw 121 dqfanfnegs pspqigesvs wsdhfgspdp shhqevrdad evvserqqyk nrivtllrkv 181 ywakqwsgkl qinvpslesl yeqipymlay mdadnwrqnl laaktlrttl eafscvpdps 241 tcdvtistpl sgetdpasfa kylcslvcnr sqekeqaqtp slspskqegq msspdsasis 301 qpppeshkdr llpktdplqe agplpappta qkpiiskgag gggssgfiip pkppspdhtk 361 dpppppppsp ippptsapda eehelerakq ekqeedelmq riksgegege rggfvlpshh 421 ytgprnpvpa gkpadpvdes sarhdirygq rlkhgdwpyl wgkdldnaqr deiikalhsh 481 vkvgtqlagn ivrsiwkake lltepvyell ksilppsdls kvplphsqqt drtedpetpg 541 etrgtgsdsp rsprpsgste dgggpssesr lpgtkvpvdp sattseakrq rteegmdiss 601 ccpggisasg aasnnsglac gggggtnlgt eslvsgcqfg knsvitssfr rclispwpdk 661 yccssahdli pgvvyetpwc yydlnvisah fspsawqrll edydafrpks lkvtiqslvf 721 kdvcqgaekq ttvqdsqsat iaifedkdyd ypyvmgggqk tvpghlpgqp ynlpkysyrt 781 lgsvkesnra smggsgytfk snqdtelfll ethdatlirg ggtfeqyyef pndlpfenlt 841 qypwdirrqd nplyqqritv msgsdrdqvg ildgdfyspf rfkghdrpam wlpgqrliqg 901 kfidthpipn tgrsgvhpnd fhtrgdghgd thrtheeriy sldtglaamp raahrptlqp 961 gprtlshavr rpdgstvvta nacayaytqe nphqepwsdl nvrhtmyrla yqrqkgfqqp 1021 gdplhirtha cygxgdvtip keeslwptvl gsctekspac lesqiwcktp nvdmvygeht 1081 pplalwgmha ppphvflrml aqegppnvst crpaqsgqtf inqygqfllc ftmvwevkpr 1141 pksikqwnpr ppisipvgqs gpafildqdg yyrlpehvws arerirskr Within this sequence (SEQ ID NO:13), X at position 1034 represents D or R.SEQ ID NO:14: Roe deer copiparvovirus, complete genome; Accession NC_055518 1 cccggacacg gaactacgtc accggatctg gaaacacgtc accggaaccg gatttacgtc 61 aggaacacgc gaggatagag aatatatact cgtcttataa tagggttttg tcgagcagta 121 gacctcatcg acgctttgcg tcgatgacgt cgttcgctcg acaaaaccct attataagac 181 gagtatatat tctctatcct cgcgtgttcc tgacgtaaat ccggttccgg tgacgtgttt 241 ccagatccgg tgacgtagtt ccgtgtccgg gttaaaggga gtccttccgc cgggacggag 301 ggtgcgtgcg tctgacgttt gttgcacacg acagcaagag ggtggttact ttttcttaat 361 tttgtggtta tattcaagaa ttcctttttt ggtcgggtgg atcgcttaat tagcaatgaa 421 tattcatcta aatggtgatt ggtgtgaccc gattccgtcc ggggtggagc taagggtata 481 taaactcgtg tacttcctgg atttttcagt tggagttctg ctttctttca gcgcagaccc 541 tcgttcgggc aagtacatga tttattcttt tatttcaatt aataaaactc ctttttcttt 601 aaatacagca atattaataa ttgttttaat tttaattgtt atttgtactg cattcttata 661 cttattagga tggctctgta ttatacagcg actatcacgt taccagatga tggcaaggcg 721 tatggacctg cccatcataa taatgtgatg tgcactatta ttaaacatag aaataatgaa 781 caatggacct atttacatga tcctgctgaa tatgcatatc atatgtgctt ggggcagatt 841 tatgtaaata tgcttgaatc tcagcttgag caggcgcact ttgccggtgc taactatgaa 901 tactttgttc agctagaaaa gggtcctcag aagaaaagat ggcatttaca tatcgtggtt 961 gatatcagta ttggacagcc tcgtaaagct agagagctgc ttgaaactgt tgagcgaatg 1021 tattccaact tagcctttgg ccgtactatt cgcactcttg atattaacaa ggagagaaat 1081 ggcagttgga agatagaaaa tgaggacttt atcattaact atctctgtaa aaaaatacca 1141 gtaaagggct gcacattcgc gtggaccaat attgaacgcg aacctattaa aagtatgtgc 1201 ggcaatattg aagctagact acagcagcat gaaaacatag atgaaaatat tcctatgttt 1261 aaacaagcct ctggagaaaa actagccaaa ttggttgaat ttatgattaa aaataagatc 1321 acagatgaac aaagatattt gcagaagtat gaagcttcct tctttagctt ttatgcaacc 1381 gttgccgggc aaaccatgtt ccgcaatgct ttgcaaattg caaaatctcg cattgcttca 1441 gacataccgc tgggtgtgtg gcttgcaggc tttacttctc taaatgagct gattgacaaa 1501 caagtaggag tgaaatctat ggaattggga aatagtaaaa ttaatgaaat tatggtgcaa 1561 aacagctata acccaatcgc agctgcttat gtcattgctg cttggtcaat gggcatgact 1621 ggacgcagaa gagcgctatg gctgtatgga gatcctcaaa caggcaaaag cattatagct 1681 cgtgctattg caactggtgc tgctagcttt ggatgtgtaa attggaccaa tgaaaacttt 1741 cccttccaag atataattgg cacttgtgtt gcttggtggg aagaaggcag aattacagag 1801 cctattgttg aagtcactaa agccctaatg gctggaggta ccatcagagt agatcgtaaa 1861 tgcagagatt ctgtagaatg taaacctcct ccatttatta ttaccagcaa ccaggatatg 1921 actttagtct attctggcaa tactatcagt tttgaacacc agggtgcgct gcaggatcgc 1981 atgatccaat ttaaatttac taaaagactc cctccagatt ttggagaaat tactcaggat 2041 gaaattaatg cctattttaa atgggcaatg tatatctata ccaacaaact ccttccatca 2101 gaatataagc attggactaa tcccactagc attggcttta tgatccaaaa acaatcaggt 2161 gtagttcatc ataccctcgt agaaagaatt gaccatcctt ttgaagaaga agaacgagaa 2221 gctcttgccg aactcgattc catgtttgaa aatgactcag acaaagaaaa tcaagacccc 2281 gagatggaac tgccccctcg caaaaagaaa aaagctctgc cggtaaggaa gagcgcatca 2341 ttactcagtg tattatttat ttatttaaat aatatactaa tgataccctc tttcttagct 2401 cccagaaagt ccaatatcgg acggcgctga ggaggttgac tcaactccaa cagcagggcc 2461 ttctggtctt gcatctatta gcagcatcga tccacaacca cactcatctg gaagtggaat 2521 tacccgctcg gataacatta tagaggacgg aatcattgaa ggagatatcc aagaagagct 2581 catcaatcca gattacaaca acaaaaacca gctaaaagaa caccacattt gctacaatca 2641 agagtgcaga gattacccag agtgccccgg gtggaagtaa gtactttaaa atttatattt 2701 acacacatct atacatacac atccctgata tacatttctt tcttaggtcg ttgctgtgtg 2761 acgaactcac cgagctgaca gaggaggaag tacttgcctt ctttgacagc gatcaggttg 2821 cagaacaatg acagatagag cccgtggaga aggagggagc agcatagctt tgcatttagg 2881 agaaacattt aaactgctta tagatcataa atataatact catcctgata ctgaagcata 2941 ctatacagat tctagtggtg ccaaatatga aaaacgtaga tatatatttg tgggcgcaga 3001 tcaagataca gaacaagcct gggctgatca gcaagcatat aataaactac ctggacaaaa 3061 aattaagggc ccacacggaa aatgggccgg ttggactttt cccaatcctc ctgatgatgt3121 ggtatggccc gaatcatcat tggacccac tagatctcag cctgatccac gtccaactcc 3181 cactagtcca cctacacaac agtttaattg gactggcgga ggatggccaa ctaacacaga 3241 attaccctct tctaatgttc ctcagatggg tattgggtca cagggcaatg tacaatttag 3301 cccaatgaca gcagacgaaa ccacgattga acgtgctaaa aatgaagggc accccattcc 3361 accaatcaca gaaagcccag aaatagcaca tgacctagaa acccttgaac atgaaaccga 3421 ggaatcagaa ttcaatatgc agcttattaa acaagctata gcagagacac atgatagcga 3481 agatatagaa actagagcta aagatggaga aggagctgat caaacttccc tcacggtaca 3541 tggcagatat gtcggaccag gaaacccgct tccggcaggc aaacccagct ccaagttgga 3601 tgaaattgct cttcgccatg atatcaggta ccatgttgaa ttaaaacata agcattggcc 3661 atatttaact tatcaatatg ccgataaaat aatgattgat gaaatcaatc aaaatatgga 3721 acaaattaaa caagaaggta atgaatggct agccaacttt atcaaaagtc tttggactac 3781 acaaaaatta tattcagctc ctatcggagt tttattagaa aatataattc cagaaatggg 3841 ctggtattct ggcgacacag caaataaaat ttataatttc aatcaatttc agcatgcact 3901 gacgcggcac ggcaagacta cctggacggg cctgaacgat ccaatacatc tgccattccg 3961 tcccgatcgc acacatccat cagagacaga ttctccttca aacgcagacg cagaccaagc 4021 agccaaaaag aaaccgccca aatcagcacc tccctcctca cactctccca ctaataaaaa 4081 cttatcttca acagatatgt ctacatgtga tgcaaatact gcgcctacag tggacactat 4141 ttgtaccaat gatggcctcc caattggtat ctctaacaat tcaacttcaa ctgcatcccc 4201 cggaggcaca gaatcacagg gagggggagg aggggccgcc aaatgtccag aaaagtggtt 4261 tggaggtgtc acttgggagg gtaatacctt cactacttat aacactcgcc gctgcatgct 4321 tactccattt aatactaaat atctggctag atcaggtgtc gacaatacgc ccagtgtaga 4381 tattgaaact ccttggtatt actttgacct aaatgctttc agttgtcaca tcaacccaca 4441 caccatgcaa gagattgttg aacatacaga tggcatacgt ccactttcac tcactatcac 4501 cattgcagaa atacaagcta aagacgttag catgggatca ggcagtacta gctccacata 4561 tactatcaca gaatcacaaa cagctaccat gctcttacac agagacagcg attatgatct 4621 tccatatcca atagggggcg gtcaagatac tataccagac catcttccag gagactggta 4681 ttccctccca cgatactgct ataaaactct cggtggcata tcagctgaac ccaaagaaca 4741 ccgtatcaca aatacctcaa cattttgcaa tggcacacgc ataacaaacc aaacatggac 4801 tgagcgacat cactcagttc aagactctga gctctttctt attgaaggaa tgccatgcac 4861 acaactccac cccaactgca gctggagcta tcaatactca ttcccacacg tctcttgggc 4921 cctaactaca caatattgtt ggaacacccg cagacaagac aacccatgtc aacaacttag 4981 attttataat atcaaaaata cacattatga agataccaaa caagacatag atgtagttat 5041 gtgtaccagc tcaagcgaca ctacatgctc aaacgagtgt ggtaccagcg ggagcaacaa 5101 caaaattaaa cgcaaacgca tcacagtaga aacaaaaggc aacgtagacc accataacag 5161 aattcaactc caaaacaata atgtaaaaat actcagagcc agtaacacac gcccagctat 5221 gtggcttcca gccccacgcc atcccaccgg agattgtgtt tttattaacc cagccaacgc 5281 cttaggcatc gcagacaaca aaatagactc acattatgca ttcagcaacc aaaaaaaaca 5341 tattatacta atagaagaag aattatacag caatggtact actcactcca aaacatgctt 5401 accaggacct gtcactcaag aaagtgctat acgcacgcca gagggcgcca tcctcataaa 5461 taccaacgcc ctcgcagtag ccagaaacaa tgcagaccaa acaacacacc cagcaatata 5521 caccaatggc gaatgcttac cgccaaacaa aacattccaa ctcgtcatca atacacgacg 5581 aggagcagac ggtccatcaa acagcacaca tatcaaaaat tccaccacag acaccactaa 5641 tttcggcatt gaacaatgct atggtatgat gccaggacaa gtagcagaaa aacaatcagg 5701 attttatgaa aaccaaatat ggtgtagaaa ccctaataca gacatggcag acggaggtgg 5761 aaatccactt atcgcccaat ggggtattaa aagcccacca cacctaattc ttgtacgcat 5821 gctacccact ccagctaact caactacaga tatgggcaaa tacaaatctc ccattatggg 5881 atcaatactt aatcaatata tgacattcca aattcaatat gcaatgaaat gggaatacct 5941 acccaaatcc agaaataaat gctggaaccc catcacgcct ccacaactac cacagccaag 6001 caacggacac aacgtcatct acaacctcga caccagacgc caaggaaacc aatactgcat 6061 cccagatgaa acttgggcat tcaagcaacg aatccgcaat cgccgctagc ctatgtaacc 6121 acaaaaataa aaattgtaat cccaaacttc tgcgtgtatt tctgacgtag tcagatcaaa 6181 tcagatctaa tcagatcaga ttagataggg cacacgtgca cgtgtgccct atctaatctg 6241 atctgattag atctgatttg atctgactac gtcagaaata cacgcagaag tttgggSEQ ID NO:15: Roe deer copiparvovirus, nonstructural protein; Accession NC_055518 and YP_010087224 1 malyytatit lpddgkaygp ahhnnvmcti ikhrnneqwt ylhdpaeyay hmclgqiyvn 61 mlesqleqah faganyeyfv qlekgpqkkr whlhivvdis igqprkarel letvermysn 121 lafgrtirtl dinkerngsw kienedfiin ylckkipvkg ctfawtnier epiksmcgni 181 earlqqheni denipmfkqa sgeklaklve fmiknkitde qrylqkyeas ffsfyatvag 241 qtmfrnalqi aksriasdip lgvwlagfts lnelidkqvg vksmelgnsk ineimvqnsy 301 npiaaayvia awsmgmtgrr ralwlygdpq tgksiiarai atgaasfgcv nwtnenfpfq 361 diigtcvaww eegritepiv evtkalmagg tirvdrkcrd sveckpppfi itsnqdmtlv 421 ysgntisfeh qgalqdrmiq fkftkrlppd fgeitqdein ayfkwamyiy tnkllpseyk 481 hwtnptsigf miqkqsgvvh htlveridhp feeeereala eldsmfends dkenqdpeme 541 lpprkkkkal pvrksaslls vlfiylnnil mipsflaprk snigrr SEQ ID NO:16: Roe deer copiparvovirus, structural protein; Accession NC_055518 and YP_010087225 1 mtdrargegg ssialhlget fkllidhkyn thpdteayyt dssgakyekr ryifvgadqd 61 teqawadqqa ynklpgqkik gphgkwagwt fpnppddvvw pessldptrs qpdprptpts 121 pptqqfnwtg ggwptntelp ssnvpqmgig sqgnvqfspm tadettiera kneghpippi 181 tespeiahdl etlehetees efnmqlikqa iaethdsedi etrakdgega dqtsltvhgr 241 yvgpgnplpa gkpsskldei alrhdiryhv elkhkhwpyl tyqyadkimi deinqnmeqi 301 kqegnewlan fikslwttqk lysapigvll eniipemgwy sgdtankiyn fnqfqhaltr 361 hgkttwtgln dpihlpfrpd rthpsetdsp snadadqaak kkppksapps shsptnknls 421 stdmstcdan taptvdtict ndglpigisn nststaspgg tesqggggga akcpekwfgg 481 vtwegntftt yntrrcmltp fntkylarsg vdntpsvdie tpwyyfdlna fschinphtm 541 qeivehtdgi rplsltitia eiqakdvsmg sgstsstyti tesqtatmll hrdsdydlpy 601 pigggqdtip dhlpgdwysl prycyktlgg isaepkehri tntstfcngt ritnqtwter 661 hhsvqdself liegmpctql hpncswsyqy sfphvswalt tqycwntrrq dnpcqqlrfy 721 niknthyedt kqdidvvmct sssdttcsne cgtsgsnnki krkritvetk gnvdhhnriq 781 lqnnnvkilr asntrpamwl paprhptgdc vfinpanalg iadnkidshy afsnqkkhii 841 lieeelysng tthsktclpg pvtqesairt pegailintn alavarnnad qtthpaiytn 901 geclppnktf qlvintrrga dgpsnsthik nsttdttnfg ieqcygmmpg qvaekqsgfy 961 enqiwcrnpn tdmadgggnp liaqwgiksp phlilvrmlp tpansttdmg kykspimgsi 1021 lnqymtfqiq yamkweylpk srnkcwnpit ppqlpqpsng hnviynldtr rqgnqycipd 1081 etwafkqrir nrr SEQ ID NO:17: DNA sequence of plasmid VB220316-1106had (the plasmid map is set forth at Fig.8). ATAAAAGTGTGATGTTTTCAAACTCTAAGACAGACATTGTGCAATCCAATATGTCTG CTCTTCCGGGTCAAATGTTATACTTCCGGTTCAAAGGTTACCGGATACACGTCATCC AAGATGGCTGCCGTTCCGGGTTATAGGTCATAACGGTTTAGGCGCGCGGAAGTGAC GTTTTTTGAATTTAGGCGCGCGGAAATGACGCCGTTTGTCGCTTACGTGTCAGCGAC CGGCGAGAAAGATGGCGTTTTTCATTTACGTTTTGATGACGTTGCTGTTCTCTGATTG GTTAGTTTTTCAAGTCCTCATTTGCATATTTAATGGACCAATAGGATTTACTTCTGCT TTTTAGGGTATAAAAGTTCGTACTTCTGCTTTTTCCCTCATTCTGTGCTTGGGAGCTG ATCTGTTTAGATCTTTTTGCTTCTCTGCGCCGAAAGCCTCTGTATTtctagacaactttgtatagaaaagttgtagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcc tggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatg ggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatg gcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcg gttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggc accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatat aagcagagctggtttagtgaaccgtcagatccaagtttgtacaaaaaagcaggctgccaccatggtcttcacactcgaagatttcgttgggga ctggcgacagacagccggctacaacctggaccaagtccttgaacagggaggtgtgtccagtttgtttcagaatctcggggtgtccgtaactc cgatccaaaggattgtcctgagcggtgaaaatgggctgaagatcgacatccatgtcatcatcccgtatgaaggtctgagcggcgaccaaat gggccagatcgaaaaaatttttaaggtggtgtaccctgtggatgatcatcactttaaggtgatcctgcactatggcacactggtaatcgacgg ggttacgccgaacatgatcgactatttcggacggccgtatgaaggcatcgccgtgttcgacggcaaaaagatcactgtaacagggaccctg tggaacggcaacaaaattatcgacgagcgcctgatcaaccccgacggctccctgctgttccgagtaaccatcaacggagtgaccggctgg cggctgtgcgaacgcattctggcgggaagcggagtgaaacagactttgaattttgaccttctgaagttggcaggagacgttgagtccaaccc tgggcccatgcagaggtcgcctctggaaaaggccagcgttgtctccaaactttttttcagctggaccagaccaattttgaggaaaggataca gacagcgcctggaattgtcagacatataccaaatcccttctgttgattctgctgacaatctatctgaaaaattggaaagagaatgggatagaga gctggcttcaaagaaaaatcctaaactcattaatgcccttcggcgatgttttttctggagatttatgttctatggaatctttttatatttaggggaagt caccaaagcagtacagcctctcttactgggaagaatcatagcttcctatgacccggataacaaggaggaacgctctatcgcgatttatctagg cataggcttatgccttctctttattgtgaggacactgctcctacacccagccatttttggccttcatcacattggaatgcagatgagaatagctatg tttagtttgatttataagaagactttaaagctgtcaagccgtgttctagataaaataagtattggacaacttgttagtctcctttccaacaacctgaa caaatttgatgaaggacttgcattggcacatttcgtgtggatcgctcctttgcaagtggcactcctcatggggctaatctgggagttgttacagg cgtctgccttctgtggacttggtttcctgatagtccttgccctttttcaggctgggctagggagaatgatgatgaagtacagagatcagagagct gggaagatcagtgaaagacttgtgattacctcagaaatgattgaaaacatccaatctgttaaggcatactgctgggaagaagcaatggaaaa aatgattgaaaacttaagacaaacagaactgaaactgactcggaaggcagcctatgtgagatacttcaatagctcagccttcttcttctcaggg ttctttgtggtgtttttatctgtgcttccctatgcactaatcaaaggaatcatcctccggaaaatattcaccaccatctcattctgcattgttctgcgc atggcggtcactcggcaatttccctgggctgtacaaacatggtatgactctcttggagcaataaacaaaatacaggatttcttacaaaagcaa gaatataagacattggaatataacttaacgactacagaagtagtgatggagaatgtaacagccttctgggaggagggatttggggaattattt gagaaagcaaaacaaaacaataacaatagaaaaacttctaatggtgatgacagcctcttcttcagtaatttctcacttcttggtactcctgtcctg aaagatattaatttcaagatagaaagaggacagttgttggcggttgctggatccactggagcaggcaagacttcacttctaatggtgattatgg gagaactggagccttcagagggtaaaattaagcacagtggaagaatttcattctgttctcagttttcctggattatgcctggcaccattaaagaa aatatcatctttggtgtttcctatgatgaatatagatacagaagcgtcatcaaagcatgccaactagaagaggacatctccaagtttgcagaga aagacaatatagttcttggagaaggtggaatcacactgagtggaggtcaacgagcaagaatttctttagcaagagcagtatacaaagatgct gatttgtatttattagactctccttttggatacctagatgttttaacagaaaaagaaatatttgaaagctgtgtctgtaaactgatggctaacaaaac taggattttggtcacttctaaaatggaacatttaaagaaagctgacaaaatattaattttgcatgaaggtagcagctatttttatgggacattttcag aactccaaaatctacagccagactttagctcaaaactcatgggatgtgattctttcgaccaatttagtgcagaaagaagaaattcaatcctaact gagaccttacaccgtttctcattagaaggagatgctcctgtctcctggacagaaacaaaaaaacaatcttttaaacagactggagagtttggg gaaaaaaggaagaattctattctcaatccaatcaactctatacgaaaattttccattgtgcaaaagactcccttacaaatgaatggcatcgaaga ggattctgatgagcctttagagagaaggctgtccttagtaccagattctgagcagggagaggcgatactgcctcgcatcagcgtgatcagca ctggccccacgcttcaggcacgaaggaggcagtctgtcctgaacctgatgacacactcagttaaccaaggtcagaacattcaccgaaaga caacagcatccacacgaaaagtgtcactggcccctcaggcaaacttgactgaactggatatatattcaagaaggttatctcaagaaactggct tggaaataagtgaagaaattaacgaagaagacttaaaggagtgcttttttgatgatatggagagcataccagcagtgactacatggaacacat accttcgatatattactgtccacaagagcttaatttttgtgctaatttggtgcttagtaatttttctggcagaggtggctgcttctttggttgtgctgtg gctccttggaaacactcctcttcaagacaaagggaatagtactcatagtagaaataacagctatgcagtgattatcaccagcaccagttcgtat tatgtgttttacatttacgtgggagtagccgacactttgcttgctatgggattcttcagaggtctaccactggtgcatactctaatcacagtgtcga aaattttacaccacaaaatgttacattctgttcttcaagcacctatgtcaaccctcaacacgttgaaagcaggtgggattcttaatagattctccaaagatatagcaattttggatgaccttctgcctcttaccatatttgacttcatccagttgttattaattgtgattggagctatagcagttgtcgcagtttta caaccctacatctttgttgcaacagtgccagtgatagtggcttttattatgttgagagcatatttcctccaaacctcacagcaactcaaacaactg gaatctgaaggcaggagtccaattttcactcatcttgttacaagcttaaaaggactatggacacttcgtgccttcggacggcagccttactttga aactctgttccacaaagctctgaatttacatactgccaactggttcttgtacctgtcaacactgcgctggttccaaatgagaatagaaatgattttt gtcatcttcttcattgctgttaccttcatttccattttaacaacaggagaaggagaaggaagagttggtattatcctgactttagccatgaatatcat gagtacattgcagtgggctgtaaactccagcatagatgtggatagcttgatgcgatctgtgagccgagtctttaagttcattgacatgccaaca gaaggtaaacctaccaagtcaaccaaaccatacaagaatggccaactctcgaaagttatgattattgagaattcacacgtgaagaaagatga catctggccctcagggggccaaatgactgtcaaagatctcacagcaaaatacacagaaggtggaaatgccatattagagaacatttccttct caataagtcctggccagagggtgggcctcttgggaagaactggatcagggaagagtactttgttatcagcttttttgagactactgaacactg aaggagaaatccagatcgatggtgtgtcttgggattcaataactttgcaacagtggaggaaagcctttggagtgataccacagaaagtatttat tttttctggaacatttagaaaaaacttggatccctatgaacagtggagtgatcaagaaatatggaaagttgcagatgaggttgggctcagatct gtgatagaacagtttcctgggaagcttgactttgtccttgtggatgggggctgtgtcctaagccatggccacaagcagttgatgtgcttggcta gatctgttctcagtaaggcgaagatcttgctgcttgatgaacccagtgctcatttggatccagtaacataccaaataattagaagaactctaaaa caagcatttgctgattgcacagtaattctctgtgaacacaggatagaagcaatgctggaatgccaacaatttttggtcatagaagagaacaaa gtgcggcagtacgattccatccagaaactgctgaacgagaggagcctcttccggcaagccatcagcccctccgacagggtgaagctctttc cccaccggaactcaagcaagtgcaagtctaagccccagattgctgctctgaaagaggagacagaagaagaggtgcaagatacaaggcttt agacccagctttcttgtacaaagtgggaattcctagagctcgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttgcccctc ccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcatt ctattctggggggtggggtggggcaggacagcaagggggaggattgggaagagaatagcaggcatgctggggagggccgcCCCC CAGCAATACACTTACTACAGTATTGATGTGTCAGGCATTCTGGTTGATTGTTTTATTT TGGCTCCGCCTACTGTATGGCCCATGTAAACGCATCTATTATGAAAATAAAATACGT CAATTGCTGATGTAATTCGTGTTGTAATTCTTCCTTGAAAAGCGCATATTTTCTTGCC GGTCTGAGTAACACCACCTATGACATCATATAAATTTGATTACGTAACTTCCTCTTTT TACTTCCTCTTTTTTTGATTACGCAATATCACAATTCTAGCAGTCAACTATTACACAA TATCACACTTTGAGACCCTGACCATCACACTTTTATTTTGTGCACTCGAGATGCGAGC ATGGGCCGCAAGGCGGCCCATGCACGCAAATCTCGAGTGCACAAAATAAAAGTGTG ATGTTTTCAAACTCTAAGACAGACATTGTGCAATCCAATATGTCTGCTCTTCCGGGTC AAAGGTTATctgcctgcaggggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgtcaaagcaac catagtacgcgccctgtagcggcgcattaagcgcggcgggggtggtggttacgcgcagcgtgaccgctacacttgccagcgccttagcg cccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgattta gtgctttacggcacctcgaccccaaaaaacttgatttgggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgac gttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaactctatctcgggctattcttttgatttataagggattttgc cgatttcggtctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgtttacaattttatggtgcactctca gtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggc atccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaaggg cctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccc tatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatga gtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgct gaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttcca atgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctc agaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatg agtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaac tcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgtt gcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtggaagccgcggtatcattgcagcactggggcca gatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtg cctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtga agatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttctt gagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaact ctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgt agcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacg atagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactg agatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaa caggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttt tgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacat gtcctgcaggcag Within this sequence (SEQ ID NO:17), the CMV promoter comprises nucleotides 475- 1063, the ORF encoding nano luciferase (Nluc(ns)) comprises nucleotides 1094-1606, and the human CFTR (hCFTR) ORF comprises nucleotides 1682-1681. The Nluc(ns) and hCFTR ORFs are separated by a linker (F2A) comprising nucleotides 1607-1681, which causes post- transitional cleavage of the encoded peptide; thus, multiple proteins can be made from a polycycstronic transcript comprising multiple ORFs separated by 2A. SEQ ID NO:18: DNA sequence of plasmid mmtvpo62_qbq (the plasmid map is set forth at Fig.16). ccctcactaaagggaacaaaagctgggtaccgggccccccctcgaggtcgacggtatcgataagcttgatatcgaattcctgcagcccgg gggatccactagttctagagcggccgccaccgcggtggagctccaattcgccctatagtgagtcgtattacgcgcgctcactggccgtcgtt ttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaaga ggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggt gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgat ggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgga acaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaattt aacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacat tcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgc ccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacga gtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttct gctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactc accagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaac ttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccg gagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaa ctacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggc tggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgta gttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttca tttaatttaaaaggatctaggtgaagatcctttttgataatctcatgacc aaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatct gctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttca gcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctct gctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagc ggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatga gaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagct tccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcgg agcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgatt ctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggag gcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaa gcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgctcccggctcgtatgttgtgtg gaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagcgcacatcgatctcctcaggcctagaagtaaaa aagggaaaaaagagtgtgtttgtcaaaataggagacaggtggtggcaaccagggacttataggggaccttacatctacagaccaacagat gcccccttaccatatacaggaagatatgacttaaattgggataggtgggtcacaatcaacggctataaagtgttatacagatccctcccctttc gtgaaagactcgccagagctagacctccttggtgtatgctaactgagaaagagaaagacgacatgaaacaacaggtacatgattatatttatc taggaacaggaatgcacttttggggaaaggttttccataccaaggaaggggcagtggctggactgatagaacattattctgcaaaaacttatg gtatgagttattatgattagcctttatttgcccaaccttgcggttcccagggtttaaataagtttatggttacaaactgttcttaaaacaaggatgtg agacaagtggtttcctgagttggtttggtatcaaatgttctgatctgagctcttagtgttctattttcctatgttcttttggaatctatccaagtcttatgt aaatgcttatgtaaaccataatataaaagagtgctgattttttgagtaaacttgcaacagtcctaacattcttctctcgtgtgtttgtgtctgttcgcc atcccgtctccgctcgtcacttatccttcacttttcagagggtccccccgcagatcccggtcaccctcaggtcggGCGTGAGAGAG GGCGTTTTTCATTTACGTTTTGATGACGTTGCTGTTCTCTGATTGGTTAGTTTTTCAAG TCCTCATTTGCATATTTAATGGACCAATAGGATTTACTTCTGCTTTTTATGGTATAAA AGTTCGTACTTCTGCTTTTTCCCTCATTCTGTGCTTTGGAGCTGATCTGTTTAGATCTT TTTGCTTCTCTGCGCCGAAAGCCTCTGTATTATGTCTCAGACCTTCTGGACGGGTATT TGCAGGCTTTTCCCTGATATTGGGAAGATTCCTGGGGTGACTCCTGAGCGGTATATT TATGCTGTAAACGTGAGTACCCGTAATGGGCAAAAGTGGCCGAAAGTTGGGACCGA GGGGCCATTGGCTGCAGGTGTCTTACAGGGGGAGGCCCTTTTCCGTGAGACCCTTAA AGAGGTCCGGAAGGTGTGCCGGCTGCCGCAAGACCCCCATCTTTTCTTTCAATTGGA GAAAGTTGATTCCAAAGGGGGTCTTCACCTTCATTTTTGTATTAGTGTTGCTGCTGGC ACTCCTAGAGATGTGTCTTCGATGTTTAAAGCCATTGAGCGTCGAGTTTCCTTTTACT ACTTTGGTGTAGAGGGCTTGACTTTTTTTACTCCTCATAAAAATAAGCATGGGGCTT GGAAGAGTAATGATGAGGGGTTTATTGTGAATTATCTTCTTAAAAAATTGCCTTTGT CTGAGTGTGTGTATGCGTGGACTAATATGGATGGGGTGATTGGCGATGCCTGTCTGA ATGAAGATAAGCGCAGGGAATTGTTGTCTGAGCGTCAAGATCAGGGAGTCATTAAA GAGCTCACTGCTCCTACTTTTAAAGCGGCTACGGGTGATAAAATGTTGAGTGTGGTG GATTGGATGTGTGATAATGATGTGACTACGGAGCGCCGATGGGAGGAAATATCGGC TGCGTCCCTGTACTCTTTCCTTGCTACCCCAGCTGGCACTCATTTGGCTAAACAGTGT CTTAGAGCTGCGAATCAGCGTATTGTGAGCACTAAACCTCTTGGTTTGAGTCTCTGT AAATTTGCCAGTGAAAAGGAGCTTCGTGCTTTTCAAAATGGGGATCCTGAGTTGTCT TCAGACAACAATAGGATCTATTACTTATTTGCTATGAATAATTACTGCCCTGATATG GCCAGTATGATTTTCTTTTGGTGGTCTATGCGCCAAACGGGTAAGAGAAACAGTATT TGGCTGTTTGGACCTGCTACAACCGGTAAAACCAATTTAGCAAGTGCTATTGCACAT ACTGCTGCCAGTTATGGGTGTGTTAACTGGAATAACGCAAATTTCCCGTTTCAAGACATTGTGAATGTGCAACTGGGTTGGTGG AGGAAGGAAAGATGACAGAGGATGTGGT TGAATGTGCTAAGGCATTGCTAGGGGGAAGTAATGTAAGAGTTGACCGCAAATGTA TGCAATCTGCGGAAGTGCAATCTCCTCCTTTTATTATCACATCCAATACGGATATGTG CCTTGTTTCTCAAGGCAGTTACATCAGTTTTGAGCACCAGCAGCCTCTCCAGGATAG AATGATTAAATTTGAGTTTAACCATGTTCTTCCTGGCAATTTCGGCCTCATTTCTGAA GATGAAGTCGTGGCCTTCTTCAGAAATGGTGCTTATAATGTGTTGAAGCATGCGTAC ATGAGAAAGGCCCAGCTTTTTGCTCTCGGTCCAGCTTCCTTGCCATATAAGCCCCCT ACGGGTGAATTAGTGTGTATAGACCAAGCTAAGTCTCCTTCTCCCTCTGCTTCTCGCC GCAGTGTGAGAAATTGGATGACGTGTCCCCCTGATCCTGTCCAGGACGATCCCGCTG AACTGGACGAGTATTTTCCTCCAGATACTCCTCCAGAGGATTGTCCTTGTCCTATTTC TCCTGTGAGGGAGTCTTGTCCCTCGCCAGGGCCTTGCCCTACCCCTCCTCGCAAAAA ACAACGGAAGAGCAAGCATTGCTCCTTGTCTGTCTCTGCGGGTAAAGTTCCTGTGGT GGTTGTGGGTGATTCTGACTCAGTCCCCCCCGAAGAAAAAGAAAAAGAGGAAGTTT CCGTGGGGGATTCCCAGGATCCACAACTGTACTGGGACCTAACTCTCAGTCAATCCG ACGTTCCTGTGCCTGAAGACGAGAGTACCCAGTTTCCTGACGACGCTGTGGACGCTT CTGATCTCATTGCTGAACAGTAGTTAAGGTATGAGTCGTTCTACTCAAAGAGATCTT TGGTCTTTGATAAAGGAGAGACTTGAAACGTATAAGGATCGAGTGAAATATTATGG TATTTTGGTGCCAGAACGTCCTTCTACCTCTGCATCTTATTTTAGCAGAGACCCACCT CCCGATCCTCCAAATGTTAAATTTGATAAACCCTATCAGGATGTAGATAGATTCTGG TTTCCAACAGACGAGTATACTGACTGGTATGTCTGGCATGGAGAGGACAGACCTCCT AGATTTACCGAGCATTCCGGTGTTCAGGGTTTTAAAACTAGGTGTGAAGGGGGGCTT CCTTTAATGTCCAGTGATCCCAAGTTTTGTCCAAAACCTGATTTTTGGGATCAGTTCG CTAATTATGATGAGGGGTCTCCGTCCCCCCAGATCGGTGAGAGTGTTTCATGGAGTG ATCATTTTGGAAGTCCCGATCCCTCTCATCATCAGGAGGTGAGGGATGCGGATGAAG TAGTTTCAGAGCGGCAGCAATATAAAAATAGGATTGTCACTTTATTAAGAAAAGTGT ATTGGGCTAAGCAGTGGTCTGGGAAATTACAAATTAATGTTCCTTCCCTTGAAAGCC TTTATGAGCAGATCCCCTATATGCTAGCCTATATGGACGCCGATAATTGGCGTCAGA ATTTGTTAGCTGCTAAAACTCTGCGAACCACTTTGGAAGCATTTTCCTGTGTTCCAGA TCCTTCCACGTGCGATGTCACAATCTCCACACCCCTATCTGGTGAAACGGATCCCGC CTCTTTTGCAAAATACTTATGTTCCCTTGTATGCAACAGGTCTCAAGAAAAAGAACA GGCGCAGACGCCTTCTTTGTCTCCATCTAAACAAGAAGGGCAGATGTCAAGTCCTGA TTCTGCATCGATCTCCCAACCTCCCCCCGAAAGTCACAAGGATAGACTGCTTCCTAA AACTGATCCCCTTCAGGAAGCAGGGCCCATTCCCGCTCCCCCCACAGTTCAGAAACC TATTATTTCTAAGGGTGCAGGCGGTGGAGGATCGTCTGGCTTCATAATCCCTCTAAA ACCTCCTAGCCCCGATCATACTCCTGATCCCCCCCCTCCTCCTCCTCCCTCTCCAATT CCTCCTCCCACATCTGCGCCTGACGCAGAGGAGCACGAGCTAGAGCGTGCTAAACA GGAGAAACAAGAGGAAGATGAGCTCATGCAAAGAATCAAATCAGGAGAAGGAGAA GGAGAACGAGGAGGCTTCGTCTTGCCTTCTCACCACTACACTGGTCCTAGAAATCCT GTCCCAGCTGGCAAGCCTGCTGACCCCGTTGATGAATCTTCTGCGAGACATGACATC AGGTATGGGCAACGTCTTAAACATGGAGACTGGCCATACCTGTGGGGGAAGGACTT GGATAATGCTCAACGAGATGAGATTATCAAAGCTCTTCATAGTCATGTCAAAGTGGG AACCCAATTGGCAGGGAATATAGTGAGGAGTATTTGGAAGGCTAAGGAGCTCTTAA CAGAACCTGTGTATGAGCTGTTAAAGTCTATTCTCCCTCCTTCAGATTTATCTAAAGT TCCTCTTCCTCATTCCCAACAGACAGACAGAACAGAAGATCCAGAAACTCCAGGGGAGACTAGAGGAACTGGATCAGACAGTCCTCGATCTCCTCGGCCTTCTGGATCAACTG AAGACGGGGGAGGTCCTTCTTCCGAGTCCAGATTACCTGGGACTAAAGTTCCAGTAG ACCCATCTGCCACCACGTCCGAAGCAAAGAGGCAGAGGACTGAGGAGGGGATGGA CATATCTTCTTGCTGTCCAGGGGGGATTTCTGCTTCTGGGGCTGCTTCAAATAACTCT GGTCTTGCTTGTGGGGGTGGGGGGGGTACTAATTTAGGGACAGAATCTCTTGTATCC GGCTGTCAGTTTGGTAAAAACTCTGTGATCACTTCATCTTTTAGACGATGTCTTATTT CACCCTGGCCTGATAAATACTGTTGCTCCTCTGCTCATGATCTTATTCCTGGAGTGGT CTACGAGACCCCCTGGTGCTATTATGATCTGAACGTCATCTCAGCCCATTTCTCTCCT TCTGCTTGGCAGAGGCTTCTAGAGGATTATGATGCCTTTCGCCCTAAATCCCTTAAA GTTACCATCCAGTCTTTAGTGTTTAAAGATGTCTGTCAAGGAGCAGAAAAACAAACG ACCGTTCAGGATTCCCAGTCAGCCACCATCGCTATCTTTGAGGATAAAGACTATGAC TATCCCTATGTGATGGGAGGGGGTCAGAAAACAGTTCCGGGTCACTTGCCCGGTCAA CCTTACAATCTTCCTAAGTATTCTTACAGAACCCTTGGTTCCGTCAAAGAGAGTGGT ATGGCCCATCGCGGCGGTTCAGGGTACACGTTCAAATCCAATCAAGACACGGAATT GTCCCTGCTTGAGACACATGATTCCACTCTTATTCGAGGCGGGGGTACTTTTGAGCA GTACTATGAATTTCCAAACGATCTTCCCTTTGAGAATTTGACTCAGTATCCTTGGGAT ATCCGTCGTCAGGATAACCCCCTCTATCAGCAGAGGATCACTGTCATGTCAGGTTCT GACAGAGATCAGGCAGGCATTCTAGGAGGAGATTTTTACTCTCCTTTCCGGTTCAAA GGTCATGATAGACCCGCCATGTGGTTGCCAGGACAGAGGTTGATTCAGGGCAAATT CATAGATACACATCCAATACCCAATACAGGGAGGAGTGGGGTTCATCCTAGCGATTT CCACACCAGGGGCGATGGTCATGGTGATACTCATAGAACCCATGAAGAGAAGATCT ACACTCTAGATACAGGTCTTGCTGCTATGCCCCGTGCTGCTCATAGACCCACTCTTC AGCCCGGACCTAGGACTCTGTCTCATGCCGTACGTAGACCCGATGGTTCCACCGTGG TCACGGCTAATGCGTGTGCTTACGCTTACACCCAGGAGAATCCTCATCAGGAACCCT GGAGTGATCTCAATGTCAGACATACCATGTATAGGTTAGCCTATCAACATCAAAAAG GGTTTCAGCAACCCGGAGACCCTCTTCATATTCGAACCCATGCTTGTTATGGGGACG GGGATGTTAGCATTCCAAAAGATGAGTCATTATGGCCTACTGTTCTGGGTAGCTGCA CAGAAAAGTCCCCTGCCTGTTTAGAGTCCCAGATCTGGTGTAAAACACCCAATGTGG ACATGGTCTATGGAGAACATACACCCCCTCTTGCTCTATGGGGTATGCGTGCTCCCC CACCTCATGTATTTCTTAGGATGCTTGCTCAAGAGGGCCCTCCTAATGTCAGTACTTG CAGACCCGCTCAATCTGGTCAGACCTTCATCAATCAATATGGTCAGTTTCTCCTCTGT TTTACCATGGTTTGGGAAGTTAAGCCTAGACCCAAGTCCATCAAGCAGTGGAATCCA CGTCCGCCTATCAGCATTCCTGTGGGTCAGTCTGGTCCTGCTTTCATTCTCGATCAAG ATGGCTACTACCGTCTCCCTGAACATGTCTGGTCTGCCAGGGAACGTATCCGCAGCA AACGCTAGTGCCCCCAGCAATACACTTACTACAGTATTGATGTGTCAGGCATTCTGG TTGATTGTTTTATTTTGGCTCCGCCTACTGTATGGCCCATGTAAACGCATCTATTATG AAAATAAAATACGTCAATTTCTGATGTAATTCGTGTTGTGATTCTTCCTTGAAAAGC GCATATTTTCTTGCCGGTCTGAGTGACACCACCTATGACATCATATAAATTTGATTAC GTAACTTCCTCTTTTTACTTCCTCTTTTTTGATTACGCAATATCACAATTCTAGCAGTC GACTATTACACAATATCACACTTTGAGACCCTGACCATCACACTTTTATTTTGTGCGC GAGATGCGAGCATGGGCCGCTTCGC Within this sequence (SEQ ID NO:18), the MMTV promoter sequence comprises nucleotides 3302-3727, the ORF encoding the Copi6-2 NS (nonstructural) protein comprisesnucleotides 3946-5934, and the ORF encoding he Copi6-2 CAP (capsid) protein comprises nucleotides 5942-9511. The amino acid sequences of the Copi6-2 NS and Copi6-2 CAP proteins are set forth at SEQ ID NOs: 19 and 20, respectively. SEQ ID NO:19: Copi6-2 NS (nonstructural protein) amino acid sequence encoded by ORF contained in vector mmtvpo62_qbq (Figure 16 and SEQ ID NO:18) MSQTFWTGICRLFPDIGKIPGVTPERYIYAVNVSTRNGQKWPKVGTEGPLAAGVLQGEA LFRETLKEVRKVCRLPQDPHLFFQLEKVDSKGGLHLHFCISVAAGTPRDVSSMFKAIERR VSFYYFGVEGLTFFTPHKNKHGAWKSNDEGFIVNYLLKKLPLSECVYAWTNMDGVIGD ACLNEDKRRELLSERQDQGVIKELTAPTFKAATGDKMLSVVDWMCDNDVTTERRWEEI SAASLYSFLATPAGTHLAKQCLRAANQRIVSTKPLGLSLCKFASEKELRAFQNGDPELSS DNNRIYYLFAMNNYCPDMASMIFFWWSMRQTGKRNSIWLFGPATTGKTNLASAIAHTA ASYGCVNWNNANFPFQDIVNVQLGWWEEGKMTEDVVECAKALLGGSNVRVDRKCM QSAEVQSPPFIITSNTDMCLVSQGSYISFEHQQPLQDRMIKFEFNHVLPGNFGLISEDEVV AFFRNGAYNVLKHAYMRKAQLFALGPASLPYKPPTGELVCIDQAKSPSPSASRRSVRN WMTCPPDPVQDDPAELDEYFPPDTPPEDCPCPISPVRESCPSPGPCPTPPRKKQRKSKHCS LSVSAGKVPVVVVGDSDSVPPEEKEKEEVSVGDSQDPQLYWDLTLSQSDVPVPEDESTQ FPDDAVDASDLIAEQ* SEQ ID NO:20: Copi6-2 CAP (capsid protein) amino acid sequence encoded by the ORF contained in vector mmtvpo62_qbq (Figure 16 and SEQ ID NO:18) MSRSTQRDLWSLIKERLETYKDRVKYYGILVPERPSTSASYFSRDPPPDPPNVKFDKPYQ DVDRFWFPTDEYTDWYVWHGEDRPPRFTEHSGVQGFKTRCEGGLPLMSSDPKFCPKPD FWDQFANYDEGSPSPQIGESVSWSDHFGSPDPSHHQEVRDADEVVSERQQYKNRIVTLL RKVYWAKQWSGKLQINVPSLESLYEQIPYMLAYMDADNWRQNLLAAKTLRTTLEAFS CVPDPSTCDVTISTPLSGETDPASFAKYLCSLVCNRSQEKEQAQTPSLSPSKQEGQMSSPD SASISQPPPESHKDRLLPKTDPLQEAGPIPAPPTVQKPIISKGAGGGGSSGFIIPLKPPSPDH TPDPPPPPPPSPIPPPTSAPDAEEHELERAKQEKQEEDELMQRIKSGEGEGERGGFVLPSH HYTGPRNPVPAGKPADPVDESSARHDIRYGQRLKHGDWPYLWGKDLDNAQRDEIIKAL HSHVKVGTQLAGNIVRSIWKAKELLTEPVYELLKSILPPSDLSKVPLPHSQQTDRTEDPET PGETRGTGSDSPRSPRPSGSTEDGGGPSSESRLPGTKVPVDPSATTSEAKRQRTEEGMDIS SCCPGGISASGAASNNSGLACGGGGGTNLGTESLVSGCQFGKNSVITSSFRRCLISPWPD KYCCSSAHDLIPGVVYETPWCYYDLNVISAHFSPSAWQRLLEDYDAFRPKSLKVTIQSL VFKDVCQGAEKQTTVQDSQSATIAIFEDKDYDYPYVMGGGQKTVPGHLPGQPYNLPKY SYRTLGSVKESGMAHRGGSGYTFKSNQDTELSLLETHDSTLIRGGGTFEQYYEFPNDLPF ENLTQYPWDIRRQDNPLYQQRITVMSGSDRDQAGILGGDFYSPFRFKGHDRPAMWLPG QRLIQGKFIDTHPIPNTGRSGVHPSDFHTRGDGHGDTHRTHEEKIYTLDTGLAAMPRAA HRPTLQPGPRTLSHAVRRPDGSTVVTANACAYAYTQENPHQEPWSDLNVRHTMYRLA YQHQKGFQQPGDPLHIRTHACYGDGDVSIPKDESLWPTVLGSCTEKSPACLESQIWCKT PNVDMVYGEHTPPLALWGMRAPPPHVFLRMLAQEGPPNVSTCRPAQSGQTFINQYGQF LLCFTMVWEVKPRPKSIKQWNPRPPISIPVGQSGPAFILDQDGYYRLPEHVWSARERIRS KR*SEQ ID NO:21: DNA sequence of MMTVPo4 (the construct map is set forth at Fig.17). ccctcactaaagggaacaaaagctgggtaccgggccccccctcgaggtcgacggtatcgataagcttgatatcgaattcctgcagcccgg gggatccactagttctagagcggccgccaccgcggtggagctccaattcgccctatagtgagtcgtattacgcgcgctcactggccgtcgtt ttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaaga ggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggt gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgat ggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgga acaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaattt aacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacat tcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgc ccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacga gtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttct gctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactc accagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaac ttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccg gagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaa ctacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggc tggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgta gttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaact gtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgacc aaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatct gctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttca gcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctct gctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagc ggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatga gaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagct tccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcgg agcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgatt ctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggag gcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaa gcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgctcccggctcgtatgttgtgtg gaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagcgcacatcgatctcctcaggcctagaagtaaaa aagggaaaaaagagtgtgtttgtcaaaataggagacaggtggtggcaaccagggacttataggggaccttacatctacagaccaacagat gcccccttaccatatacaggaagatatgacttaaattgggataggtgggtcacaatcaacggctataaagtgttatacagatccctcccctttc gtgaaagactcgccagagctagacctccttggtgtatgctaactgagaaagagaaagacgacatgaaacaacaggtacatgattatatttatc taggaacaggaatgcacttttggggaaaggttttccataccaaggaaggggcagtggctggactgatagaacattattctgcaaaaacttatg gtatgagttattatgattagcctttatttgcccaaccttgcggttcccagggtttaaataagtttatggttacaaactgttcttaaaacaaggatgtg agacaagtggtttcctgagttggtttggtatcaaatgttctgatctgagctcttagtgttctattttcctatgttcttttggaatctatccaagtcttatgt aaatgcttatgtaaaccataatataaaagagtgctgattttttgagtaaacttgcaacagtcctaacattcttctctcgtgtgtttgtgtctgttcgcc atcccgtctccgctcgtcacttatccttcacttttcagagggtccccccgcagatcccggtcaccctcaggtcggGGAGGCCGAAA AAGAGGAAGTTTGTCATTTGCGTTTTGGAGACCGTCGCGAGCAGAACTCCGTCGTTT TCGGCCTGTATTTGCAGATGGAAACCTACTGGACAGGTATTTGCAGACTTTTTCCTGATGTTTTAAAAATACCTGGTGTTTATG AGGACGCTATATTTTTGAAGTTCCTATTTC TACTCGTGATTGCATGAAATGGCCTGATATATTTGGCAACGAGAATAATAGTGAAAA TCAACAGTCTGGCGCGGCGCCTGCGGCGCCGCGCGAAAATCTTAATAGTAATCTGGT AATCGCTGTTCGGCAGGCGGAGGCTTTGTTTAGAGAGCTGCAGAAAGAGCTTAGAA AATCATGTCGTTTAGGGGTAGATCCTGGCATTTTTATGCAGTTAGAAGAAGTAGACT CAAAAGGTGGCTTGCACTTGCACTGGTGTGTGTCTGTGTCCGCTGGTACTCCGCGGG ATGTGCTTACAATTTTCAAAAATACAGAGAAGAAGGTCTCTCTGTACTATTTTGGGG TGGAGGGCCTAAGCTTCTTTGTGCCCCATAAGAATAAACACGGGGCCTGGAAGAGC ACGGACGAGGGCTTTATCTACAACTATCTGCTTAAAAAACTGCCGCTAAAAGAGTGT TTATATGCTTGGACCACCATCGGTGGAGCCATCGGTGATGCTTGCCTAAATACTGAT AAGAGAAAGGAGTTGCTGGATAATAGACAGGACCCAGCAGTGATCGAAGAGCTCTC AGCTCCCATGTACAAATGTGCCACCGGGGAGAAAATGCTTGATATCGTGCAGTGGCT GGTGGATAACAACATCTGCTCTGAGAGCAGATGGGAAAATAAGAATGCTCTAAGTC TATACTCGTTTCTGGCCACCCAGGCAGGTGGATACATGGCTAAACAGTGTCTGAGAA TCGCTCAGCAAAAGTTATTGAAAGAGAAACCTCTGGGGTTGACTCTGATGGAATTCA AGGATATGAATGCTCTGCGGCGCTTTCAGCAGGATGAGGGGGAAATGACTTTTGAC AATAACAGAATGCATTATATCTTTGCCATTAACAACTATGATCCTAAAATTGCTTCG GTGATAATGTACTTTTGGAGCATGAAACAAACGGGAAAGAGGAACTGTGTGTGGTT TTACGGGCCTGCCACAACAGGAAAGACTAACATGGCTCAAGCCATCTGCCACAGTT CTGCAAACTATGGCAATGTGAACTGGAATAATGCAAACTTCCCGTTTCAAGATATCG TGGGGGCTCAGGTAGGGTGGTGGGAAGAGGGAAAGATGACTGGTGATATGGTCGAA GCTGCTAAAGCACTACTGGGGGGAACTGCTTTGCGAATCGACCGCAAGTGCATGCA ATCTATTGAGGTTAACAGTCCACCTTTCCTCATAACCTCAAATGTGGACATGACTATT GTACAAGAGGGAAGTTTTGTAAGCTTTGAACATCAGCAACCATTAGAGGACAGGAT GATAAAGTTTAGCTTTAATATGACCCTGCCGGGCAATTTTGGTTTGATTACCAGTGA GGAAGTGAAATCTTTTTTTCGAATGGGAGCTAAACTTGCTGCGCAACCGGACATTAT GAACTGCCCTATATTTAAAAAAGGACCTGCCAGTATTAGACATTTAGTTCCTGTTGG AGAGATCCCACCCCCAAAAGAAATGAAGCATAAAAGGCAGCCACTCTACATGAGAG CGGAACCAGATGAAATTCAAGACAATCCAGAAGAACTGGACCACTGGTTCGAAGAA GAAGCACCGAAAAAGAAGAAACAGAAAACAAAAAATACTGCAACTAAGAACCCTG CTGAGACGGTGGAGATTATAACTGAGACTGAATTCATCCCTGCACCAGGTAAGAGA TGAGTACTTATTTACTATCAGAATAAAGGATAAACTGTACCCAGCAGTAGTTGATAA GTGCCCCTCTCTTACAGATACACAGCCACAACTGGTGTTTGACATCCAGTTAGAAGA GGAAGCAGAAATTTCAGATATCATCGGAGAACAATAAAATGTTCGGCGGACAAGGT ATTATACCGATACTAACATGGGAGCAATTAGAAGCTTTTATGTGGGCTGGGCAAGG AATGTCAATTGACTATTACAGAAGCTGTTTAAGCGATTGTATGCTATTTGGGGAAAA ATTTAACATTCATATGCCAAAAACAAAAAATTTATTATTAGAAGCTGAATACCTATA TAGACTTTTTCACAGTGGTTTTGCCAATAGTGCACAAGGTTTCAGAGAAAGAGTAGA AAGATGGAGAACAGAAAGCAAACTGAGATGTCCCCAATTTGATAGACCCATGGATG CCTCACAAAGGCATGCATACTTAGGATTTTTCTATCAAGCCCTCAGTAAATTGCCGG AAAATGCCTCTGAGGAAGATATTCTGCAGACCATACATGATTCTGATGACACCAGTA AAGAAAAATTCTATGCATTTATGGAAAAAATTCAGCAAGAACCAGAATATGTGTTT AAAGAGCCTGATAGCATTCCGCAACCAGAAGCTCCTGTTACAGCAGTTCCGGTTGAG ACATCACCAACTGAAAACAGGTACCTTCTCTTACACATCAAGATACTAAGAAAGACAAGGTGGAGGAACGTTTGCCTTGTCCC TAGATTTTTGTGATGAACATTGGCAGGGC AGACACCCGCTAGGATTCAAGGAAGAAGAAGAAGAAATACAAAAAGAAATAGAGG AAGACAGAAGAGAAGAAACAGAAACAATCGAAAAAGCGCAACAGGGTGAAGGAG AACATGAAAAGGGAGGACTCACCTGGCCCGGTCATCGCTACACAGGTCCATTCAAT CCTCTCCCTCATGGAAAACCTACTGATCAACTTGACGAAGCAGCTCTTCGACATGAT ACAAGGTACAAAACAATGCAGAAACACGGTCACTGGCCTCATTTATGGGCACCATT TGTTGACAGACAGATGAGCCAAGAAATTCAACAGGTTTTAAAAGGTTCTACAAAAC TGAGCCAAAAACTACTTGCTAACTTCATCATAGCACTATGGCGAGCAAAAGAAAAA ATAGGAGCTCCTATATATGAGATTGTAAAAGGGGTTTTTCCAAGTGTTGATAAAAAA ACTGTTGAAAGCCTTTTACCGCACCCTGACCCTATACCTGCTCCTCCATCTTCTCCAC AGCGAGGATCCAAACGTGCATCTCCTCCTCAGAGTCCTAATGCACATGATGAAGATA CAATGAGCGGGCACAAGCGTCAGAAAACTATGGAAGTGGAATCTGAATGTGATAAG TCTTTGCTTTGTCCAACGCAGAATGCTGGAGCTGATTTTGAGCTTTGCGGGACGGGA GGGGGGGCAACTAATGAGAGTTGGACATGGGTGGGAGGGACACAATTTACCGATAC ATCTATTAGGACATTTGGTACTAGAAGATGTGTTCTCTCAGCGTTTCCTGACACTTAC TGTTCTATGATGTCCGGAGACGCTATACCTTCTATTATTTTTAATACACCATGGTACT ATTATGATCTAAACATTATGTCCTGCCATTTCTCTCCAAGTGCTTTTCAAACTTTAAT TGAAGATTATGATGCATTTAGACCTAGATCGCTAACAGTTCATTTAAAAGAGCTTGT AATAAAAGATGTATGCCAGCAACAAGGTTTACAAGCTGAGCAGGTATCTGACAATA ACTCTGCTACACTGCTTGCTTTTGAAGATGTTAATTATGAACTTCCATATGTTTTAGG TGGTGGTCAAGTATCTGTGCCAGGACATCTACCGGGACAACCATATCAACTACCAAA ATACTCATACAGAACTGTTGGAAAACCAGACCCAAACAGCGGCTTCGTGCCGGGAA GGAACACACATCCAGATCAAGGACCAGGACATCCAAAAGCAAGTAAAACAATTTGG TACTCTCAATATTTAGAAACCCAAGACACCGAATTCTATATATTAGAAAACCACAAA GCAACAATTTTACACTCTGGAAATACATTTTCCCAAAATTACAATTTTCCTGATCTAC CTTTTGAGCAGTTGACACAGTATATGTGGGATGCACGGAGGCAGGACAATCCATTG ATAGATCAGAGGATACAGGTGATGAGCAGAATGTATGATGACGGCCCACAGAAAAC ATTTGCTATCAAAGTGAACCCATACATTGTACCATTCACAGTAAAAAGCACCAGCAG ACCAGCTATGTTCTTAGCGGGAGGAAGATTTAAAGATGGTGATTATTCAATAACAGG TCCAGGAGATAGACAAAAAACAAGTTTCAAATATTACAATGATCCTCCATGGATCAT CACCAGAGATACCTATCTCTTCTCCAGCGATTTAGCTAAAACTGAAAGAGAACAGCC AGGACCCAGACAGGGAGACACAGTGGTTAGGACCCCTGATGGAACACTGATAGTGA CTACTAATGCATTAGCTTATGGGTACACAACAGAATATCTAAAAAACATTCCGCTTT TGAGTTCCAAATACCATGGTGTTGAAAACTTCAGACTAGCTGTTGAAAATGAAAGA GGATATTCAATGCCAGGTCACCCGTCACATATCAGAGAAACATTATTCAGAGGTAA ACTGCCAAGTGAGATAAGGGAATCAACTATTAAATCAGAGGATCAGAGAAAAGAA ATAACATTTCCAGATTACATGGGTTCTGTAAATGAAAAAACAACAGCAAATTTAGA ATCGCAGATATGGTCTCAGATACCGAACACTGATATCACTGAAAAATGTACAACAC CACCACTATCCATTTGGGGTATGAAAAACCCACCACCGATGGTTTTCCTGAGACTCC TGGCACAGATGGGACCACCGAGAAGAAGCGCCTGCAGCGGATCCATTCCAAGCAAT ACATATTTGAACCAATATTGCCAATTTTTGCTTACATACGAAATGGAATGGGATGTT ATTAAAAGAACCAGAAAAACGGTGAGGTGGAATCCAATTCCTCCCCCGCAAATTCC GATGGGACCTAACAATCTTCCTGTTTATATTTTGAACAAAGAGGGACAATACAGAATGCCGACGGAAGTTTGGACCGCAAAACAGAGACCCAGACACCGCAGATGATATCAAT AAAGTTTTTGAAATTAAAAAAAAAGACTTCCTCTTTATTG Within this sequence (SEQ ID NO:21), the MMTV promoter comprises nucleotides 3302-3727, the ORF encoding Copi4 NS1 comprises nucleotides 5094-5606, the ORF encoding Copi4 NS2 comprises nucleotides 5759-5673, and the ORF encoding Copi4 CAP (capsid) comprises nucleotides 6637-8823. The amino acids of the proteins encoded by the Copi4 ORFs are set forth at SEQ ID NOs: 8 (NS1), 9 (NS2), and 10 (CAP). SEQ ID NO:22: DNA sequence of MMTVPo5 (the construct map is set forth at Fig.18). ccctcactaaagggaacaaaagctgggtaccgggccccccctcgaggtcgacggtatcgataagcttgatatcgaattcctgcagcccgg gggatccactagttctagagcggccgccaccgcggtggagctccaattcgccctatagtgagtcgtattacgcgcgctcactggccgtcgtt ttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaaga ggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggt gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgat ggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgga acaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaattt aacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacat tcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgc ccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacga gtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttct gctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactc accagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaac ttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccg gagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaa ctacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggc tggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgta gttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaact gtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgacc aaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatct gctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttca gcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctct gctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagc ggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatga gaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagct tccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcgg agcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgatt ctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggag gcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaa gcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgctcccggctcgtatgttgtgtggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagcgcacatcgatctcctcaggcctagaagtaaaa aagggaaaaaagagtgtgtttgtcaaaataggagacaggtggtggcaaccagggacttataggggaccttacatctacagaccaacagat gcccccttaccatatacaggaagatatgacttaaattgggataggtgggtcacaatcaacggctataaagtgttatacagatccctcccctttc gtgaaagactcgccagagctagacctccttggtgtatgctaactgagaaagagaaagacgacatgaaacaacaggtacatgattatatttatc taggaacaggaatgcacttttggggaaaggttttccataccaaggaaggggcagtggctggactgatagaacattattctgcaaaaacttatg gtatgagttattatgattagcctttatttgcccaaccttgcggttcccagggtttaaataagtttatggttacaaactgttcttaaaacaaggatgtg agacaagtggtttcctgagttggtttggtatcaaatgttctgatctgagctcttagtgttctattttcctatgttcttttggaatctatccaagtcttatgt aaatgcttatgtaaaccataatataaaagagtgctgattttttgagtaaacttgcaacagtcctaacattcttctctcgtgtgtttgtgtctgttcgcc atcccgtctccgctcgtcacttatccttcacttttcagagggtccccccgcagatcccggtcaccctcaggtcggGGAGGCCGAAA AAGAGGAAGTTTGTCATTTGCGTTTTGGAGACCGTCGCGAGCAGAACTCCGTCGTTT TCGGCCTGTATTTGCAGATGGAAACCTACTGGACAGGTATTTGCAGACTTTTTCCTG ATGTTTTAAAAATACCTGGTGTTTATGAAGGACGCTATATTTTTGAAGTTCCTATTTC TACTCGTGATTGCATGAAATGGCCTGATATATTTGGCAACGAGAATAATAGTGAAAA CTGTGAGTCTGGCGCGGCGCCTGCGGCGCCGCGCGATGAAATTGACAGTAATCTAGT AACGGCTGTTAGACAAGGGGAGGCTCTATTTAGAGAGCTTCAAAAAGAACTTAGAA AATCCTGTAGATTAGGAGTAGATCCTGGCATTTTCATGCAATTAGAAAGAGTTGACT CAAAAGGTGGCTTGCACTTGCACTGGTGTGTGTCTGTGTCCGCTGGTACTCCGCGGG ATGTTTTAACTATATTCAAAAATACAGAAAAAAAAGTTTCATTATATTACTTTGGTG TTGAGGGACTTAGCTTTTTTGTGCCACACAAAAATAAACACGGAGCATGGAAAAGC ACAGATGAAGGGTTTATTTATAATTATTTGCTAAAAAAACTACCGCTGAAAGAATGT CTTTATGCATGGACTACAATTGGAGGTACAATAGGTGAAGCCTGTTTAAATACAGAA AAAAGAAAAGAACTATTAGATAATAGACAAGATCCAGCAGTTATTGAAGAATTATC TGCTCCCATGTACAAATGTGCCACTGGAGAAAAAATGCTAGACATTGTACAGTGGTT GGTGGACAATAATATTTGTTCTGAATCCAGATGGGAGGGAAAAAATGCTCTAAGCTT ATACTCATTCTTAGCCACACAAGCTGGAGGATATATGGCAAAACAATGCTTAAGAAT CGCTCAGCAAAAATTACTAAAAGAAAAATCACTAGGGTTAACCTTAATGGATTTTAA AAACATGGATGCTTTAAGAGCTTTCCAACAAAGTGACATGGAGTGTTCATTCGATCA TAACAGAATACATTACATTTTTGCAGCTAACAACTATGATCCTAAAATTGCTGCAGT TATAATGTTTCACTGGAGCATGAAACAAACGGGAAAAAGAAACTGTGTATGGTTTT ACGGTCCTGCTACAACAGGAAAAACAAATATTGCACAGGCAATCTGCCATAGCTCA GCTAATTATGGCAATGTTAACTGGAACAATCCAAATTTTCCTTTTCAAGATATTGTA GGAGCTCAGGTAGGGTGGTGGGAAGAAGGGAAAATGACAGGAGACATGGTAGAAG CTGCAAAAGCTTTGCTGGGGGGAACTGCTTTGCGCATCGACCGCAAATGTATGCAAT CTGTTGAAGTCAACAGTCCACCGTTTATTATAACATCGAATGTGGACATGACCGTGG TTCAAGAAGGAAGTTTTGTAAGCTTTGAACACCAACAGCCGTTAGAGGACAGGATG ATAAAATTTTCATTTAACCTGACACTACCTGGAAACTTTGGTCTGATTACAACTGAA GAAGTGAAATCTTTTTTCCGGATGGGTGCAAAACTTTCAGTTAAACCTGAAATCATG AATTGCCAAATTTTCAAAAGAGGACCTGCCAGCATCCGCCACCTAGTTCCTCTTGGA GAAATTCCTCCACCAAAGGAGATGCATAAAAAGCGACAGCCACTCTATTTGAGAGC TGAACCAGATGAAGAACAAGAAACACCAGACGTCTTGGATCATTGGTTTGAAGAAC CAAGTCAAAAAAGAAAGAAGACAGAAGACCCTGCAAACACGACACCTCCTGCGGC TTATGAGAATTTAGATGACAACTTTGAACCTGTTCCAGGTAAGAATTTTGCATTTATC ATTTTTTAATGTTCCAAAACAATAGAGCAAATTGGTGATATGTGCATAATTCTTACA GATAGCCAAGTGAACCTGATATTTGACGTGGTCTACGAAGAGACACCAGAGGTGGACGAAGTGGAGGAACAATGAGCTTTAGTGGGTATTCTAAAAATCTCCCCCCGGGTTTA GAGGAAGTTACATTCCCATTTTGGGTTGATTTTTTGCTTGCCAGAATAGCTGATTTTA TTAATTGGTGTGGGTATTATAATATTAAATGTCCAGAAGCAGAAAAGGTATTTAGTA TTGGACAATCTACACAGGTTTTACTTAAATGGCCGGGTGCACAGGGAAAAGAAAAC CGAGTTAAGAACTTTACCGAAGCTGCGTTTCCATATATGAAAGTACCTGTGAGACCA GACAACATTGAATGGATTAAAATCCATGAGATGCTACATAATTATGATAGACAAAT AACACCGCAGACAACTGAGAATGATTTACTTGCAGCTATCACTGCTGACTTCGATCA GAGAGAGATCATCCATCCAGTCACCGGCGAGAAATGGGTTTTCGGTAAGAAAACAG AAGCTTTTGCTACTGATTTGGAAGAAACCGTGGATGAAGAAGATCCTGATACAGAG AAAAAACAACCTACTGATAAAACACAAAGTAATAACGAGAAAGGGGAAGTTGGTG AAAAGAAAGAAGAAGGTGATACCCCTACGTCAAATGAGGAACATCACCAATCAAG AAAACTATTAGAACACGACTCAAGCGAAGAACAACCAGAAGAAGCTGGTCACCGA GAACAGAAAGAACTAGAAGACAATATTGAAGACATCAAACATGGAGCGGGAGAAG ACCAAACCGGAACCGGTATCAACTGGCCAGGACATCGCTACACAGGTCCTGGAAAT CCACTCCCTCACGGAGCTCCTCGCAATGAAATTGATCTCTCTGCTGCGAAACATGAT ATCAGGTACAAACAATATTCTCGATATGGTCACTGGCCATACATTTGGGCGCCATAT ATTGATAAAAAAATGCAAGAAGATATTAGAGAGATAGTAAAAAAAGGTTTAGGATT AGAAGGTAAACTTTTAGGTAACCTTATATCGGCTTTATGGCAAGCAAAATACAGATT AGGAGCCCCGATATATGAAATTTTAAAAACAATTTTACCCCCGAAAAGTATGCCTAC TAAAGAATCTGTAGAAAAACATTTACCAAAACCTTTGCCCATTGATCCTCCACAGAC ATCCTTACCAGGTGCATCTCCTCCTCGAACTCCTGACTTGGGTGGCGAGACTGGAAT GAATGAAGAGCCTCCAGCAAAAAGAAGAATGACAGAAGACAGATGTGACAGCACC ACAAGGTGCGAAACATTGGACACACAATATGAGGATTCTAAAATGGCGGGAGGGGG TGGGGGGGGAGGGAATCAACCTAAAAGTTCTTGGATTGGGGGGGCTTTCTTTACTGA TACGACGGTTACTACTTATGGTACTAGAAGGTGTGTGCTTAGCTCTTTTCCGCATAAC TACTGCACCACAGAGAGCGGGGATCATATACCTAGCCTTGTTGTCTGTACTCCATGG TACTATTATGATCTTAACATTCTATCAGCTCATTTCTCTCCCTCTGCTTGGCAAACGC TTTTAGAAGAGTATGATGCTTTTAAACCTTTAAAATTAGAAGTTAAAATTAAAGAGA TAGTTGTTAAAGATGTTAATAATATGACAGGGAAACAATGCTGTGACACAGTTTCTG ACAATGCCATGGCTGCAGTGCTGTGTTTTGAAGATACACATTACGAGCTGCCATATG TTTTGGGAGGGGGACAGCTAACAGTGCCTGGTCATCTTCCAGGACAAACTTATGAAC TTCCAAAATACTGCTATAGAACTGTGGGAAAACCGCATAGCGAGATGTGGTCGCCT GTAGATGGTTCCAAAAGAGCCCACTTAGACATGCCTTTTGTTCAGCCAACACAGAAC ACTGAGTTCTTTATTTTAGAGAACAGACACTCTACCATCCTTCACACAGGCAATGAA TTCTTTCAAACCTATGACTTTCCAGATTTACATTTTGAGCAGCTAACACAGTACATGT GGGACGCGAGGAGACTTGACAATCCAATGAAAGGTCAAAGAATACAGGTTATGAAA AACAAACCTACAGAAAACAAAGATCAAATGTTTGGTATCAGAGCTTCGAGTTACCT CGTTCCCTGGATTGTCAACTCTCTAAACAGACCTGCTATGTTTTTGCAAGGAGGAAG ATTAAAAGACGGGGATTATTCCATTGTTGGGCCTGGGACCAGAGAACAGGCGACAT ACCACTACTTTAATGATACACCTGTCGTGGTTGAAAGAGATATTTACAAATTTACAA CTAGTATGCTTAAAAGAGAAACTCAACAGCCAGGACCGAGAACACAGGAAACAAC GGTAAAAACACCTGATGGGACCATAATTATAACAACTAACAGTTTAGCGTATGGAC AGGTGCCTGAAAACATTGATAACATACCGAGTGATCACAAAGCCGCTTTCGGGGTT ACAGGGTACAGGCTTGCTGTCGCTGAACAGAGAGGGTATAGCACACCTGGAATGCCTTCTCATATAAGGGAGATATTATTGAC AAAACACCGAAACTTTTAGAAAAAGATC AGCAAGAAATCACATTTCCAAACTTTGAAGGGTCTGTCAGCGAAAAAACTTCCGCTA ATCTAGAGTCTCAGATTTGGGCTTATATCCCTAACACTGATAACAAACATAACTGTG GAACACCCCCTTTATCTATATGGGGAATGGAAAATCCTCCACCTATGGTTTTTTTGA GGTTACTCCCTCAACTGGGACCCCCTGAAAAATCCAGCTGTTCTGGAAGCAAACCTT CTAAAAAGTTCTTAAATCAGTACTGCCAATTTTTACTGGAATATACTGTAACATGGG CTGTTGTGAGGCGAAAGAAACATACTCCGAGGTGGAACCCTATGCCGGGGGTCACA ATTCCAACTTATAACAACGATCCTGTGTACATCCTTGACCAAAATGGATTTTATAAA TTGCCAGAAACTGTTTGGACAGCAAAGCAACGTGTTAGAGCGAGAAGATAATAAAA AAATAACCAAACACACCC Within this sequence (SEQ ID NO:22), the MMTV promoter comprises nucleotides 3302-3727, the ORF encoding Copi5 NS comprises nucleotides 3813-5618, and the ORF encoding Copi5 CAP (capsid) comprises nucleotides 5738-8713. The amino acids of the proteins encoded by the Copi5 ORFs are set forth at SEQ ID NOs: 23 (NS) and 24 (CAP). SEQ ID NO:23: Copi5 NS (nonstructural protein) amino acid sequence encoded by ORF contained in vector MMTVPo5 (Figure 18 and SEQ ID NO:22) METYWTGICRLFPDVLKIPGVYEGRYIFEVPISTRDCMKWPDIFGNENNSENCESGAAPA APRDEIDSNLVTAVRQGEALFRELQKELRKSCRLGVDPGIFMQLERVDSKGGLHLHWC VSVSAGTPRDVLTIFKNTEKKVSLYYFGVEGLSFFVPHKNKHGAWKSTDEGFIYNYLLK KLPLKECLYAWTTIGGTIGEACLNTEKRKELLDNRQDPAVIEELSAPMYKCATGEKMLD IVQWLVDNNICSESRWEGKNALSLYSFLATQAGGYMAKQCLRIAQQKLLKEKSLGLTL MDFKNMDALRAFQQSDMECSFDHNRIHYIFAANNYDPKIAAVIMFHWSMKQTGKRNC VWFYGPATTGKTNIAQAICHSSANYGNVNWNNPNFPFQDIVGAQVGWWEEGKMTGD MVEAAKALLGGTALRIDRKCMQSVEVNSPPFIITSNVDMTVVQEGSFVSFEHQQPLEDR MIKFSFNLTLPGNFGLITTEEVKSFFRMGAKLSVKPEIMNCQIFKRGPASIRHLVPLGEIPP PKEMHKKRQPLYLRAEPDEEQETPDVLDHWFEEPSQKRKKTEDPANTTPPAAYENLDD NFEPVPGKNFAFIIF* SEQ ID NO:24: Copi5 CAP (capsid protein) amino acid sequence encoded by ORF contained in vector MMTVPo5 (Figure 18 and SEQ ID NO:22) MSFSGYSKNLPPGLEEVTFPFWVDFLLARIADFINWCGYYNIKCPEAEKVFSIGQSTQVL LKWPGAQGKENRVKNFTEAAFPYMKVPVRPDNIEWIKIHEMLHNYDRQITPQTTENDL LAAITADFDQREIIHPVTGEKWVFGKKTEAFATDLEETVDEEDPDTEKKQPTDKTQSNN EKGEVGEKKEEGDTPTSNEEHHQSRKLLEHDSSEEQPEEAGHREQKELEDNIEDIKHGA GEDQTGTGINWPGHRYTGPGNPLPHGAPRNEIDLSAAKHDIRYKQYSRYGHWPYIWAP YIDKKMQEDIREIVKKGLGLEGKLLGNLISALWQAKYRLGAPIYEILKTILPPKSMPTKES VEKHLPKPLPIDPPQTSLPGASPPRTPDLGGETGMNEEPPAKRRMTEDRCDSTTRCETLD TQYEDSKMAGGGGGGGNQPKSSWIGGAFFTDTTVTTYGTRRCVLSSFPHNYCTTESGD HIPSLVVCTPWYYYDLNILSAHFSPSAWQTLLEEYDAFKPLKLEVKIKEIVVKDVNNMTGKQCCDTVSDNAMAAVLCFEDTHYELP VLGGGQLTVPGHLPGQTYELPKYCYRTVG KPHSEMWSPVDGSKRAHLDMPFVQPTQNTEFFILENRHSTILHTGNEFFQTYDFPDLHFE QLTQYMWDARRLDNPMKGQRIQVMKNKPTENKDQMFGIRASSYLVPWIVNSLNRPAM FLQGGRLKDGDYSIVGPGTREQATYHYFNDTPVVVERDIYKFTTSMLKRETQQPGPRTQ ETTVKTPDGTIIITTNSLAYGQVPENIDNIPSDHKAAFGVTGYRLAVAEQRGYSTPGMPS HIREILLTKTPKLLEKDQQEITFPNFEGSVSEKTSANLESQIWAYIPNTDNKHNCGTPPLSI WGMENPPPMVFLRLLPQLGPPEKSSCSGSKPSKKFLNQYCQFLLEYTVTWAVVRRKKH TPRWNPMPGVTIPTYNNDPVYILDQNGFYKLPETVWTAKQRVRARR* SEQ ID NO:25: DNA sequence of MMTVPo6 (the construct map is set forth at Fig.6). ccctcactaaagggaacaaaagctgggtaccgggccccccctcgaggtcgacggtatcgataagcttgatatcgaattcctgcagcccgg gggatccactagttctagagcggccgccaccgcggtggagctccaattcgccctatagtgagtcgtattacgcgcgctcactggccgtcgtt ttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaaga ggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcgccctgtagcggcgcattaagcgcggcgggt gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgat ggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgga acaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaattt aacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacat tcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgc ccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacga gtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttct gctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactc accagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaac ttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccg gagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaa ctacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggc tggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgta gttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaact gtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgacc aaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatct gctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttca gcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctct gctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagc ggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatga gaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagct tccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcgg agcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgatt ctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggag gcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaa gcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgctcccggctcgtatgttgtgtg gaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagcgcacatcgatctcctcaggcctagaagtaaaa aagggaaaaaagagtgtgtttgtcaaaataggagacaggtggtggcaaccagggacttataggggaccttacatctacagaccaacagat gcccccttaccatatacaggaagatatgacttaaattgggataggtgggtcacaatcaacggctataaagtgttatacagatccctcccctttcgtgaaagactcgccagagctagacctccttggtgtatgctaactgagaaagagaaagacgacatgaaacaacaggtacatgattatatttatc taggaacaggaatgcacttttggggaaaggttttccataccaaggaaggggcagtggctggactgatagaacattattctgcaaaaacttatg gtatgagttattatgattagcctttatttgcccaaccttgcggttcccagggtttaaataagtttatggttacaaactgttcttaaaacaaggatgtg agacaagtggtttcctgagttggtttggtatcaaatgttctgatctgagctcttagtgttctattttcctatgttcttttggaatctatccaagtcttatgt aaatgcttatgtaaaccataatataaaagagtgctgattttttgagtaaacttgcaacagtcctaacattcttctctcgtgtgtttgtgtctgttcgcc atcccgtctccgctcgtcacttatccttcacttttcagagggtccccccgcagatcccggtcaccctcaggtcggGCGTGAGAGAG GGCGTTTTTCATTTACGTTTTGATGACGTTGCTGTTCTCTGATTGGTTAGTTTTTCAAG TCCTCATTTGCATATTTAATGGACCAATAGGATTTACTTCTGCTTTTTATGGTATAAA AGTTCGTACTTCTGCTTTTTCCCTCATTCTGTGCTTTGGAGCTGATCTGTTTAGATCTT TTTGCTTCTCTGCGCCGAAAGCCTCTGTATTATGTCTCAGACCTTCTGGACGGGTATT TGCAGGCTTTTCCCTGATATTGGGAAGATTCCTGGGGTGACTCCTGAGCGGTATATT TATGCTGTAAACGTGAGTACCCGTAATGGGCAAAAGTGGCCGAAAGTTGGGACCGA GGGGCCATTGGCTGCAGGTGTCTTACAGGGGGAGGCCCTTTTCCGTGAGACCCTTAA AGAGGTCCGGAAGGTGTGCCGGCTGCCGCAAGACCCCCATCTTTTCTTTCAATTGGA GAAAGTTGATTCCAAAGGGGGTCTTCACCTTCATTTTTGTATTAGTGTTGCTGCTGGC ACTCCTAGAGATGTGTCTTCGATGTTTAAAGCCATTGAGCGTCGAGTTTCCTTTTACT ACTTTGGTGTAGAGGGCTTGACTTTTTTTACTCCTCATAAAAATAAGCATGGGGCTT GGAAGAGTAATGATGAGGGGTTTATTGTGAATTATCTTCTTAAAAAATTGCCTTTGT CTGAGTGTGTGTATGCGTGGACTAATATGGATGGGGTGATTGGCGATGCCTGTCTGA ATGAAGATAAGCGCAGGGAATTGTTGTCTGAGCGTCAAGATCAGGGAGTCATTAAA GAGCTCACTGCTCCTACTTTTAAAGCGGCTACGGGTGATAAAATGTTGAGTGTGGTG GATTGGATGTGTGATAATGATGTGACTACGGAGCGCCGATGGGAGGAAATATCGGC TGCGTCCCTGTACTCTTTCCTTGCTACCCCAGCTGGCACTCATTTGGCTAAACAGTGT CTTAGAGCTGCGAATCAGCGTATTGTGAGCACTAAACCTCTTGGTTTGAGTCTCTGT AAATTTGCCAGTGAAAAGGAGCTTCGTGCTTTTCAAAATGGGGATCCTGAGTTGTCT TCAGACAACAATAGGATCTATTACTTATTTGCTATGAATAATTACTGCCCTGATATG GCCAGTATGATTTTCTTTTGGTGGTCTATGCGCCAAACGGGTAAGAGAAACAGTATT TGGCTGTTTGGACCTGCTACAACCGGTAAAACCAATTTAGCAAGTGCTATTGCACAT ACTGCTGCCAGTTATGGGTGTGTTAACTGGAATAACGCAAATTTCCCGTTTCAAGAC ATTGTGAATGTGCAACTGGGTTGGTGGGAGGAAGGAAAGATGACAGAGGATGTGGT TGAATGTGCTAAGGCATTGCTAGGGGGAAGTAATGTAAGAGTTGACCGCAAATGTA TGCAATCTGCGGAAGTGCAATCTCCTCCTTTTATTATCACATCCAATACGGATATGTG CCTTGTTTCTCAAGGCAGTTACATCAGTTTTGAGCACCAGCAGCCTCTCCAGGATAG AATGATTAAATTTGAGTTTAACCATGTTCTTCCTGGCAATTTCGGCCTCATTTCTGAA GATGAAGTCGTGGCCTTCTTCAGAAATGGTGCTTATAATGTGTTGAAGCATGCGTAC ATGAGAAAGGCCCAGCTTTTTGCTCTCGGTCCAGCTTCCTTGCCATATAAGCCCCCT ACGGGTGAATTAGTGTGTATAGACCAAGCTAAGTCTCCTTCTCCCTCTGCTTCTCGCC GCAGTGTGAGAAATTGGATGACGTGTCCCCCTGATCCTGTCCAGGACGATCCCGCTG AACTGGACGAGTATTTTCCTCCAGATACTCCTCCAGAGGATTGTCCTTGTCCTATTTC TCCTGTGAGGGAGTCTTGTCCCTCGCCAGGGCCTTGCCCTACCCCTCCTCGCAAAAA ACAACGGAAGAGCAAGCATTGCTCCTTGTCTGTCTCTGCGGGTAAAGTTCCTGTGGT GGTTGTGGGTGATTCTGACTCAGTCCCCCCCGAAGAAAAAGAAAAAGAGGAAGTTT CCGTGGGGGATTCCCAGGATCCACAACTGTACTGGGACCTAACTCTCAGTCAATCCG ACGTTCCTGTGCCTGAAGACGAGAGTACCCAGTTTCCTGACGACGCTGTGGACGCTTCTGATCTCATTGCTGAACAGTAGTTAA GTATGAGCCGTTCTACTCAAAGAGATCTT TGGTCTTTGTTAAGGGAGAGACTTGAAACGTATAAGGATCGAGTTAAATATTATGGT ATTTTGGTGCCAGAACGTCCTTCTACCTTTGCATCTTATTTTAGTAAAGACCCACCTC CAGATCCTCCAACTGTTAAATTTGATAAACCCTATCAGGATGTAGATAGATTCTGGT TTCCAACAGACGACTATACTGACTGGTATGTCTGGCATGGAGAGGACAGACCTCCTA GATTTACCGAGCATTCCGGTGTTCAGGGTTTTAAAACTAGGTGTGAGGGGGGGCTTC CTTTAATCCCCAGTGATCCCAAATTTTGCCCCATACAAAATTTTTGGGATCAGTTCGC TAATTTTAATGAGGGGTCTCCGTCCCCCCAGATCGGTGAGAGTGTTTCATGGAGTGA TCATTTTGGAAGTCCCGATCCCTCTCATCATCAGGAGGTGAGGGATGCTGATGAAGT AGTTTCAGAGCGACAGCAATATAAAAATAGGATTGTCACCTTATTAAGAAAAGTTTA TTGGGCTAAGCAGTGGTCTGGGAAATTACAAATTAATGTTCCTTCCCTCGAAAGCCT TTATGAGCAGATCCCCTATATGCTAGCCTATATGGACGCTGATAATTGGCGTCAGAA TTTGTTAGCTGCTAAAACTCTGCGAACCACTTTGGAAGCATTTTCCTGTGTTCCAGAT CCTTCCACGTGCGATGTCACAATCTCCACACCCCTATCTGGTGAAACGGATCCCGCC TCTTTTGCAAAATACTTATGTTCCCTTGTATGCAACAGGTCTCAAGAAAAAGAACAG GCGCAGACGCCTTCTTTGTCTCCATCTAAACAAGAAGGGCAGATGTCAAGTCCTGAT TCTGCATCGATCTCCCAACCTCCCCCCGAAAGTCACAAGGATAGACTGCTTCCTAAA ACTGATCCCCTTCAGGAAGCAGGGCCCCTTCCCGCTCCCCCCACAGCTCAGAAGCCT ATTATCTCTAAGGGTGCAGGCGGTGGAGGGTCGTCTGGCTTCATAATCCCTCCAAAA CCTCCTAGCCCCGATCATACTAAAGATCCCCCCCCTCCTCCTCCTCCCTCTCCAATTC CTCCTCCTACATCTGCGCCTGACGCAGAGGAGCACGAGCTAGAGCGTGCTAAGCAG GAGAAACAAGAGGAAGATGAGCTCATGCAAAGAATCAAATCAGGAGAAGGAGAAG GAGAACGAGGAGGCTTCGTCTTGCCTTCTCACCACTACACTGGTCCTAGAAATCCTG TCCCAGCTGGCAAGCCTGCTGACCCCGTTGATGAATCTTCTGCGAGACATGACATCA GGTATGGGCAACGTCTTAAACATGGAGACTGGCCATACCTGTGGGGGAAGGACTTG GATAATGCTCAGCGAGATGAGATTATCAAAGCTCTTCATAGTCATGTCAAAGTGGGA ACCCAATTGGCAGGGAATATAGTGAGGAGTATCTGGAAGGCTAAGGAGCTCTTAAC AGAACCTGTGTATGAGCTGTTAAAGTCTATTCTCCCTCCTTCAGATTTATCTAAAGTT CCTCTTCCTCATTCCCAACAGACAGACAGAACAGAAGATCCAGAAACTCCAGGGGA GACTAGAGGAACTGGATCAGACAGTCCTCGATCTCCTCGGCCTTCTGGATCAACTGA AGACGGGGGAGGTCCTTCTTCCGAGTCCAGATTACCTGGGACTAAAGTTCCAGTAGA CCCATCTGCCACCACGTCCGAAGCAAAGAGGCAGAGGACTGAGGAGGGGATGGAC ATATCTTCTTGCTGTCCAGGGGGGATTTCTGCTTCTGGGGCTGCTTCAAATAACTCTG GTCTTGCTTGTGGGGGTGGGGGGGGTACTAATTTAGGGACAGAATCTCTTGTATCCG GCTGTCAGTTTGGTAAAAACTCTGTGATCACTTCATCTTTTAGACGATGTCTTATTTC ACCCTGGCCTGATAAATACTGTTGCTCTTCTGCTCATGATCTTATTCCTGGAGTGGTC TACGAGACCCCTTGGTGCTATTATGATCTGAACGTCATCTCAGCCCATTTTTCTCCTT CTGCTTGGCAGAGGCTTCTAGAGGATTATGATGCCTTTCGGCCTAAATCCCTTAAAG TGACCATCCAGTCTCTAGTGTTTAAAGATGTTTGTCAAGGAGCAGAAAAACAAACG ACCGTTCAGGATTCCCAGTCAGCCACCATCGCTATCTTTGAGGATAAAGACTATGAC TACCCCTATGTGATGGGAGGGGGTCAGAAAACAGTTCCCGGTCACTTGCCCGGTCAG CCTTACAATCTTCCCAAGTATTCTTACAGAACCCTTGGTTCCGTCAAAGAAAGTAAT AGGGCCAGTATGGGCGGTTCAGGGTACACTTTCAAATCCAATCAAGACACGGAATT GTTCCTGCTTGAAACACATGATGCTACTCTTATTCGAGGCGGGGGTACTTTTGAACAGTACTATGAATTTCCAAACGATCTTCCT TCGAAAATTTGACTCAGTATCCTTGGGAT ATCCGCCGTCAGGATAACCCCCTCTATCAGCAGAGGATCACTGTCATGTCAGGTTCT GACAGAGATCAGGTAGGCATTCTAGATGGAGATTTTTACTCTCCTTTTCGGTTCAAA GGTCATGATAGACCCGCCATGTGGCTGCCAGGACAGAGGTTGATTCAGGGCAAATT CATAGATACGCATCCAATACCCAATACAGGGAGGAGTGGGGTTCATCCTAATGATTT TCACACAAGGGGTGATGGTCATGGGGATACCCATAGAACACATGAAGAGAGGATTT ACAGTCTAGATACAGGTCTTGCTGCTATGCCACGTGCCGCTCATAGACCCACCCTTC AGCCCGGACCTAGGACTCTGTCTCATGCCGTACGCAGACCCGATGGTTCCACCGTGG TCACGGCTAATGCGTGTGCTTACGCTTACACCCAGGAGAATCCTCATCAGGAACCCT GGAGTGATCTCAATGTCAGACATACCATGTATAGGTTAGCCTATCAACGTCAAAAAG GTTTTCAGCAACCCGGGGACCCTCTTCATATTCGAACCCATGCTTGTTATGGGGACG GGGATGTTACCATTCCAAAAGAAGAGTCCTTATGGCCTACTGTTCTGGGTAGTTGCA CAGAAAAGTCCCCTGCCTGTTTAGAGTCCCAGATTTGGTGTAAAACACCAAATGTGG ACATGGTCTATGGAGAACACACACCCCCTCTTGCTTTATGGGGTATGCATGCTCCCC CACCCCATGTATTTCTCAGGATGCTTGCTCAAGAGGGTCCTCCTAATGTCAGTACTTG CAGACCGGCTCAATCTGGTCAGACCTTCATCAATCAATATGGTCAGTTTCTCCTCTGT TTTACCATGGTATGGGAAGTTAAGCCTAGACCCAAGTCCATCAAGCAGTGGAATCCA CGTCCGCCCATCAGCATTCCTGTTGGTCAGTCTGGTCCTGCTTTCATTCTTGATCAAG ATGGCTACTACCGTCTCCCAGAACATGTCTGGTCTGCCAGGGAACGTATCCGCAGCA AACGCTAGTGCCCCCAGCAATACACTTACTACAGTATTGATGTGTCAGGCATTCTGG TTGATTGTTTTATTTTGGCTCCGCCTACTGTATGGCCCATGTAAACGCATCTATTATG AAAATAAAATACGTCAATTTCTGATGTAATTCGTGTTGTGATTCTTCCTTGAAAAGC GCATATTTTCTTGCCGGTCTGAGTGACACCACCTATGACATCATATAAATTTGATTAC GTAACTTCCTCTTTTTACTTCCTCTTTTTTGATTACGCAATATCACAATTCTAGCAGTC GACTATTACACAATATCACACTTTGAGACCCTGACCATCACACTTTTATTTTGTGCGC GAGATGCGAGCATGGGCCGCTTCGC Within this sequence, the MMTV promoter comprises nucleotides 3302-3727, the ORF encoding Copi6 NS comprises nucleotides 3946-5934 and the ORF encoding Copi6 CAP (capsid) comprises nucleotides 5942-9511. Also present is an ORF encoding vp2, which comprises nucleotides 7727-9511. The amino acids of the proteins encoded by the Copi6 ORFs are set forth at SEQ ID NOs: 12 (NS) and 13 (CAP). SEQ ID NO:26: MMTV promoter DNA sequence from vector mmtvpo6 aaggaaggg gcagtggctg gactgataga acattattct gcaaaaactt atggtatgag ttattatgat tagcctttat ttgcccaacc ttgcggttcc cagggtttaa ataagtttat ggttacaaac tgttcttaaa acaaggatgt gagacaagtg gtttcctgag ttggtttggt atcaaatgtt ctgatctgag ctcttagtgt tctattttcc tatgttcttt tggaatctat ccaagtctta tgtaaatgct tatgtaaacc ataatataaa agagtgctga ttttttgagt aaacttgcaa cagtcctaac attcttctct cgtgtgtttg tgtctgttcg ccatcccgtc tccgctcgtc acttatcctt cacttttcag agggtccccc cgcagatccc ggtcaccctc aggtcggSEQ ID No:27 Copi6 TR conserved sequence GTGCAAAATAAAAGTGTGATGTTTTCAAACTCTAAGACAGACATTGTGCAATCCAAT ATGTCTGCTCTTCCGGGTCAAAGGTTAT SEQ ID NO:28 Copi6 terminal left-hand element (“LHE”) ATAAAAGTGTGATGTTTTCAAACTCTAAGACAGACATTGTGCAATCCAATATGTCTG CTCTTCCGGGTCAAATGTTATACTTCCGGTTCAAAGGTTACCGGATACACGTCATCC AAGATGGCTGCCGTTCCGGGTTATAGGTCATAACGGTTTAGGCGCGCGGAAGTGAC GTTTTTTGAATTTAGGCGCGCGGAAATGACGCCGTTTGTCGCTTACGTGTCAGCGAC CGGCGAGAAAGATGGCGTTTTTCATTTACGTTTTGATGACGTTGCTGTTCTCTGATTG GTTAGTTTTTCAAGTCCTCATTTGCATATTTAATGGACCAATAGGATTTACTTCTGCT TTTTAGGGTATAAAAGTTCGTACTTCTGCTTTTTCCCTCATTCTGTGCTTGGGAGCTG ATCTGTTTAGATCTTTTTGCTTCTCTGCGCCGAAAGCCTCTGTATT Seq ID NO:29 Copi6 terminal right-hand element (“RHE”) CCCCCAGCAATACACTTACTACAGTATTGATGTGTCAGGCATTCTGGTTGATTGTTTT ATTTTGGCTCCGCCTACTGTATGGCCCATGTAAACGCATCTATTATGAAAATAAAAT ACGTCAATTGCTGATGTAATTCGTGTTGTAATTCTTCCTTGAAAAGCGCATATTTTCT TGCCGGTCTGAGTAACACCACCTATGACATCATATAAATTTGATTACGTAACTTCCT CTTTTTACTTCCTCTTTTTTTGATTACGCAATATCACAATTCTAGCAGTCAACTATTAC ACAATATCACACTTTGAGACCCTGACCATCACACTTTTATTTTGTGCACTCGAGATGC GAGCATGGGCCGCAAGGCGGCCCATGCACGCAAATCTCGAGTGCACAAAATAAAAG TGTGATGTTTTCAAACTCTAAGACAGACATTGTGCAATCCAATATGTCTGCTCTTCCG GGTCAAAGGTTAT SEQ ID NO:30: Sika deer copiparvovirus (SDCopiPV-MZ12-1435), complete genome; Accession LC677177 1 tttcaaccct aacttcccct ttccaaccct aaccctaacc ctaattgcgc aattgtaaaa 61 aagatggctg acttccggtt ccgggtcatt ttgaccgtca cttccctttt tgattgtgac 121 agctcgcagc ggcctatagg ggattaggga tcaaaaaatg cggaaattga aatgtcttaa 181 aaacagacaa cacactaaat acttcccttt tctgtcgggt ggctggacta acaaccaata 241 caaccgtgag tatgctttct tattattatg gcacctggaa ctgtttccca tctccggaga 301 ttattcctgg tattgctaaa gatccttatg ttaaaaaaat taaattatta aaaggaggaa 361 attataaatg gccagaatta gatgaaaaat atctcttcgc agcacaatgc tgccaaggat 421 tattcataga aatttgcaaa caatgcagaa ttgaatgcaa aacaattaaa gatcctccca 481 ttttcatcca attagaagaa ggagaacatg gaaaattaca tgctcatttt gtcattagca 541 ccacaatagg aacagctaga gacatgagtc aaatattcaa aacagcagaa caacaattta 601 atttttatta tctaggaaca agaggaattg tatggaacaa acccaaaaaa aatagaaatg 661 gcagttggag tacttgtaat gaaaatttta taaaattata tctattacca aaattaccaa 721 tgaatcaatg cttatatgca tggacaacca tggatggaga atacgctgat gcttatctaa 781 acatagatga aagagagaaa ttcaaacaac taaaaagaaa aaaacaatac ttactaacta 841 ataataaaga agaagaagaa tcagatgatg aggcaggacc tatatttaaa aaagcaagcg 901 gagaacaaat gataaacata gtccaatttc tagtagaaaa tgatataaca accgaagaaa 961 aatggcaaca aaaatatttt aatagctatt gtacattctt aagttccaca agtggaactc 1021 atctattaaa aagctcacta acattagcaa gaagcacaat ctgcagagaa aaatcattag 1081 cattatcact ctgtggattt aaaaataaaa cacaactact aagcttctta aatgaacata1141 atcccacctc tatggaagaa aataaatat ggaaactatt tttacaaaat ggatatgatc 1201 cagatgaagc agcagctatt ctctatgcat ggagtagaaa aataacaggc aaaagaaatg 1261 caatttggat tagtggacca cccactacag gaaaaagcaa tctaggacag gccatagcca 1321 gaagtgcagc atgttatggg tgtgttaatt ggaataacaa aaattttcca ttcatggata 1381 ttataaacac tcaagtagct atttgggatg aaggaatcat aacagaagat atcattgaac 1441 aaactaaatg tgtcctcgca ggacaagaaa ctagaattga tagaaaatgc accacaagtg 1501 ttccatgcat tcctccttgt ttttttataa caagtaacca agacatcaca ttagtacaaa 1561 atggaaatct atatgtaaca actcacagac gcccactaga agatagaatg ttacacttta 1621 cattcgatca aaaatgcaaa acagatatgg gactattagg ccaaaatgat atcagaaact 1681 tttggagatg gggggcatac tgcttacaca aagcaaccca caaccgttat tcgttattaa 1741 gaaagccacc cacagaatgg ccttttgtaa tacccaaaaa tgccacagaa actgctattg 1801 gctatgtact taaaaaaaaa ccactatggc caacggacac cgaagatgaa gacattatat 1861 atatcgatga tgaagacata ctagaagctc tcgaacccac tgaaaacata gactccatcc 1921 tggaggaccc agaaaactac caaccaaaac ctaaggtaag aaatatatca tatattatat 1981 aaaaataaac atactaaact gacataaata ataatgtatg gtatatttct tacagaaaaa 2041 aaaagaagct ggaggaacca ccgatatatc agaacctgag cacggaaaca caccaccaag 2101 agtgttggaa gatcacgaag ctgctgaact tcttcttcag ctggctagtg atcaccagcc 2161 tgaaactcct gaatctcttc cacccctgga aggagaagaa acaacagaag aaccagatct 2221 acaaaaagaa caataggcaa gtaaatatgg ctttaagagg acctatgcca gctatcaaaa 2281 tttttgaaaa taatcaaaca attatggaaa atagtataaa tatacttaga catccaacac 2341 caggagatat agtaaaaaaa ccttatatca gtggaggaga acatgaccca tatgactttg 2401 aacgtcatta tctagataaa tggagtcatg atcataattg gtctataact ttaccatggg 2461 aatatgaaag aagagcttgg ttatatgcat attatagcag tctttattat ttagcagtaa 2521 attactacct aacatcagta cctattccaa atgtagatgc tagacttgga gaattatggt 2581 catatgaagt aagactatat ttaggagaaa tggaaatagg agacagagac tcttcttatc 2641 catataaaca atttttattc ttaattaatc aagcagtaga tgaaaaagtc gatccagata 2701 tactagaact acaaaaagca gttgcagcca taggcggagg tatttcagaa ggaccagata 2761 aaaaatacac attagatgaa tacagagatt taaattggaa tgtatggaaa caagcaactg 2821 cagacttatt aacagaatat aaagaaaaag tatatcaaag aatttataat tataataaac 2881 aaaaacaaca agaatttcat aattatatac aaaaaacaca acatgacgca tatatgaaac 2941 aacagcatta cccacacata tacgaacctg acgaaaacat acctgacatt aattgggaca 3001 aagcaagata tgaatggcaa atgaaaaata aatatccaca caaaacacat aaatatgacg 3061 gaccgaatat tgactgggac tctgtagcta aagctcttgc agaaaaagaa aaacaaaaag 3121 aagaagatgc gcttaggaaa gtacaggaat caacaccccc accccatgaa ccgcatggag 3181 gagggcctgg acttacatac ccagggagca gatacatcgg accagggaac ctcataccgt 3241 atggtcctcc tactgatgac attgacaatg ctgcagctct acatgacatt aggtatgaaa 3301 caatgatatc acatttacat tggccttata tatatgatca atcagatgac tatttaatag 3361 aagatattaa aaatgctgaa aaaaattata catttttagg aaacttaata attgctataa 3421 tgtattttaa aaaaaaagtt ggaaaaccta taatagatgc cttagaaaaa gtatggccac 3481 ctgaacctat tgaaaattta ccatcttttc aacagataaa acaacaattg gatcaaataa 3541 tacaacactc ggaatcaaca acaccaattt catcacactc atcgaactta ttaccagacg 3601 catcatcaca aacatctgaa acaaaaaaat caaaagaaac atcaccagaa aaaactgaaa 3661 aagaattaac atcaccaaaa ccaatacaaa ctcctccaac atctccaaaa aaggacacac 3721 cagacactcc tcaaaaacca ccaacaaaaa aaatcaaaga ggaacctgaa acaccacaga 3781 agaaagatat gtcaacagga caaactgcca ctgaccaaag aggaaaccat gccggtattg 3841 actcacatat ggcttccgca gacgcaccaa ctattgtgca aggagggggc gggggaggaa 3901 aaccaacatg tggtaaagta tggtggggag gaacagaatg gaaagataat catgtaacta 3961 ctttcagcac cagaagatgc gtcttaaaac cctatccaga taactactat tcacaaagat 4021 caatggacaa tataccagga atagtagttg taaccccatg gtactatttt gattttaact 4081 gcatgagctg tcattggtcc ccagctcaat atcaaacttt aattgaaaca caagatgaaa 4141 ttagacccgt aagtatgaaa ataatgatac accacctcgt cttcaaagac gtaacaacag 4201 gcagtgactc tcaaactgcc atacaagacg tatcttctgg tgccatatta ttacatagag 4261 atggagatta taaattccca tatccaatgg gaggaggaca actcacacat ccaggacaca 4321 tgccaggcag cttttatgaa ttaccaagat atagttatag aacattagcc aaagtagatc4381 cagtaatagc acatgcacaa acacaagtg gaagtcatgc atccacagta catttacatt 4441 attcacccac acaagacaca gaattattat tagtagagga tcaaccctca aaaatgcttt 4501 tcacaggaga ttgctatgaa tttaactatg actttcctgc tttacctttc gctaaactaa 4561 cacaataccc ttggaatcct cgcagacaag ataaccctct agcagaacaa aaattcttaa 4621 ctatgactaa tattttagaa gctgatgtat ttgcacctca tggaggaaca aaactcgtac 4681 ctttaccatt ttcatcaaaa atgagaccag ctcaatggct accaggccct aaattcaaac 4741 aaggagatta tgcagtaata aaaccagaag gagcaggagg aactcaacat tggtttaaac 4801 aaaaaaccac aaaagacaca cccataagaa cagtaagagc cacagatatt gtaacaggag 4861 gagataataa ttgggaaaca ttacaaccag gaccagacac agtatcaaat attgtaaaaa 4921 aaccagaagg agatattata gtaactgcta atggattagc agtaattatc cctgatgaca 4981 ttaaccaaca ttacaaccaa tccagtagac aagcagacgg atatgtaaaa ttacccatat 5041 taccactacg aggacataac ggaccagatg atccacaaca aatcagacat caaaacataa 5101 cagaccacac ataccaagaa gtaacatttg caagatatcc aggtgctaca tgggaaagaa 5161 aatcattaca ttatgaaact gaattatgga ctaaaattcc caacacagac tttgtagata 5221 tgccacaaga ttccccacta acacaatggg caatgaaaaa cccaccagac ttaatactaa 5281 taagaatgtt acaaacatta ggaccaccag aaaataattt agacacagga agtaaacaat 5341 caaatacagt actaaatcaa tattgtcaat tcctagtatc atactccata acatgggaaa 5401 caagacccag atcaaaacaa acaccaagat ggaatccaat accaccacca caattaccat 5461 taagaaatga tggaaaacca atatatgtaa tgaatattga aacccccgaa aaacactatg 5521 gtggggtcta tctcacacct gatgaagtat gggtagccaa acaaagagta agagctcaca 5581 gataatggta aatgaagttc agaattaaaa aaaattgtat aatcaataaa atcgacaatt 5641 tgtttgtcaa caaaaaaagc ttaagatgta cttctttcgc gggcgagaat tgggaaaaag 5701 gggcgtggcc aggacccgga aatagggagg agccacaaac gtcacgtccg gttgaccccg 5761 gaaaggaagc catatttatg acaattgcgc aatgcgacaa ccaaatatgg aaaaagcgga 5821 agttagggtt aaaactctga tatggcagcg ca SEQ ID NO:31: Sika deer copiparvovirus (SDCopiPV-MZ12-1435), nonstructural protein; Accession: BDE68837.1 GI: 2214710412 1 mlsyyygtwn cfpspeiipg iakdpyvkki kllkggnykw peldekylfa aqccqglfie 61 ickqcrieck tikdppifiq leegehgklh ahfvisttig tardmsqifk taeqqfnfyy 121 lgtrgivwnk pkknrngsws tcnenfikly llpklpmnqc lyawttmdge yadaylnide 181 rekfkqlkrk kqylltnnke eeesddeagp ifkkasgeqm inivqflven ditteekwqq 241 kyfnsyctfl sstsgthllk ssltlarsti crekslalsl cgfknktqll sflnehnpts 301 meenniwklf lqngydpdea aailyawsrk itgkrnaiwi sgppttgksn lgqaiarsaa 361 cygcvnwnnk nfpfmdiint qvaiwdegii tediieqtkc vlagqetrid rkcttsvpci 421 ppcffitsnq ditlvqngnl yvtthrrple drmlhftfdq kcktdmgllg qndirnfwrw 481 gayclhkath nrysllrkpp tewpfvipkn atetaigyvl kkkplwptdt edediiyidd 541 edilealept enidsiledp enyqpkpkvr nisyii SEQ ID NO:32: Sika deer copiparvovirus (SDCopiPV-MZ12-1435), structural protein; BDE68838.1 GI: 2214710413 1 malrgpmpai kifennqtim ensinilrhp tpgdivkkpy isggehdpyd ferhyldkws 61 hdhnwsitlp weyerrawly ayysslyyla vnyyltsvpi pnvdarlgel wsyevrlylg 121 emeigdrdss ypykqflfli nqavdekvdp dilelqkava aigggisegp dkkytldeyr 181 dlnwnvwkqa tadllteyke kvyqriynyn kqkqqefhny iqktqhdaym kqqhyphiye 241 pdenipdinw dkaryewqmk nkyphkthky dgpnidwdsv akalaekekq keedalrkvq 301 estpppheph gggpgltypg sryigpgnli pygpptddid naaalhdiry etmishlhwp 361 yiydqsddyl iediknaekn ytflgnliia imyfkkkvgk piidalekvw ppepienlps421 fqqikqqldq iiqhsesttp isshsnllp dassqtsetk ksketspekt ekeltspkpi 481 qtpptspkkd tpdtpqkppt kkikeepetp qkkdmstgqt atdqrgnhag idshmasada 541 ptivqggggg gkptcgkvww ggtewkdnhv ttfstrrcvl kpypdnyysq rsmdnipgiv 601 vvtpwyyfdf ncmschwspa qyqtlietqd eirpvsmkim ihhlvfkdvt tgsdsqtaiq 661 dvssgaillh rdgdykfpyp mgggqlthpg hmpgsfyelp rysyrtlakv dpviahaqtq 721 sgshastvhl hysptqdtel llvedqpskm lftgdcyefn ydfpalpfak ltqypwnprr 781 qdnplaeqkf ltmtnilead vfaphggtkl vplpfsskmr paqwlpgpkf kqgdyavikp 841 egaggtqhwf kqkttkdtpi rtvratdivt ggdnnwetlq pgpdtvsniv kkpegdiivt 901 anglaviipd dinqhynqss rqadgyvklp ilplrghngp ddpqqirhqn itdhtyqevt 961 farypgatwe rkslhyetel wtkipntdfv dmpqdspltq wamknppdli lirmlqtlgp 1021 pennldtgsk qsntvlnqyc qflvsysitw etrprskqtp rwnpipppql plrndgkpiy 1081 vmnietpekh yggvyltpde vwvakqrvra hr SEQ ID NO:33: PLA Activity motif conserved between VP / CAP proteins of AAV and Copiparvovirus YXGXG HDXXY, wherein “X” is any amino acid. SEQ ID NO:34: Motif of unknown function conserved between VP / CAP proteins of AAV and Copiparvovirus TPWXYXDXNXXXXHXXPXXXQ, wherein “X” is any amino acid. SEQ ID NO:35: Motif of unknown function unique to Copiparvovirus VP / CAP RRQDNP SEQ ID NO:36: Motif of unknown function unique to Copiparvovirus VP / CAP RPAXWLP, wherein “X” is any amino acid. SEQ ID NO:37: Motif of unknown function unique to Copiparvovirus VP / CAP DXDYXXPYXXGGGQXTXPXHXPGXXYXLPXYXYXTL, wherein “X” is any amino acid. TECHNICAL EXAMPLES
[0068] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.EXAMPLE 1
[0069] This example demonstrates that vector construction using Copi6 as a backbone with the cytomegalovirus (CMV) promoter driving expression of did not effectively produce vectors.
[0070] Constructs referred to in this Example include (a) CMVpo6 tj (Figure 3), in which the ORFs encoding NS (NS1 Or “Copi6 NS” (“nonstructural”)) and CAP (Copi6 CAP) are placed in-stream under the transcriptional control of the CMV promoter, (b) U3795HA140-3 MMTVpo6 tj (Figure 4), in which an ORF encoding NS1 is placed under the transcriptional control of the MMTV promoter, and an ORF encoding VP1 is fused downstream to the NS1 ORF and under the transcriptional control of the CMV promoter, (c) mmtvNSCMVVP2po6 tj (Figure 5), in which the ORF encoding NS is placed under the transcriptional control of the MMTV promoter and an ORF encoding VP2 is placed about 2300 bp downstream of the NS ORF and under the transcriptional control of the CMV promoter and (d) mmtvpo6, in which the ORFs encoding NS (NS1 or “Copi6 NS” (“nonstructural”)) and Copi6 CAP are placed in-stream under the transcriptional control of the MMTV promoter. Additionally, as depicted in Figure 7, the MMTV promoter driving the expression of NS was engineered into mmtvpo6 with an upstream ORF and AUG (ATG) to limit transcription.
[0071] These four constructs, as well as a control vector (A3670T) engineered to remove the upstream ORF added to affect expression of the NS ORF (see Figure 7), were transfected into 293T cells, using CaPO4 transfection with benzonase phenol:chloroform in a 10 cm dish. Following transfection, the titer of resulting vectors obtained was measured. In general, the results demonstrated that the use of the CMV promoter to drive expression of the Copi6 NS and CAP ORFs led to low viral titers, but the use of the MMTV promoter and upstream ORF produced acceptable titers. EXAMPLE 2
[0072] This example demonstrates that production of Copi6 vectors according to the present invention does not require helper virus (such as adenovirus).
[0073] As, given the results of Example 1 that the Copi6 vector, but not others employing the CMV promoter to drive expression of the Copi6 NS and CAP ORFs, did not efficiently produce viruses, additional constructs based on Copi6 were produced and tested. These are as indicatedin Table 1. For the experiment, either 6.7 kb a one (Table 1, Row A, control) or Copi6 vectors containing AAV genomic sequences having either 6.7 kb (Table 1, Rows B and C) or 8.7 kb (Table 1, Rows D and E) were tested for the formation of vectors either in (Table 1, Rows B and D) or without (Table 1, Rows C and E) the presence of helper adenovirus. To test the constructs, they were transfected into 293T cells, using CaPO4transfection with benzonase phenol:chloroform in a 10 cm dish. Following transfection, the titer of resulting vectors obtained was measured.
[0074] The results indicated that the presence of an adenoviral helper virus (Table 1, Rows B vs. C and D vs. E, less than 2-fold difference in titer) was not observed to significantly impact the titer of Copi6 vectors. Moreover, while the Copi6 vectors were able to efficiently package genomes of 6.7 kb (Table 1, Rows B and C), a marked decrease in efficiency was observed when the genome size was increased to 8.7 kb (Table 1, Rows D and E). Preliminary data indicate that the Copi6 vectors can package at least up to 7.3 kb within its encapsulated genome with a titer of 1.3E+12 viral genomes / ml. Also, data demonstrate that vectors based on Copi6-2 likewise can be produced at high titers without relying on any helper adenovirus.Table 1 Constructs Transfected Titer of virus isnot deemed s gn cant. EXAMPLE 3
[0075] This example presents additional data concerning the properties of Copi6 vectors according to the present invention.
[0076] A vector (VB220316-1106had, Figure 8, see also Figure 21) was constructed to introduce an ORF encoding the nano luciferase protein and the human CF transmembrane conductance regulator (CFTR) protein into the Copi6 vector backbone. This ORF coding sequence comprises 6,070 nucleotides, making the resultant genome contained within the vector 6.2 kB. The resulting Copi6 vector is termed “Po66.8” (see Figure 21).
[0077] As shown in Figure 9, Po66.8 particles were produced and could be resolved via election microscopy, after purification from 293T cells. The approximate size of such viral particles was observed to be approximately 35 nm, whereas that of typical AAV vectors is much smaller, at 26 nm.
[0078] Moreover, as depicted in Figure 10, when assayed for luciferase activity, while Po6 6.8 efficiently transduced COS cells (a primate kidney cell line), transduction of pk15 cells (aporcine kidney cell line) produced no significa tly greater signal than background (negative control). The assay was conducted using relative light units as the read-out.
[0079] In another experiment, vectors were produced as follows: 293 T cells were co- transfected with 6µg / plate of mmtvpo6, 6µg / plate of AAV-2GFP and 6µg / plate of RepX26- Recombinant (rAAV-GFP) and harvested 48hr later. For production of Copi6 vectors only mmtvPo6 plasmid and a vector plasmid with Copi6 terminal repeats were transfected. Vectors were purified by CsCl gradient centrifugation (RI1.382), following freeze and thaw and the addition of 1% chaps detergent. These preparations then were incubated for 10 minutes at 37 ºC with slow shaking and then Benzonase (Sigma) was added to a final concentration of 20 U / ml. These then were incubated for another 40 min slow shaking at 37 ºC.
[0080] The lysates then were centrifuged at 38,000 rpm for 72 hrs in a SW40 rotor. Fractions corresponding to a RI of 1.395 showed peak DNase-resistant genome copy numbers for the vector as determined by quantitative real-time PCR probes specific to the cytomegalovirus (CMV) promoter contained within the packaged genome. The results (Figure 11) demonstrate that fraction 3 (F3) of a Copi6-capsid vector of the present invention comprising an AAV genome of 7.3 kB had a titer of 1.00E+12 vg / ml (vector genomes / ml) and displayed a refractive index of 1.395. By contrast, the refractive index of standard AAVs is typically 1.372.
[0081] Additionally, a sequence and structural analysis reveals that, whereas the terminal sequences of standard AAVs are symmetrical, those of Copi6 are not (see Figure 15). Also, the structure of the Cop6 capsid protein (Figure 22) was elucidated using the AlphaFold online service operated by the European Molecular Biology Laboratory. Included in the depiction is the location of residue 1034, which can be mutated (D1034R) to alter ligand binding.
[0082] An additional experiment was conducted to compare the phospholipase 2 (PLA2) activity of the Copi6 vector against AAV2. In this assay phospholipase activity is monitored by the hydrolysis of sn-2 ester linkage of phospholipids over time. 5 x 109Copi6 and 4 x 1010AAV2 were assayed and the fluorescence intensity (515 / 575 nm with an excitation of 460nm) was measured. The results are depicted in Figure 23.EXAMPLE 4
[0083] This example presents data and information concerning two other copiparvovirus vectors, derived respectively from Roe deer copiparvovirus and Sika deer copiparvovirus, respectively.
[0084] Expression vectors were constructed containing the nonstructural (NS) and structural (VP) candid protein (see Figure 24 for vector diagrams). These were expressed as noted above, either in the presence of absence of adenoviral “helper” viruses, to produce the respective copiparvoviruses. As revealed in Figure 26, the production of Roe deer copiparvovirus particles was not influenced by the presence of adenovirus, whereas the production of Sika deer copiparvovirus particles was significantly impacted. However, it has not been determined whether Roe deer or Sika deer copiparvovirus NS proteins can package AAV ITRs alone or whether they require AAV rep proteins.
[0085] Additionally, as with the Copi6 CAP protein, the VP proteins of Roe deer or Sika deer copiparvovirus were elucidated using the AlphaFold (see Figure 25), revealing similarity in structure.
[0086] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0087] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate valuefalling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0088] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
CLAIM(S):
1. A genetic vector comprising a genome, wherein: a. the genome comprises a first DNA sequence encoding a polypeptide able to form viral capsids, wherein the encoded polypeptide comprises an amino acid sequence at least 95% identical to the VP or SP, or CAP (“structural” or “capsid”) protein of a copiparvovirus, and b. the genome comprises a second DNA sequence comprising a promoter derived from mouse mammary tumor virus (MMTV), and which comprises a nucleic acid sequence at least 95% identical to SEQ ID NO:26, wherein the promoter is operably linked to the first DNA sequence.
2. The genetic vector according to claim 1, wherein the polypeptide encoded by the first DNA sequence comprises an amino acid sequence at least 95% identical to a sequence selected from SEQ ID NOs: 10, 13, 16, 20, 24, and 32.
3. The genetic vector according to claim 1, wherein the polypeptide encoded by the first DNA sequence comprises an amino acid sequence selected from SEQ ID NOs: 10, 13, 16, 20, 24, 32, and 35-37.
4. The genetic vector according to claim 1, wherein the polypeptide encoded by the first DNA sequence comprises an amino acid sequence consisting essentially of SEQ ID NO:
13.
5. The genetic vector according to any one of claims 1-4, wherein the second DNA sequence consists essentially of SEQ ID NO:
26.
6. The genetic vector according to any one of claims 1-5, wherein the genome comprises an ORF upstream of (5’ to) the second DNA.
7. The genetic vector according to any one of claims 1-6, wherein the genome comprises a third DNA encoding a copiparvovirus nonstructural protein.
8. The genetic vector according to claim 7, wherein the nonstructural protein comprises an amino acid sequence at least 95% identical to a sequence selected from SEQ ID NOs: 8, 9, 12, 15, 19, 23, and 31.
9. The genetic vector according to any one of claims 1-8, which rescues, replicates, and packages an AAV2 ITR in vitro using cells and without the presence of a helper virus.
10. The genetic vector according to claim 9, wherein the helper virus is adenovirus or HSV.
11. A genetic vector comprising a capsid comprising a polypeptide comprising an amino acid sequence at least 95% identical to the VP or SP, or CAP (“structural” or “capsid”) protein of a copiparvovirus and a genome comprising non-copiparvovirus DNA.
12. The genetic vector according to claim 11, wherein the polypeptide comprises an amino acid sequence at least 95% identical to a sequence selected from SEQ ID NOs: 10, 13, 16, 20, 24, and 32.
13. The genetic vector according to claim 11, wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 10, 13, 16, 20, 24, 32, and 35-37.
14. The genetic vector according to claim 11, wherein the comprises an amino acid sequence consisting essentially of SEQ ID NO:
13.
15. The genetic vector according to any one of claims 11-14, which displays refractive index of 1.395 as measured by density of the fraction on a CsCl gradient.
16. The genetic vector according to any one of claims 1-15, wherein the genome comprises an ORF encoding a polypeptide other than a copiparvovirus protein, optionally which polypeptide comprises a human polypeptide.
17. The genetic vector according to any one of claims 1-16, wherein the genome comprises an AAV ITR, optionally comprising non-viral DNA.
18. The genetic vector according to any one of claims 1-17, wherein the genome comprises an AAV2 or an AAV5 or bovine AAV ITR, optionally comprising non-viral DNA.
19. The genetic vector according to any one of claims 1-18, wherein the genome comprises greater than 5.2 kB of DNA.
20. The genetic vector according to any one of claims 1-19, wherein the genome comprises 7.9 kB of DNA or less.
21. The genetic vector according to any one of claims 1-20, wherein the genome comprises left and right terminal elements (TEs), which are asymmetrical.
22. A composition comprising the genetic vector according to any one of claims 1-21 and a pharmaceutically or physiologically acceptable carrier.
23. A method of introducing a non-copiparvoviral gene into a cell, comprising infecting the cell with the genetic vector according to any one of claims 1-21, wherein the genome of the genetic vector comprises an ORF encoding a polypeptide other than a copiparvoviral protein, optionally which polypeptide comprises a human polypeptide.
Citation Information
Patent Citations
Methods for analysis of viral capsid protein composition
US11345929B2
Closed-ended linear duplex DNA for non-viral gene transfer
US20190032083A1
Methods for analysis of viral capsid protein composition
US20200299728A1
Campaign-ready series of recombinant adeno-associated virus (RAAV) complementing plasmids
US20210047650A1
